IκBα inhibits apoptosis at the outer mitochondrial membrane through a novel, NF-κB–independent, interaction with VDAC1 by Pazarentzos, Evangelos
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 1 
 
 
IκBα inhibits apoptosis at the outer 
mitochondrial membrane through a novel,  
NF-κB–independent, interaction with VDAC1 
 
by 
 
Evangelos Pazarentzos 
 
 
 
 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy 
 
Imperial College London 
Faculty of Medicine 
Department of Medicine 
Division of Experimental Medicine 
  
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 2 
 
Acknowledgements  
I would like to express my deep and sincere gratitude to my supervisor, 
Professor Stefan Grimm. His knowledge on the subject and the valuable 
discussions have been of great value to me. His understanding and personal 
guidance have provided a good basis for the present thesis. At the same level I 
would like to express my sincere gratitude to Dr Anne-Laure Mahul-Mellier. 
Without her the project milestones and several scientific and technical issues 
wouldn’t have been resolved and special thanks have to be given to her for all the 
guidance throughout this PhD work.  
I am also grateful to Cancer Research UK for offering me the studentship 
which apart from the total project support, helped me with the tuition fees, living 
expenses and congresses support for the duration of the project. 
Moving from Greece in 2007 has proved challenging at the initial stages of 
my stay in London and at Imperial College London. I would like to dedicate this 
present thesis to my parents Voula and Christos and to my sister Anna. Without 
the support of my family and their valuable advice in difficult moments of this 
period, this work would never have been as successful as it proved to be.   
Contribution to the success of this project and to my personal life 
achievements has to be recognised for my valuable friends. It would have been 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 3 
 
very difficult to overcome certain situations without them on the personal level (all 
my true friends in Greece – Zacharias, Eva, Chrysta, Marianna, Stamatis, Maria, 
Vasilis, Petros) and on scientific and personal level (Dr Christopher Watson, Dr 
Enrico Cristante, Ioanna Eleftheriadou).    
I wish to thank Professor Nicholas D Mazarakis and Professor Aristidis 
Eliopoulos for their suggestions and advice during the evaluation of this thesis. 
Professor Mazarakis deserves special gratitude for always being next to me and 
supporting me for difficult scientific and professional challenges. Part of my recent 
success in my future career is due to his deep knowledge of the field and the 
people around it. Without him, I believe, the postdoc position in UCSF and the 
offers I got from Salk Institute and Harvard University, wouldn’t have been feasible. 
Last but not least I would like to thank all the members of the Apoptosis 
research group (Mr Christoph Datler, Ms Ghada Abuali, Mr Bevan Lin, Dr Ryota 
Iwasawa, Ms Wanwisa Chaisaklert and Mr Ming Hwang) for their help and advices     
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 4 
 
Declaration of Originality 
I, Evangelos Pazarentzos, hereby declare that the work presented in this 
thesis is my own and to the best of my knowledge is original. The content of this 
thesis has not, is not and will not be submitted in any form for another degree or 
diploma at any university or other institute of tertiary education. Any contents in 
this thesis, including figures, data, ideas and material obtained from other sources 
are appropriately cited and acknowledged in the text and a full list of references is 
given at the end of this thesis.  
 
 
 
 
 
 
 
 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 5 
 
Abstract 
The inducible transcription factor NF-κB is tightly regulated by the 
inhibitory IκB-family of proteins that associate with the transcription factor and act 
in response to stress stimuli. The best studied inhibitory protein is IκBα which 
resides in the cytosol where it retains NF-κB. Our study shows that IκBα also 
associates with the outer mitochondrial membrane (OMM) and exerts an 
unexpected novel anti-apoptotic function, independent of NF-κB inhibition. IκBα-/- 
cells become refractory to apoptosis when IκBα is specifically reconstituted at the 
OMM. We found that cancer cells with constitutively active NF-κB accumulate IκBα 
at the OMM and when its expression is down-regulated these cells are sensitised 
to apoptosis. At the OMM IκBα associates with VDAC1 and hexokinase II (HKII). 
Our findings show that IκBα inhibits the dissociation of HKII from VDAC1 and 
prevents Bax-mediated cytochrome c release. Deletion mutants of IκBα reveal a 
domain necessary for apoptosis inhibition that is different from the domain for 
NF-κB retention, thereby separating the two functions. These results reveal an 
unexpected activity of IκΒα in guarding the integrity of the OMM against 
apoptosis induction and open possibilities for more specific interference in 
diseases involving deregulated NF-κB.  
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A.1.  Cell Death 
Homeostasis is a term referring to a property of a system, which controls its 
internal structure and stabilises any parameter that may affect the balance so as to 
keep the performance of the system high. Typically, the term is used in biology to 
describe anything from a cell to a multicellular organism. It was first used by 
Claude Bernard and Walter Cannon and extensive research has commenced on the 
molecular factors that might influence homeostasis. Cell death is a critical process 
for the control of homeostasis and tissue integrity in multicellular organisms. Two 
major, yet fundamentally different forms of cell death have been identified that 
accomplish homeostasis: necrosis and apoptosis. 
A.1.1.  Necrosis 
The origin of the word necrosis comes from the ancient Greek “nekros”, 
whose literal translation is “a dead body”. This form of cell death is a spontaneous, 
passive process resulting in an early disruption of the plasma membrane and the 
progressive breakdown of cellular organelles accompanied by organelle swelling 
(oncosis). The swelling leads to the lysis of the cell and the leakage of cellular 
contents into the extracellular space, which provokes an inflammatory response 
(Figure A.1.) (Leist & Jaattela, 2001). Neighbouring cells can also undergo necrosis 
upon lysis of an individual cell, thus necrotic cell death can affect a group of cells 
(Stoica & Faden, 2010). Cellular necrosis is caused by several external causes, 
Imperial College  
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mostly strong perturbation of the environment (extreme high or low temperatures 
for example), mechanical trauma, infections and poisons. Clinically, hypoxic cells or 
tissues that underwent ischemic injury often show necrotic cell death. Additionally, 
venoms produced by certain animals or infections by particular bacteria can cause 
rapid and severe necrosis, for example Group A streptococcus in necrotizing 
fasciitis (Roje et al., 2011). As mentioned above, necrotic cell death is generally 
caused by extreme stress or a major failure in homeostatic regulation (Raffray & 
Cohen, 1997; Syntichaki & Tavernarakis, 2003). Consequently, it is essentially the 
accidental death of a cell and can be caused by conditions that are so extreme in 
nature that the cell has not the opportunity to respond (Syntichaki & Tavernarakis, 
2003). However, recently the view that necrosis is not merely an accidental cell 
death is gaining support. Cells whose apoptosis system is inhibited or 
compromised, can still die following an apoptotic stimulus but show all the 
characteristics of necrosis (Edinger & Thompson, 2004). Whether this type of cell 
death is physiologically relevant or whether it occurs only in very distinct 
circumstances in nature is a field of intense investigation.  
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A.1.2.  Apoptosis 
In the early 1970s, John Kerr and his group noticed a peculiar form of cell 
death in acute liver injury in rats and named this process shrinkage necrosis (Kerr 
et al., 1972). Later, during the same decade, having studied the features of 
shrinkage necrosis in comparison with necrosis, this form of cell death was given 
the name “apoptosis”. The term ‘apoptosis’ is often used to describe the process 
of programmed cell death (PCD); also referred to as cell suicide. However, some 
authors have pointed out that the terms “apoptosis” and “PCD” should not be 
deemed interchangeable since during development, when most of the cell death is 
‘programmed’ in some way, there is some cell death that does not fit the defining 
characteristics of apoptosis. Some of these features will be mentioned later. 
Nevertheless, many authors have not adopted this distinction in their writing 
(Haanen & Vermes, 1995; Kiechle & Zhang, 2002; Sloviter, 2002) and in this text, 
unless declared otherwise, the terms ‘apoptosis’, ‘programmed cell death’, and ‘cell 
suicide’ will also be used synonymously. 
 Apoptosis is a mode of cell death quite distinct from necrosis, not just 
because it is a programmed and regulated mechanism but also in terms of its 
morphology and biochemistry (Bohm & Schild, 2003). It can be characterized by 
special morphological (Figure A.2., Table A.2.) and biochemical features (Figure 
A.3., Table A.2) such as blebbing of the plasma membrane, chromatin 
condensation, cell shrinkage, nucleus fragmentation, energy dependence, 
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containment of lysosomal enzymes and the absence of an inflammatory response 
(Bohm & Schild, 2003; Kiechle & Zhang, 2002).  
In multicellular organisms, apoptosis plays an important role in, among 
other scenarios, the immune response, development, and tissue homeostasis 
(Bohm & Schild, 2003; Haanen & Vermes, 1995; Janssen et al., 2000; Kerr et al., 
1972). In particular apoptosis is important for the elimination of unnecessary 
neurons during the development of the nervous system, the removal of auto-
immune lymphocytes in the thymus, and the maintenance of the stability in cell 
numbers in dynamic tissues such as the skin and those of the gut (Haanen & 
Vermes, 1995). Apoptosis exerts its effect even in unicellular organisms that seem 
capable of employing this mode of cell death for their suicide. Bacteria as 
unicellular organisms will commit to an altruistic death in order to prevent damage 
or promote survival of the total population. For instance, a viral infection would 
promote the activation of the cell death machinery of this bacterium in order to 
prevent the spread of the infection. Another example would be the autolytic 
pathway of the bacteria which serves as a programmed suicide mechanism and 
allows the exchange and acquisition of the lysed bacteria DNA from other 
surrounding bacteria (Lewis, 2000). Though PCD may look detrimental from the 
perspective of an individual cell, it can have a positive effect in a more complex 
multicellular community – namely the elimination of defective cells in order to aid 
the survival of those that function properly. Removal of DNA-damaged cells for 
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A B 
C 
reducing the mutation rate is another aspect of apoptosis that multicellular 
organisms can benefit from and this response is also observed in both unicellular 
prokaryotes and eukaryotes (Lewis, 2000; Pereira et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1. Necrotic and apoptotic cell death. (A) Necrotic cell undergoing 
cell lysis and the contents of the intracellular organelles are released into the 
extracellular environment. (B) Late stage apoptotic cell forming several 
membrane enclosed vesicles as depicted by the presence of small vacuolar 
structures in the cytosol. (C) An apoptotic cell is engulfed for clearing. Figure 
was taken from thesis of Dr A-L Mahul Mellier 
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Apoptosis is an integral part of cell homeostasis with several distinct or 
interconnected aspects. Morphological changes, cell cycle alterations, DNA and 
phenotypical variability, although important, are not central to the findings of this 
study and hence will not be extensively covered. However, those aspects of 
apoptosis that link molecular signalling pathways to disease will be discussed and 
extensively analysed with special emphasis on genes and proteins affecting the 
signalling pathways of apoptosis inhibition or execution and its connection to 
tumourigenesis. 
 
 
Apoptosis Necrosis 
Affects individual cells Affects group of neighbouring cells 
No inflammatory response Major inflammatory response 
Cell shrinkage Cell swelling 
Membrane blebbing with maintained 
integrity  Loss of membrane integrity 
Increase of mitochondrial membrane 
permeability, release of proapoptotic factors 
and formation of apoptotic bodies 
Organelle swelling and lysosomal 
leakage 
Chromatin condensation and controlled 
DNA fragmentation Random DNA degradation 
Apoptotic bodies ingested by neighbouring 
cells  Macrophage phagocytosis of lysed cells 
Table A.1.  Differences between apoptosis and necrosis 
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Figure A.2. Time lapse images of apoptotic cells: morphological features. 
Hela cells were transfected with eGFP and cells undergoing spontaneous 
apoptosis were captured. Initially cells present equal cytoplasmic staining and 
gradually spherical structures start appearing when cells begin to die (second 
pane onwards). As apoptosis progresses, numerous apoptotic bodies appear and 
eventually cells round up and lose focal adhesion. Pictures were taken using a 
Leica scanning confocal microscope in intervals of 2 hours. 
15 μΜ0 15 μΜ0 15 μΜ 
15 μΜ 
15 μΜ 15 μΜ 15 μΜ 
15 μΜ 15 μΜ 15 μΜ 
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A 
Figure A.3. Time lapse images of apoptotic cells to visualise biochemical 
features. Hela cells were transfected with the cytosolic calcium indicator YC3.6. 
Cells were subsequently treated with doxorubicin (2µΜ) and CaspaTag caspase 
3/7 sulforhodamine (a dye that only binds to activated caspase-3 or/and -7 and 
emits red fluorescence upon binding). The top 6 panels show the time course of 
cytosolic calcium increase (as indicated by the increased green fluorescence) and 
the activation of caspase 3/7 (as indicated by the red fluorescence). The bottom 
two figures show the cytosolic calcium elevation and the caspase 3/7 activation of 
a representative cell. Images and graphs were taken from the thesis of Dr R. 
Iwasawa 
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Morphological Features Biochemical Features 
Cell shrinkage Free [Ca
+2
]
c 
 rise 
Chromatin condensation DNA degradation 
Nuclear fragmentation Caspase activation 
Membrane blebbing  Loss of mitochondrial membrane 
potential 
Cell detachment Phosphatidylserine externalisation 
Production of apoptotic bodies 
 
Phagocytosis of cell corpses 
 
 
 
 
 
 
 
 
 
Table A.2. Morphological and biochemical features of apoptotic cells. 
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A.1.3.  The two major pathways of apoptosis initiation  
 
Two major pathways that lead to the induction of programmed cell death 
are known: the extrinsic and intrinsic pathway. Apoptosis can be instigated by the 
activation of death receptors (DR) on the cell surface or can be induced by 
signaling processes that are initiated within the cell as a result of stress and/or 
damage by, say, exposure to particular drugs (Elliott & Elliott, 2009; Kiechle & 
Zhang, 2002). The former type of apoptosis is termed receptor-mediated or 
extrinsic while the latter is called mitochondria-mediated or intrinsic (Figure A.5.)  
Apoptotic pathways involve many proteins that are required to orchestrate 
the complex signalling pathways. The two apoptosis pathways share a basic 
signaling cascade: the initiation phase, the integration/decision phase and the 
execution phase. The initial reception of the apoptotic signal is highly 
heterogeneous and depends on the nature of the death-inducing signals. In the 
extrinsic pathway, it is the ligand interacting with a “death receptor” and in the 
case of the intrinsic pathway, it is damage inflicted on cellular organelles (such as 
the nucleus, endoplasmic reticulum, lysosomes, Golgi apparatus or mitochondria). 
The integration/decision phase involves the formation of a caspase-activation 
complex and initiation of the enzymatic activity of the caspase proteases. Cells 
then pass the point of no return and are destined to die. In the last, the execution 
phase, morphological and biochemical changes occur due to the cleavage of 
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cellular proteins by caspases. The biggest difference between the extrinsic and the 
intrinsic pathway is the initial reception of the death signals. In the extrinsic 
pathway the cell obtains its first apoptotic signal from plasma membrane 
receptors, whereas BH3-only proteins of the Bcl-2 family usually sense the signals 
in the intrinsic pathway. 
In essence, the receptor-mediated, extrinsic pathway is initiated by DRs, 
situated at the cell’s plasma membrane, when binding to their ligands. This 
process, via specific mediators, goes on to trigger a proteolytic cascade that leads 
to the cleavage of specific proteins in the cell, thus committing the cell to 
apoptosis (Ashkenazi, 2008). 
The mitochondria-mediated, intrinsic apoptotic pathway does not require 
the binding of ligands to receptors at the cell surface but rather is a stress-induced 
process involving mitochondria. In particular, specific cellular events take place 
under conditions of cell stress that lead to the disruption of the outer 
mitochondria membrane (OMM). This allows the release of several pro-apoptotic 
mitochondrial factors, which trigger a cascade of effector caspases that can then, 
as in the extrinsic pathway, commit the cell towards apoptosis (Green & Kroemer, 
2004). 
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A.1.3.1.  Extrinsic apoptotic pathway 
 
As mentioned above the extrinsic or death receptor-dependent pathway of 
apoptosis receives its signal from plasma membrane receptors (Ashkenazi & Dixit, 
1998). These receptors belong to the tumour necrosis factor (TNF) receptor 
superfamily and are characterized by the presence of two to five copies of 
cysteine-rich extracellular repeats. This superfamily includes Fas (also known as 
Apo-1 or CD95), TNF-receptor-1 (TNF-R1), death receptor-3, TNF-related 
apoptosis inducing ligand receptor-1 (TRAIL-R1 or DR4), TRAIL-R2 (DR5) and 
death receptor 6. Of all the plasma membrane receptors that can mediate a signal 
for apoptosis the TNF-R1- and the Fas receptor are the most intensively studied 
and hence will be further discussed. 
A.1.3.1.1.  TNF receptor-mediated extrinsic pathway 
 
Tumour necrosis factor (TNF) is a multifunctional pro-inflammatory cytokine 
mainly produced by macrophages. TNF is involved in the progression of many 
diseases such as rheumatoid arthritis and Crohn’s disease and inhibitors of TNF are 
used for therapeutic purposes. TNF can bind two kinds of TNF receptors (TNFR), 
TNFR1 and TNFR2 (de Jong et al., 2001). 
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On the plasma membrane, TNF-R1 forms, upon binding its ligand, a 
homotrimer. This brings the death domain (DD) in the cytosolic moiety of the 
proteins in close proximity, which facilitates the recruitment of several adaptor 
proteins to form a death-inducing signaling complex (DISC) leading to the 
activation of initiator caspases. In the absence of TNF the receptor is bound to 
Silencer of DD (SODD), which inhibits the recruitment of the adaptor proteins for 
caspase activation thus acting as a negative regulator of apoptosis (Figure A.5.)  
(Jiang et al., 1999). Upon binding of the ligand, SODD dissociates from the TNF-R1 
complex exposing the DD and facilitating the recruitment of another DD-
containing protein, the “TNF-R1-associated death domain protein” (TRADD) 
(Figure A.5.) (Hsu et al., 1995)). Following the binding of TRADD to the TNF-R1 
complex, there are two possible consequences. 
One scenario is that the DD of TRADD recruits the “receptor interaction 
protein (RIP)” and the “TNF receptor-associated factor-2” (TRAF2) (Chen & 
Goeddel, 2002; Hsu et al., 1996). This tetra-protein complex consisting of TNF-R1, 
TRADD, RIP1, and TRAF2 is known as complex I (Figure A.5.), (TNF receptor 
mediated pathway, left). This complex can lead to one of three different responses 
(Figure A.5.). In one case the “nuclear factor-κB” (NF-κB) is activated and promotes 
survival of the cells (Lin et al., 1999). This is triggered and regulated by the 
phosphorylation of its inhibitor IκBα. This begins with the recruitment of the 
heterodimer of IκBα kinases (IKKα and IKKβ) and the regulatory protein NEMO 
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(also known as IKKγ) to the TNF-R1 signaling complex I by TRAF2 (Devin et al., 
2003). RIP1 seems to stabilise the IKK complex. In the second response, c-Jun N-
terminal kinase (JNK) is activated through complex I. Upon activation of JNK, it 
translocates to the nucleus and activates transcription factors, for example, c-Jun 
and ATF-2, by phosphorylation. These transcription factors control the regulation 
of several genes including those involved in apoptosis regulation, for example c-
IAP and c-FLIP (Hu et al., 1997; Srinivasula et al., 1997)) thereby preventing the 
induction of apoptosis. In the last response, “RIP1-associated ICH-1/CED-3 
homologous protein with death domain” (RAIDD) or synonymously known as 
“caspase and RIP adapter with death domain” (CRADD) associates with RIP 
(Ahmad et al., 1997; Duan & Dixit, 1997). A domain similar to the caspase 
recruitment domain (CARD) of RAIDD is able to activate initiator procaspase-2 to a 
mature caspase-2 for the induction of cell death (Baud & Karin, 2001; Duan & 
Dixit, 1997; Shearwin-Whyatt et al., 2000). 
The second, fundamentally different scenario of TNF-R1-mediated 
apoptosis involves a different set of proteins that are recruited to the receptor. 
TRADD associates with TNF-R1 complex through its DD, which then recruits “Fas-
associated death domain” (FADD). In addition to a DD, FADD also contains a death 
effector domain (DED) for the recruitment of DED-containing initiator caspases 
(procaspase-8 and -10). The complex of TNF-R1, TRADD, FADD and procaspases-8 
or -10 is known as “complex II” (Figure A.5.). This recruitment of procaspases 
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results in a temporal elevation of caspases concentration around the TNF-R1, 
which leads to their mutual cleavage and activation (Kim et al., 2000) via the 
proximity-induced dimerization model. The activated caspase-8 or -10 then cleave 
and activate effector caspases such as procaspase-3 or -7 for the execution of cell 
death (Figure A.5.) 
Consequently, the TNF-R1 activation does not uniformly induce cell death 
as it can both result in a pro-survival pathway or in a pro-apoptotic pathway. The 
NF-κB pathway and the JNK pathway lead to the expression of pro-survival 
proteins (Stehlik et al., 1998; Wajant et al., 2003). A study in mice indicated that the 
loss-of-function of proteins involved in the NF-κB activation pathway are either 
embryonic lethal or results in neonatal fatality (Beg et al., 1995b). This indicates 
that the ability of TNF to induce apoptosis is concomitantly suppressed in vitro by 
a constitutive activation of NF-κB. Research I conducted during this PhD thesis as 
part of another project revealed that the ubiquitin-specific protease USP2a is a 
component of the TNFR1 complex and has a pivotal role in the conversion of 
complex I into complex II and hence the decision for cell death over survival 
(Mahul-Mellier et al., 2011). 
A.1.3.1.2.  Fas receptor-mediated extrinsic pathway 
 
Fas is a heavily glycosylated 40-45kDa plasma membrane protein involved 
in cytotoxic T-cell killing. The Fas receptor homotrimerizes at the plasma 
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membrane upon ligand binding similarly to the TNF-R1 (Ashkenazi & Dixit, 1998; 
Pitti et al., 1996; Smith et al., 1994). Association of the Fas ligand with the Fas 
receptor forms a platform for caspase activation known as “death inducing 
signalling complex (DISC)” via the DD of the Fas receptor (Figure A.5.) Fas receptor 
mediated pathway (Boldin et al., 1995; Chinnaiyan et al., 1995; Kischkel et al., 1995; 
Nagata, 1997). The adaptor protein FADD is first recruited to the Fas-receptor, and 
the DED of the FADD allows the association of procaspases-8 or -10 (Chinnaiyan et 
al., 1995; Medema et al., 1997). The formation of the DISC quickly increases the 
local concentration of pro-caspases, which in turn cleave each other and thereby 
become mature, active caspases (Boatright et al., 2003; Donepudi et al., 2003; 
Walczak & Krammer, 2000). As is the case of the TNFR complex, activated caspase-
8 or -10 then activate downstream effector pro-caspases such as procaspases-3 or 
-7 (Stennicke et al., 1998), which execute apoptosis by substrate cleavage (Figure 
A.5.) 
A.1.3.1.3.  Caspases and execution of apoptosis in the 
extrinsic pathway 
 
The caspases that bind the adaptor proteins of the DISC are called initiator 
(or activator) caspases and comprise caspases-8 and -10 (Ashkenazi, 2008; 
Budihardjo et al., 1999). All caspases involved in apoptosis in a physiologically 
normal cell are present as inactive precursors (“pro-caspases”) which, when 
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brought into close proximity of one another, are, due to the low intrinsic protease 
activity possessed by pro-caspases, able to cleave each other to form a large and 
small subunit that associate as tetramers to make up the active form of the 
enzyme. Once activated, the caspases can go on to cleave other pro-caspase 
molecules into their active states. Active caspases are thus able to activate even 
more caspases to ultimately result in a caspase cascade (Budihardjo et al., 1999; 
Elliott & Elliott, 2009; Kiechle & Zhang, 2002; Mancini et al., 1998). 
Activated initiator caspases proceed to cleave and activate a group of 
caspases known as effector caspases (e.g. caspases-3, -6, and -7). These effector 
caspases can also cleave and activate further caspases, to enhance the caspase 
cascade (Ashkenazi, 2008; Budihardjo et al., 1999; Mancini et al., 1998). Effector 
caspases are able to process key proteins such as ICAD (inhibitor of caspase 
activated DNase), thereby facilitating DNA degradation by caspase-activated 
DNases (CAD), and cleaving intermediate filament proteins, which generate 
nuclear lamins that are involved in the composition of the cytoskeleton, ultimately 
producing the cellular phenotype of apoptosis (McConkey et al., 1996; Mow et al., 
2001; Nicholson & Thornberry, 1997). 
A.1.3.2.  The intrinsic pathway of apoptosis induction 
As its name suggests, the intrinsic pathway or the mitochondria-dependent 
pathway of apoptosis is initiated from an organelle within the cell. This is usually in 
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response to cellular signals resulting from irreparable DNA damage, presence of 
toxic levels of oxidative stress, endoplasmatic reticulum stress, growth factor 
deprivation, calcium flux, UV irradiation or treatment with chemotherapeutic 
drugs. All these signals converge on mitochondria (Figure A.5.) (Green et al., 2004) 
for the induction of mitochondrial outer membrane permeabilisation (MOMP 
(Green & Kroemer, 2004)). 
For years mitochondria have solely been considered a chemical 
powerhouse and a cellular compartment that hosts several biosynthetic and 
biodegrading pathways. It still is the organelle where the vast majority of ATP is 
produced. So its role in the survival of the cell is considered critical. Now this 
organelle is also regarded as the major player in the intrinsic pathway of 
apoptosis. Proteins that are involved in the respiratory chain are major players in 
the apoptotic machinery. Cytochrome c (Cyt-c) or complex II proteins are some 
examples (Lemarie & Grimm, 2011; Lemarie et al., 2011). The architecture of 
mitochondria as revealed through biochemical and electron microscopy studies 
posess a rather complex structure. (Newmeyer & Ferguson-Miller, 2003). Outer 
membrane and intermembrane space proteins proved to be major players in the 
apoptotic machinery such as Cyt-c. During apoptosis, the permeabilisation of the 
OMM often coincides with the reduction of the mitochondrial membrane potential 
(∆Ψm) over the inner mitochondrial membrane (Goldstein et al., 2000). 
Maintaining the ∆Ψm appears now as an important prerequisite for cell survival.  
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 Details of the induction of MOMP will be discussed in later sections, but 
the activation of Bax or Bak seems to be fundamentally required for MOMP. The 
signalling cues for the activation of the intrinsic pathway either directly promote 
Bax/Bak activation or achieve this indirectly by modulating/inhibiting the activity 
of anti-apoptotic Bcl-2 family members, such as Bcl-2 or Bcl-XL (Figure A.5.). 
A.1.3.2.1.  The Bcl-2 family members 
Bcl-2 was first identified as a proto-oncogene by a common translocation in 
human follicular B-cell lymphoma and the overexpression of Bcl-2 in transgenic 
animal models mimicked the human disease (McDonnell et al., 1989; McDonnell & 
Korsmeyer, 1991; Tsujimoto et al., 1985). Unlike other oncogenes that promote cell 
proliferation to produce cancer, Bcl-2 was found to inhibit cell death induced by 
multiple physiological and pathological stimuli (Hockenbery et al., 1990; Kinloch et 
al., 1999; Vaux et al., 1988). There are over twenty Bcl-2 family members identified 
and examples are shown in Table A.3.. The sequence alignment of Bcl-2 family 
members revealed that they share at least one of the possible four conserved Bcl-
2 homology domains (BH domain) and often contain trans-membrane domains 
(TM) at the C-terminus for membrane anchorage (Figure A.4.). Functionally, the 
Bcl-2 family members can be divided into three groups: anti-apoptotic, pro-
apoptotic, and BH3-only pro-apoptotic (Table A.3.). The anti-apoptotic members, 
such as Bcl-2 and Bcl-XL (Boise et al., 1993), contain all four BH domains (BH1, 
BH2, BH3 and BH4 domains, Figure A.4.). The pro-apoptotic members, Bax (Oltvai 
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et al., 1993) and Bak (Chittenden et al., 1995; Farrow et al., 1995; Kiefer et al., 1995) 
for example, contain only three BH domains (BH1, BH2 and BH3 domains, Figure 
A.4.. Lastly, BH3-only members, such as Bim and Bid possess only the BH3 domain 
(Figure A.4.) and act by either suppressing the activity of anti-apoptotic Bcl-2 
family members or by activating/promoting the activity of pro-apoptotic members 
of the Bcl-2 family. 
The founding family member, Bcl-2, is a 26kDa protein localized to 
mitochondria (Hockenbery et al., 1990), the endoplasmic reticulum (ER) and other 
peri-nuclear membranes (Korsmeyer, 1995). It is involved in the maintenance of 
mitochondrial membranes. It balances the interaction between other members of 
Bcl-2 family members such as Bax. Together with other anti-apoptotic Bcl-2 family 
members or with other mitochondrial apoptosis modulators, Bcl-2 works to 
prevent MOMP and the release of cytochrome c from mitochondria, and thereby 
promotes cell survival. 
On the contrary, pro-apoptotic members promote the release of cytochrome c 
from mitochondria, and this decision is regulated by the ratio between anti-
apoptotic and pro-apoptotic Bcl-2 members present in the cell (Danial & 
Korsmeyer, 2004). Bax was the first pro-apoptotic member of Bcl-2 family to be 
identified through its interaction with Bcl-2 (Oltvai et al., 1993). In its inactive state, 
Bax is localized largely in the cytosol as a monomer although some Bax molecules 
are loosely attached to the outer mitochondrial membrane. Upon reception of 
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apoptosis signals, however, Bax undergoes an allosteric conformational change 
and gets inserted into the outer mitochondrial membrane (OMM) (Desagher et al., 
1999). The activated Bax then undergoes homo-oligomerization or hetero-
oligomerization with Bak, another pro-apoptotic Bcl-2 member (Gross et al., 1998). 
This oligomerization has been postulated to form a pore to allow the release of 
inter-membrane space (IMS) proteins (discussed later in detail). The double 
knockout of Bax and Bak makes cells resistant to almost all death-stimuli for the 
intrinsic pathway of apoptosis (Lindsten et al., 2000; Wei et al., 2001) and hence, 
these two proteins constitute a required gateway for the intrinsic pathway to be 
operative in mitochondria (Wei et al., 2001). BH-3 only members trigger apoptosis 
in response to various stimuli by acting as upstream sentinels, which selectively 
respond to specific signals by first receiving the death signals and transmitting 
them to other members of Bcl-2 family proteins (Cheng et al., 2001).  
 
 
Anti-apoptotic members 
Bcl-2 Bcl-XL Bcl-W Bfl-1 Boo/Diva Mcl-1 Bcl-B 
Pro-apoptotic members 
Bax Bak Bok Bfk Bcl-Xs 
BH3-only pro-apoptotic 
Bim Bik Bad Bmf PUMA NOXA Nip3 Bid 
Table A.3. The Bcl-2 family members 
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BH4 BH3 BH1 BH2 TM 
BH3 BH1 BH2 TM 
Anti-apoptotic 
Bcl-2, Bcl-XL 
Pro-apoptotic 
Bax, Bak 
BH3 TM 
BH3 
Pro-apoptotic BH3-only 
Bim, Bik 
 
 
Bid, Bad, Bmf, PUMA 
Figure A.4. Bcl-2 family members. The Bcl-2 family members can be divided 
into three functional groups: anti-apoptotic, pro-apoptotic and pro-apoptotic 
BH3-only. Their functions vary but at least one of the Bcl-2 homology domains 
(BH domains) is present in all members. Anti-apoptotic members contain all 
four BH domains (BH1,2,3 and 4) whereas pro-apoptotic members possess only 
three BH domains (BH1,2 and 3). Many family members also contain a trans-
membrane domain for membrane anchorage. Bcl-Xs contains a BH3 and BH4 
domain and NOXA contains two BH3 domains. Mcl-1 contains only BH1 and 
BH3 domains. 
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A.1.3.2.2.  The intrinsic pathway and commitment to 
apoptosis 
Following the activation of Bax and the induction of MOMP, several pro-
apoptotic proteins are released from mitochondria into the cytosol (Figure A.5.), 
These include endonuclease G (endoG), Omi/Htra2, apoptosis inducing factor 
(AIF), Smac/Diablo (second mitochondria-derived activator of caspases), and most 
importantly cytochrome-c (Halliwell & Gutteridge, 2007; Leung & Halestrap, 2008; 
Liu et al., 1996a; Pereira et al., 2007). AIF translocates to the nucleus and brings 
about apoptosis in a caspase-independent manner by causing chromatin 
condensation and DNA fragmentation (Kang et al., 2010). Smac/Diablo is believed 
to act by inhibiting the activity of caspase through blocking proteins belonging to 
the inhibitors of apoptosis (IAP) family (Adrain et al., 2001; Halliwell & Gutteridge, 
2007). Released cytochrome-c forms a complex comprising itself, an adaptor 
protein called “apoptotic proteinase activating factor-1” (Apaf-1), procaspase-9, 
and ATP as a heptamer known as the apoptosome. The apoptosome is capable of 
activating caspase-9 (Acehan et al., 2002; Li et al., 1997; Srinivasula et al., 1998). 
Caspase-9 can then cleave effector caspases -3, -7 and -6, in a similar way as the 
initiator caspases of the receptor-mediated pathway, and initiate a caspase 
cascade leading to apoptosis (Adrain et al., 2001; Beurel & Jope, 2006; Brown & 
Borutaite, 2008; Halliwell & Gutteridge, 2007; Kang et al., 2010). 
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MOMP can also occur in a manner independent of Bax activation, namely 
through the opening of the permeability transition pore that will be extensively 
discussed later. 
A.1.3.2.3.  Bid connects the extrinsic and intrinsic pathway 
The extrinsic and intrinsic pathways of apoptosis are initiated in a 
fundamentally distinct manner. Thus, the two pathways were thought to be 
completely separable. However, they both depend in their execution on effector 
caspases activation. The knockout of either caspase-8 (Varfolomeev et al., 1998) or 
FADD (Yeh et al., 1998) abrogates the responses mediated by death receptor 
ligand-induced apoptosis whereas the mitochondrial pathway of apoptosis 
remains intact. Conversely, the knockout of either Apaf-1 (Cecconi et al., 1998; 
Yoshida et al., 1998) or caspase-9 (Hakem et al., 1998; Kuida et al., 1998) abolishes 
apoptosis induced by stimuli affecting the intrinsic pathway like cell stress but the 
cells still execute apoptosis through death receptor ligands. A controversy arose 
when expression of Bcl-2 was found to alleviate Fas-induced apoptosis (Scaffidi et 
al., 1998). This led to the consideration that mitochondrial Bcl-2 family members 
may be involved in the extrinsic pathway. It was later found that a BH3-only 
protein, named Bid, bridges the two pathways. Recruitment and the activation of 
procaspase-8 in the DISC complex provides sufficient concentration of activated 
caspase-8 for the execution of apoptosis in certain cell types (type I cells). 
However, in type II cells activation of caspase-8 in the DISC complex is insufficient 
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to fully induce apoptosis and requires the presence of Bid. Bid is a substrate of 
caspase-8 (Gross et al., 1999; Li et al., 1998; Luo et al., 1998) and the truncated Bid 
(tBid-after activation from caspase-8) translocates to mitochondria where it 
triggers the release of Cyt-c by interacting with Bax (Figure A.5.) (Desagher & 
Martinou, 2000; Eskes et al., 2000; Zamzami et al., 2000). This promotes the 
formation of the apoptosome and the activation of procaspase-9. The ectopic 
expression of Bid was also found to enhance the activation of procaspase-3 
induced by TNF indicating the importance of Bid in linking the extrinsic and the 
intrinsic pathways of apoptosis (Luo et al., 1998) 
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Figure A.5. Overview of extrinsic and intrinsic apoptosis pathways.  
Receptor-mediated extrinsic pathway  
Upon binding of TNF to the TNF-R1, SODD dissociates and the receptor forms 
either complex I or complex II. Complex I consists of TNF-R1, TRADD, TRAF2 and 
RIP. It can either activate NF-κB, recruit RAIDD to activate procaspase-2 or activate 
the JNK pathway. USP2a levels are important for the decision of formation of 
complex II. The latter is constituted of TNF-R1, TRADD, FADD and either pro-
caspase 8 or -10. These caspases are activated at this complex. The ligation of Fas-
L to the Fas-R results in the homo-trimerization of Fas-R and recruitment of FADD 
along with the pro-caspases-8 or -10. Those group together to form the DISC 
where procaspases-8 or -10 are activated and in turn they activate downstream 
caspases.  
Mitochondria-mediated intrinsic pathway  
Cellular stress such as DNA damage, calcium influx, UV irradiation, 
chemotherapeutic drug treatment, growth factor deprivation, ischemia or ER-
stress, signal to BH3-only members of the Bcl-2 family. They either supress the 
anti-apoptotic Bcl-2 family proteins or promote the activation of Bax to induce the 
permeabilisation of the outer mitochondrial membrane. The permeabilisation 
occurs either by Bax forming pores or via the activation of the PT-pore. Both lead 
to the rapture of the OMM and release of pro-apoptotic proteins from the 
mitochondria intermembrane space such as cytochrome-c, AIF, endonuclease G or 
Smac/DIABLO. Released cytochrome-c forms a complex with Apaf-1 and pro-
caspase-9 that is termed apoptosome where caspase-9 is activated and alone or 
through caspases3/7 lead to apoptosis. 
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A.1.3.3.  Alternative forms of cell death  
As mentioned earlier, classic apoptosis is defined by biochemical and 
morphological changes which include caspase activation, mitochondrial 
dysfunction, membrane blebbing, and DNA fragmentation. There are, however, 
some forms of cell death that cannot easily be categorised. An irreversible 
inhibitor of caspases (zVAD-fmk), that binds to the catalytic site of a caspase 
through an aspartate residue by mimicking the cleavage site and a fluoromethyl 
ketone (fmk) group forming a covalent inhibitor-enzyme complex (Thornberry et 
al., 1994), should be able to inhibit all apoptotic pathways. However, not all cell 
death pathways are inhibited by this compound. Ectopic expression of Bax without 
another death stimulus triggers cell death leading to the breakdown of 
mitochondrial function (loss of membrane potential, release of Cyt-c, AIF and 
other pro-apoptotic proteins), which was reported not to be inhibited by zVAD-
fmk (Xiang et al., 1996). Moreover, other proteases like granzymeA/B, cathepsins 
and calpains, seem to play a role in apoptosis (Johnson, 2000; Leist & Jaattela, 
2001). Caspase-independent apoptosis is thus triggered by these proteases with 
many apoptotic characteristics still present.  
Upon MOMP apoptosis inducing factor (AIF) is released from mitochondria. 
As mentioned before, AIF translocates to the nucleus when released and induces 
chromatin condensation and DNA fragmentation (Susin et al., 2000). This process 
is also promoted by another inner mitochondrial protein, endonuclease G, which 
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likewise translocates to the nucleus upon its release (Li et al., 2001). This apoptotic 
function is pivotal for mouse morphogenesis during embryoid body cavitation 
(Joza et al., 2001). Of note, this death-inducing pathway also cannot be inhibited 
by zVAD-fmk (Green & Reed, 1998; Vermeulen et al., 2002; Xiang et al., 1996). 
Virally infected cells are eliminated by T cells and natural killer cells by a 
process of granule exocytosis pathway. The cytotoxic granules deliver a pore-
forming protein, perforin, and a family of serine proteases. These granzymes have 
two isoforms and one of them, granzyme B, is able to activate caspase-3 and -9, 
which leads to the cleavage of Bid and iCAD resulting in apoptosis (Alimonti et al., 
2001). Statins can induce apoptosis via activation of caspases but without the 
release of cytochrome c but with Smac and Omi/HtrA2 (Ghavami et al., 2010). 
Calpains represent another example of cell death proteases that initiate a type of 
cell death that is difficult to be classified with the known characteristics of 
apoptosis. It is known that calpains share some substrates of caspases but the fine 
line between necrotic and apoptotic cell death resides in the balance of these 
cysteine proteases (Harwood et al., 2005). During development and in neuronal 
cells, another type of cell death is observed. It is termed “paraptosis” and it is 
characterised by vacuolation and mitochondria swelling (as observed in necrosis) 
but also it requires energy and new protein synthesis (as observed in apoptosis). 
Although caspase 9 is required for paraptosis, its function is different between 
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apoptosis and paraptosis since BAF (Boc-Asp(O-methyl)CH2F) caspase inhibitor is 
incapable of inhibiting caspase 9 during paraptosis (Sperandio et al., 2000). 
A.1.3.4.  The mitochondrial membrane potential 
Permeabilisation of the OMM leading to a loss of ∆Ψm is regarded as a 
critical event in the mitochondria-mediated apoptosis pathway, but whether loss 
of ∆Ψm is the decisive mechanism for apoptosis induction or a consequence is still 
under intense investigation. There are two significant ways in which loss of ∆Ψm 
can take place (Green & Kroemer, 2004). Bax proteins can associate with the OMM 
and form pores that lead to its permeabilisation as well as sequester Bcl-2 
proteins, which suppress apoptosis thereby contributing towards the initiation of 
the disruption of the OMM, and ultimately the release of pro-apoptotic factors 
into the cytoplasm (Beurel & Jope, 2006; Green & Kroemer, 2004; Kiechle & 
Zhang, 2002) Beurel & Jope, 2006). Another route for the loss of ∆Ψm is through 
the activation of the mitochondrial permeability transition pore complex (Grimm & 
Brdiczka, 2007). 
A.1.3.4.1.  Dissecting the molecular mechanism of MOMP  
The mitochondria have been presented so far in this thesis as pivotal 
organelles for the intrinsic pathway of apoptosis. One of the key regulatory events 
in the mitochondria-dependent apoptosis pathway is the mitochondrial outer 
membrane permeabilisation (MOMP), which results in the release of proteins from 
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the intermembrane space (IMS) of mitochondria (Kroemer et al., 2007) with Cyt-C 
being an example. The MOMP is regarded as the “point of no return” in the 
cascade of events leading to apoptosis (Kroemer & Reed, 2000) and precedes 
apoptotic cell death both in vitro (Zamzami et al., 1995a) and in vivo (Zamzami et 
al., 1995b). The molecular mechanism of OMM permeabilisation remains not fully 
understood, although it has been observed universally during apoptosis. As 
mitochondria release all of their Cyt-c within minutes following the apoptotic 
stimulus in a temperature-independent manner, it was thought that an enzymatic 
transport is not involved in this process (Goldstein et al., 2000). It is now widely 
accepted that an enzymatic process of transport is not responsible since the 
transporter proteins of the pore do not function as such but become unspecific 
channels. There are now two dominant theories to explain the mechanism of 
MOMP. One involves the pro-apoptotic Bcl-2 family member proteins, Bax and 
Bak, and their oligomerization and insertion into the OMM to form a pore (see 
above). The other theory involves a mega-protein complex known as permeability 
transition (PT) pore that connects the inner and outer mitochondrial membranes 
and is converted into an unspecific channel to allow membrane permeabilisation. 
A.1.3.4.2.  Bax oligomerization and pore formation   
Structural similarities of Bcl-2 family members with bacterial toxins that get 
inserted into the membrane were the initial reason why Bcl-2 family members 
were thought to be involved in MOMP (Suzuki et al., 2000). It was made clear later 
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that they are indeed major regulators of MOMP (Kroemer, 1997; Susin et al., 1996; 
Vaux & Korsmeyer, 1999; Wei et al., 2001): Anti-apoptotic members of Bcl-2 family 
were shown to prevent the release of Cyt-c from mitochondria indicating that Bcl-
2, regulates the integrity of the OMM (Gross et al., 1999; Kluck et al., 1997; Yang et 
al., 1997; Zamzami & Kroemer, 2001). On the contrary, pro-apoptotic members of 
the Bcl-2 family, such as Bax or Bak, were reported to induce Cyt.-c release (Rosse 
et al., 1998). In healthy cells, Bax is localized mainly in the cytosol as a non-active 
monomer but there are some Bax molecules loosely attached to mitochondrial 
membrane (Hsu et al., 1997; Wolter et al., 1997). It was discussed earlier that upon 
an apoptotic stimulus Bax undergoes an allosteric conformation, which is required 
for a Bax-induced MOMP (Antonsson et al., 2000; Desagher et al., 1999). This 
activated form of Bax is then believed to homo-oligomerize to create selective 
protein-permeable pores (Figure A.6.) that allow Cyt-c to be released into the 
cytosol (Dewson & Kluck, 2009). Bax activation possibly coincides with Bak 
activation, which exists inserted into the OMM in healthy cells (Griffiths et al., 
1999) and likewise undergoes an allosteric conformational change so it becomes 
activated to homo-oligomerize contributing to the pore formation (Green, 2005; 
Mikhailov et al., 2003). Growing evidence allows supports that the BH3 domain of 
Bax and/or Bak is exposed and the oligomerization takes place between BH3 and 
the hydrophobic groove of another activated Bax or Bak molecule (Dewson & 
Kluck, 2009). This pore allows proteins in the IMS to be released into the cytosol 
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without affecting the function of the inner mitochondrial membrane (IMM) and/or 
the mitochondrial matrix. However, how these factors, especially Bax, “find their 
way” to the OMM or how they interact with the OMM to form a macromolecular 
protein-permeable pore remains an on-going conundrum. It is possible that the 
lipid-protein interaction is important (Lucken-Ardjomande & Martinou, 2005; 
Zamzami & Kroemer, 2003) and it is also possible that Bax or Bak do not form a 
pore but simply destabilize the lipid bilayers instead (Basanez et al., 2002). 
Transgenic double knockout Bax/Bak -/- cells are resistant to apoptosis 
induced by UV irradiation, staurosporin (STS), growth factor deprivation, 
etoposide, and ER stress by thapsigargin and tunicamycin (Wei et al., 2001). 
Ectopic expression of anti-apoptotic Bcl-2 proteins can likewise inhibit the 
apoptosis induced by overexpression of BH3-only proteins (Gross et al., 1999), 
which induce apoptosis via Bax or Bak. Vesicles composed of purified 
mitochondrial outer membranes can be permeabilized in response to the activated 
form of recombinant Bax and vesicles made of mitochondrial lipids without the 
presence of any mitochondrial proteins were permeabilized by the introduction of 
recombinant monomeric Bax in the presence of Bid or Bid-derived BH3 peptide 
(Antonsson et al., 2000; Eskes et al., 1998; Jurgensmeier et al., 1998; Narita et al., 
1998).  
Bcl-2 family members are very important for the regulation and initiation of 
MOMP as explained above. Yet, more signals contribute to MOMP upstream of 
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Bcl-2 members. Bim, Bid and PUMA which are BH3-only proteins directly associate 
with Bcl-2 family and act upstream of Bax or Bak activation, whereas Bad or Bik 
inhibit the activity of anti-apoptotic Bcl-2 therefore favouring the process of 
MOMP (Cheng et al., 2001; Kuwana et al., 2002; Letai et al., 2002). There are other 
non-Bcl-2 family proteins that possess similar properties. The tumour suppressor 
p53 regulates the expression of BH3-only members such as Puma and Noxa by 
certain stimuli (Vousden & Lu, 2002), and Puma-deficient cells display resistance to 
p53-induced apoptosis (Jeffers et al., 2003). However, p53 can also trigger MOMP 
and apoptosis in the absence of its transcription factor activity through direct 
activation of Bax (Chipuk et al., 2004) or Bak (Leu et al., 2004). Additionally, many 
other nuclear proteins function in the cytosol leading to MOMP. An example is 
histone 1.2, which is released upon X-ray-induced DNA damage and can trigger 
apoptosis (Konishi et al., 2003). Hexokinases, which reside in the cytosol can 
interact with VDAC, and this interaction can inhibit the MOMP induced by Bax 
(Majewski et al., 2004a). VDAC-Hexokinase interaction will be extensively covered 
in other sections of this study. 
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A.2.  The mitochondrial permeability 
transition pore (PTP) 
In late 80s research conducted on calcium (Ca2+) led to the discovery of the 
permeability transition (PT) concept (Hunter et al., 1976). It was observed that Ca2+ 
addition to isolated mitochondria led to a transition of mitochondria with an 
increase in the permeability of the inner mitochondrial membrane (IMM). This led 
to matrix swelling and eventually to a catastrophic collapse of the mitochondria 
membrane potential (∆Ψm) and the shutdown of the energy synthesis. Patch-
clamp experiments showed that a megachannel or PT-pore as it was named, 
mediated high conductances, which were attenuated by cyclosporine A (CsA), 
Mg2+ and adenosine di-phosphate (ADP). However, the same molecules could 
inhibit the effects observed on isolated mitochondria after calcium administration. 
This observation lead to the proposal that the megachannel was responsible of the 
Ca2+-dependent permeability transition (Broekemeier et al., 1989; Petronilli et al., 
1989; Szabo & Zoratti, 1991, 1992). 
The PTP complex is composed of several, albeit not clearly defined, 
proteins. It is currently believed that the major PTP complex consists of “voltage-
dependent anion channel” (VDAC), an OMM protein; “adenine nucleotide 
translocator” (ANT), which spans the IMM; and “Cyclophillin D” (CypD), which 
associates with ANT and resides in the matrix (Figure A.6.) (Beutner et al., 1996; 
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Crompton et al., 1998). In addition, hexokinase-II (HK), peripheral benzodiazepine 
receptor (PBR) associate with the OMM and creatine kinase1 (CK1) is localized in 
the IMS, all of which have been reported to interact with the PTP complex (Verrier 
et al., 2004). The above mentioned PT-pore components constitute the classical 
PT-pore although the exact composition of the PTP is still the subject of scientific 
debate, since there are several reports that describe contradictory information 
about the composition of the pore. Nevertheless, the classical PT-pore fits the 
results of the present study and further insight will be given at later chapters.  
Irrespective of any dispute on the pore composition there is agreement on the 
localisation of this structure at contact sites between the outer and the inner 
mitochondrial membrane (Brdiczka, 1991; Crompton, 2000). A consensus on the 
approximate size of this megachannel also exists with the PTP being a multi-
protein complex of 600 kDa (Beutner et al., 1996; Faustin et al., 2004). PTP proteins 
can also be part of other sub-complexes that control energy metabolism or 
initiation of cellular death (Crompton et al., 2002; Zoratti et al., 2005). The outer 
mitochondrial membrane has a semi-permeable nature due to VDAC which allows 
the passage of small solutes of up to 1.5kDa allowing the exchange of respiratory-
chain substrates such as NADH, FADH, and ATP/ADP between the IMS and the 
cytosol. In contrast, the IMM is almost impermeable and this sustains an 
electrochemical proton gradient (∆Ψm) by the oxidative phosphorylation by 
complex I to IV of the respiratory chain (Colombini, 1983; Mitchell & Moyle, 1965a, 
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b). Under physiological conditions, ∆Ψm ranges between 120 to 180mV, with the 
intra-mitochondrial side being negative. This polarization attracts lipophilic cations 
and they accumulate at 100 to 1000 fold higher concentration in the matrix than in 
cytosol. As a result, several different cationic fluorochromes are employed to 
measure the ∆Ψm (Castedo et al., 2002). 
A.2.1.  PT-Pore under physiological conditions 
It is common knowledge that the mitochondria are the energy factories of 
every cell and in order to maintain the normal functions such as the ∆Ψm, the 
biosynthesis of molecules and the movement of metabolites, mitochondria have 
to be tightly controlled. ADP/ATP channelling is one of the main functions of the 
PT-pore. Matrix, IMS and cytosol are all compartments that are involved in this 
process including ANT and VDAC. CK and hexokinase are feeding this process 
according to cellular energy demand (Brenner & Grimm, 2006). 
The pool of adenine nucleotides, the matrix pH, the redox state and the 
∆Ψm are all parameters that need to be controlled and in turn regulate the 
physiological function of the PT-pore (Halestrap et al., 1997). A transient 
permeability of the IMM to protons, water and solutes can stabilise the 
mitochondria homeostasis under certain conditions but more extended alterations 
can also affect the cell fate by changing the physiological function of PT-pore (Le 
Bras et al., 2005). 
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A.2.2.  PT-Pore under apoptotic/necrotic conditions 
Cellular stress such as excessive production of reactive oxygen species 
(ROS) or the deregulation of calcium homeostasis lead to the opening of the PTP 
(Bernardi, 1999; Duchen, 2000; Zoratti & Szabo, 1995). Persistent PTP opening 
initiates a bioenergetic crisis accompanied by depletion of ATP, calcium 
deregulation and influx of solutes and H2O. Ultimately, these changes result in the 
loss of the mitochondrial membrane potential (∆Ψm), a distorted balance of 
osmotic pressure leading to swelling of the mitochondrial matrix and cristae 
remodelling (Figure A.6.) (Kroemer & Reed, 2000; Susin et al., 1998). The matrix 
swelling induces the swelling of the IMM and finally the rupture of the OMM 
leading to the release of IMS proteins such as Cyt-c and AIF (Figure A.6.), resulting 
in the loss of mitochondrial structure and functional integrity (Green & Kroemer, 
2004; Zamzami & Kroemer, 2001). Apoptosis through calcium-mediated 
mitochondrial PT has been observed in variety of treatments such as calcium 
ionophores, thapsigargin, neurotoxins, chemotherapeutic agents and pro-
oxidants. Such calcium-mediated apoptosis can often be suppressed by the 
repression of calcium uptake into mitochondria (treatment with ruthenium red or 
its derivative Ru360) or by the inhibition of PTP by cyclosporine A, sangliferin or 
bongkrekic acid (Waldmeier et al., 2002). The opening of PTP does not necessarily 
result in the permeabilisation of membranes. Transient opening (“flickering”) of the 
PTP is physiological and provides mitochondria with a fast calcium release, which 
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helps to regulate calcium homeostasis and signalling thereby preventing the 
induction of apoptosis. Calcium is released from ER and is taken up from 
mitochondria but it can still be released without affecting the mitochondrial 
integrity through the PT-pore “flickering” (Petronilli et al., 1999; Zoratti & Szabo, 
1995). In addition, although the loss of the mitochondrial membrane potential has 
been regarded as one of the characteristics of apoptosis, this - especially if it 
happens only for a short duration - does not necessarily originate from persistent  
PTP opening as many different signals can induce a transient loss of ∆Ψm. As it 
will be discussed later, the duration and the strength of the stimulus determines 
the involvement of PT pore in necrosis or apoptosis (Kroemer et al., 1998). 
It has been proposed that there are three different possibilities about how 
the permeabilisation of the OMM is accomplished in cooperation with the PT pore 
during apoptosis and they all deal with the kinetics of Bax. The first scenario 
proposes that PT-pore opening precedes the Bax translocation from the cytosol to 
the mitochondria (Precht et al., 2005). In the second scenario the PT-pore opens 
only after Bax has translocated to the OMM (Eldering et al., 2004; Weaver et al., 
2005), whereas according to the third scenario Bax and Bak co-operate on the 
OMM forming pores and allowing permeabilisation without the involvement of the 
IMM or the PT-pore (Eskes et al., 1998; Piret et al., 2004). An explanation for the 
difficulty to determine the scenario involved in OMM permeabilisation could lie in 
the different detection sensitivities of the methods used. The detection of one 
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pathway or protein activation is not enough to determine the sequence of events 
since another, more sensitive method can be utilized and the activation of another 
factor or signalling pathway would appear earlier.  
Apoptosis is not the only type of cell death that the PT pore can regulate. 
Numerous examples of cell damage show that the PT-pore is also involved in 
necrosis (Grimm & Brdiczka, 2007). When comparing the energy dependence of 
the apoptosis signals a general conclusion can be drawn: if ATP is involved the cell 
will undergo apoptosis and where energy is not needed the passive, necrotic 
procedure will be activated (Leist et al., 1997). Ischemia of cells with subsequent 
reperfusion represents an instance of PT-pore involvement in necrosis. During this 
process free ADP and Ca+2 increase and the subsequent reperfusion is 
characterised by an imbalance of high intra-mitochondrial substrates for the 
respiratory chain versus low ADP, which in turn leads to superoxide production 
and oxidative stress (Crompton & Costi, 1990). Oxidative stress then activates the 
PT-pore and results in further increase of the free ADP. In agreement with this 
example, cyclosporin A, which is a PT-pore inhibitor, was found to protect 
cardiomyocytes from ∆Ψm collapse and cell death induced by 
ischemia/reperfusion (Grimm & Brdiczka, 2007).  
  Cyclophillin D as a pore component was also seen to be involved in 
necrosis and in some cases the respective experimental procedure determined the 
involvement of cyp-D only in necrosis and not apoptosis. One study (Nakagawa et 
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al., 2005) showed that upon H2O2 administration the PT-pore was involved via cyp-
D and claimed that only necrosis is regulated by PT-pore. On the other hand H2O2 
was also used in a study in which Cyp-D was absent and it was found that 
apoptosis was affected (Baines et al., 2005). The difference in those studies is 
probably due to the different concentrations of the drugs that were used to 
induce cell death. Consequently, the duration and the strength of the signal for 
the induction cell death can determine which type of cell death is induced but 
conclusion for the exclusive involvement of the PT-pore in either of the pathways 
cannot be drawn.  
 Hence, depending on the experimental model, the PT-pore can be 
consequence or cause of the fatal signalling pathway and only after the 
characterization of the cell death type can its real contribution be defined.  
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Figure A.6. Mechanism of MOMP and apoptosis induction.  
Bax/Bak pores (left side). Pro-apoptotic members of Bcl-2 family member, Bax 
and Bak, form a macromolecular protein permeable pore after Bax has been 
activated and translocated to the outer mitochondrial membrane by homo-
oligomerization. The pore allows the egression of intermembrane space proteins, 
such as Cyt-c and AIF. 
PT-pores (right side). The classical permeability transition pore (PTP) complex 
which is comprised of VDAC1, ANT1, cyclophilin D (cyp-D) and Hexokinase, 
regulate the MOMP. In healthy cells (upper panel), PTP complex allows small 
molecules such as NADH and FADH to pass between cytosol and mitochondrial 
matrix. However, upon stress such as calcium influx or ROS production, the PTP 
becomes leaky resulting in the influx of water into the matrix. This causes matrix 
swelling, cristae remodelling and eventually rapture of the OMM allowing pro-
apoptotic proteins to get released into the cytosol. Hexokinases bind to VDAC at 
the OMM and occupy the binding site where Bax can bind. Upon apoptosis, 
hexokinases are released and Bax can bind to VDAC allowing the opening of a 
mega pore which leads in the release of pro-apoptotic proteins from the IMS.  
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A.2.3.  VDAC and hexokinase as PT-pore components and 
modulators 
VDAC was characterized as a hexokinase binding protein at the OMM and 
soon it became apparent that hexokinase I or II bind to the OMM and this binding 
is enhanced via their interaction with VDAC1 (as one of the most abundant OMM 
proteins) (Fiek et al., 1982). Hexokinases are differentially expressed in most  
tissues but in cancer cells hexokinase II (HXKII) is highly overexpressed and bound 
to mitochondria contributing to high tumour glycolysis, also known as the 
Warburg effect (Pedersen et al., 2002). There are four isoforms of hexokinases 
identified so far but HXKI and HXKII are mostly involved in mitochondria binding, 
have greater glucose affinity and possess a 15aa N-terminal sequence that allows 
them to bind to VDAC1 (Azoulay-Zohar et al., 2004).  
Recent studies demonstrate that the VDAC1-HXKII interaction is critical and 
when stabilized, prevents apoptosis induction in tumours (Pastorino & Hoek, 2003; 
Vyssokikh & Brdiczka, 2004). Conversely, disruption of this protein complex can 
induce apoptosis or sensitise tumour cells to cell death (Zaid et al., 2005). 
Hexokinase as an anti-apoptotic molecule promotes the “closed” conformation of 
VDAC, leading to inhibition of Ca+2 –induced apoptosis through the PT-pore.  
(Azoulay-Zohar et al., 2004). Binding of HXKII to VDAC1 restricts the availability of 
free VDAC sites that can interact with Bax and also prevents Bad to associate with 
the OMM and induce apoptosis (Capano & Crompton, 2002; Pastorino et al., 
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2002). Another model of how the VDAC1-HXKII complex affects the PT-pore could 
be through ANT-1. Cyp-D alters the conformation of ANT-1 which in turn alters 
the VDAC1 conformation that allows strong binding of hexokinase so that the 
permeability transition is inhibited and so that ultimately the PT-pore cannot open. 
According to that model the level of Cyp-D and its interaction with ANT-1 
stabilises VDAC1 through enhanced hexokinase binding (Crompton, 1999; 
Machida et al., 2006; Vyssokikh & Brdiczka, 2003).  
As mentioned above, Cyclophillin D (CypD) is a member of the PT-pore 
megachannel localized in the matrix of mitochondria. Overexpression, knockout 
and knock-down studies conclude that CypD appears to be a critical component 
of the PT-pore with anti-apoptotic or pro-apoptotic characteristics (Baines et al., 
2005; Schinzel et al., 2005; Schubert & Grimm, 2004). Recent studies demonstrate 
that mitochondrial binding of HXKII is affected by Cyp-D and the anti-apoptotic 
effects of Cyp-D maybe exerted via the stabilized binding of HXKII to mitochondria 
(Chiara et al., 2008; Machida et al., 2006) thereby contributing to the high 
glycolytic rate that is observed in cancers and enhancing the Warburg effect (see 
below).  
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A.3.  The NF-κB system  
A.3.1.  The inducible transcription factor NF-κB 
The “nuclear factor κ-light-chain-enhancer of activated B-cells” (NF-κB) 
family of transcription factors is expressed in a diverse number of cell and tissue 
types and is understood to play an important role in the inflammatory response 
(Baeuerle & Henkel, 1994; Baichwal & Baeuerle, 1997). NF-κB is in its active state 
dimeric; this can be a homodimer or heterodimer of five known subunits: NF-κB1 
(p50/p105), NF-κB2 (p52/p100), RelA (p65), RelB, and c-Rel (Gilmore, 2006). All the 
subunits possess a structurally conserved region of about 300 amino acids, termed 
the Rel homology domain (RHD), which contains the domains necessary for 
subunit dimerization, nuclear localisation, and also DNA binding. The subunits also 
feature a region called the transactivation domain (TD), which is necessary to 
promote the transcription of target genes. However, two subunits, NF-κB1 and NF-
κB2, when they form homodimers, can only act as repressors of transcription since 
they do not have the TD (Li & Verma, 2002). An example of their ability to 
positively and negatively regulate transcription is exemplified with the KAI1 
metastasis suppressor gene. In this case p50 is converted into a suppressing 
complex with the help of the β-catenin oncoprotein (Kim et al., 2005). All the 
subunits can be classified in two groups. The “NF-κB protein” group contains p50 
and p52, which is generated after removal of the c-terminus of p105 and p100 
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respectively, and the “Rel group” of proteins consisting of p65, RelB and c-Rel. In 
most cells NF-κB dimers are mainly, but not exclusively, composed of NF-κB1 and 
RelA (p50/p65) (Aggarwal, 2000; Bauerle et al., 2010). 
The site were NF-κB transcription factors bind is a highly variable 9-10 base 
pair DNA sequence (κB site) with the following consensus  5’-GGGRNWYYCC-3’ 
where R=A or G, N=any nucleotide, W=A or T and Y=C or T. With the exception of 
RelB, all the subunits from both groups can form homodimers. This high 
combination capacity of the NF-κB subunits gives the cell, dependent on its 
protein expression profile, the ability to activate specific genes since the various 
dimers exhibit differential binding affinities to promoters (Gilmore, 2006)  
In most cells NF-κB is present with its subunits sequestered in the cytosol 
by a family of inhibitory proteins called “inhibitors of κB” (IκB), which will be 
further covered below (Baeuerle & Henkel, 1994; Li & Verma, 2002). In stimulated 
cells a sequence of molecular events take place that lead to the degradation of 
these inhibitory proteins, allowing the NF-κB dimer to enter the nucleus and carry 
out its function as a transcriptional activator or repressor. The cytokines 
interleukin-1 (IL-1) and TNF-α, the latter of which we discussed earlier as being 
involved in apoptosis induction, are two of the most important activators of NF-κB 
(Li & Verma, 2002). In fact, almost every cytokine of the TNF family and also 
chemotherapeutic apoptosis-inducing agents activate NF-κB (Aggarwal, 2000). 
Figure A.7. shows the structural organization of Rel and NF-κB protein families.  
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A.3.2.  Inhibitors of NF-κB  
IκBs are primarily cytoplasmic proteins and function by sequestering and 
maintaining the inactivity of NF-κB (Gilmore, 2006). The IκB family, as the NF-κB 
transcription factor family, has several members such as IκBα, IκBβ, IκBε and Bcl-3, 
all of which are identifiable by the presence of several copies of a structural motif 
known as ankyrin repeat – the motif is involved in protein-protein interactions 
(Hayden & Ghosh, 2012). Different IκBs bind differentially to NF-κB dimers and 
their expression levels also vary in different tissues. From biochemical studies and 
after their structures were determined it became apparent that IκBs are directly 
interacting with NF-κBs by making multiple contacts (Chen & Ghosh, 1999). 
Generally, the contact sites cover the nuclear localization signal (NLS) and 
sequences responsible for DNA binding. 
The general structural organisation of IκBs is shown on Figure A.7. The best 
characterised IκB family member is IκBα (Figure A.8. The structural analysis of the 
IκBα:NF-κB complex revealed that IκBα contains 5 or 6 ankyrin repeats (depending 
on the classification of the sixth ankyrin repeat as independent or as part of the C-
terminus domain of the IκBα protein (Jacobs & Harrison, 1998; Sachdev et al., 
1998b). For this study the five ankyrin repeat structure was followed as described 
in the protein database Uniprot. The IκBα is comprised of three distinct regions: 
The N-terminal regulatory domain for signal dependent degradation, the ankyrin 
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repeat domain and the C-terminal part, which contains a PEST sequence (Haskill et 
al., 1991). 
Bacterial infections, cytokines, or stress signals, all lead to the 
phosphorylation of the N-terminal part of IκBα at position 32 and 36. This 
phosphorylation allows the ubiquitination of the protein at lysines 21 and 22 by 
K48 ubiquitin chains, leading to its proteasomal degradation (DiDonato et al., 
1996; DiDonato et al., 1997; Lee et al., 1997; Lee et al., 1998; Palombella et al., 
1994; Rodriguez et al., 1996; Roff et al., 1996; Scherer et al., 1995). Proteolytic 
removal of IκBα leads to the exposure of the NLS of p65 or similar subunits, which 
in turn allows the translocation of NF-κB into the nucleus. A mutation on residues 
32 and 36 substituting the serines with alanines converts IκBα into a super-
repressor (IκBα-SR) since proteolytic degradation cannot take place and NF-κB is 
permanently inhibited (Van Antwerp et al., 1996).  
The ankyrin repeat domain (ARD) allows the interaction of IκBα with NF-κB 
subunits. For example, there are several contact sites on IκBα that are responsible 
for the interaction with p65 or p50. ANK1 and ANK2 bind to the NLS of p65 
allowing IkBa to adopt the correct conformation to bind to the rest of p65. ANK3 
has the fewest sites for p65 binding and ANK4 and ANK5 also facilitate binding of 
p50 and the dimerization domain of p65 (Jacobs & Harrison, 1998).      
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 72 
 
It is believed that the ankyrin repeats of IκBα bind directly to the NLS of 
only one of the two NF-κB dimer subunits – this is enough to prevent NF-κB’s 
transcriptional activity (Li & Verma, 2002). The NLS of the other, unbound, subunit 
allows entry of an inactive IκBα:NF-κB complex into the nucleus while a nuclear 
export sequence (NES) found on the IκBα molecule at aa45-54, facilitates the 
export of this complex out of the nucleus. In this way a balance is maintained by 
continually shuffling the inactive complexes between the two compartments 
(Baeuerle & Henkel, 1994; Li & Verma, 2002; Turpin et al., 1999). The export 
process has been found to be much more efficient than the import process, 
thereby creating a much higher quantity of the inactive complex in the cytoplasm. 
Mutagenesis of IκBα within the second ankyrin repeat (IκBα-110A3) at residues 
115,117 and 120 render IκBα completely incapable to enter the nucleus in this 
complex and inhibit DNA binding and transcriptional activation (Sachdev et al., 
1998b). The precise reason why a cell would carry out the energy dependent 
process of moving the inactive IκBα:NF-κB complex in and out of the nucleus is 
not clear.  
There are several functions attributed to IκB proteins. In the cytoplasm, IκBs 
prevent the translocation of NF-κB to the nucleus, whereas in the nucleus, IκBα 
can dissociate DNA-bound NF-κB from the DNA and also export the NF-κB back 
to the cytoplasm as an inactive complex (Baeuerle & Henkel, 1994; Ghosh et al., 
1998; Gilmore, 2006; Li & Verma, 2002). Responsible for the dissociation of DNA-
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bound NF-κB is the C-terminal part of IκBα. When in the nucleus, IκBα, through its 
acidic residues at the c-terminus (aa282-308), is able to remove DNA-bound NF-
κB and export it to the nucleus. Deletion analysis of IκBα C-terminus revealed that 
deletion of aa280-317 inactivated the ability of IκBα to inhibit p65, p50 (Hatada et 
al., 1993b) and c-Rel ∆282-308 (Luque & Gelinas, 1998). Deletion of the PEST-like 
sequence within the C-terminus of IκBα completely abrogated the ability of IκBα 
to release NF-κB from the DNA (Ernst et al., 1995). 
Generation of IκBα-/- mice gave further insight into the properties of IκBα. 
These mice show constitutive NF-κB activation, enhanced granulopoiesis and 
neonatal lethality, suggesting IκBα to be the prototype IκB that can primarily 
control the p50/p65 complex (Beg et al., 1995a; Hayden & Ghosh, 2012). TNF 
stimulation of these cells extensively activated the NF-κB pathway and due to the 
absence of IκBα the kinetics of NF-κB termination of transcription was very slow. 
The expression of IκΒβ under the promoter of IκBα reconstituted the kinetics of 
NF-κB signalling (Beg et al., 1995a; Cheng et al., 1998; Klement et al., 1996). The 
mechanism by which IκBα and other IκBs control the NF-κB response became 
more complicated through the finding that the model of cytoplasmic 
sequestration is only partially true since the absence of IκBα, IκΒβ and ΙκΒε does 
not alter the distribution of p65 between cytosol and nucleus but confirmed that 
stimulus-dependent NF-κB activation requires the above mentioned IκBs 
(Tergaonkar et al., 2005). 
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Figure A.7. Structural organisation of NF-κB and IκB proteins. Members of the 
NF-κB, and IκB families are shown. NF-κB family members form dimers with the most 
abundant being the p50/p65 heterodimer. p65 has a strong transactivation domain 
(TAD) and is responsible for most of NF-κB’s transcriptional activity. p50/p65 and p50/c-
Rel dimers are regulated by IκBs which cause their retention in the cytosol. All NF-κB 
proteins contain a Rel-homology domain (RHD) which mediates their dimerization and 
binding to the DNA. IκBs trap NF-κB proteins by masking the NLS which is within the 
RHD. Activation of NF-κB requires the proteolytic degradation of IKBs via their N-
terminal region which contains sequences prone to ubiquitination. PEST sequences are 
acidic and are required for the inhibition of NF-κB from DNA binding. GRR: glycine-rich 
region; LZ: leucine zipper domain; DD: death domain. On the right the amino-acid 
sequence length is shown.    
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A.3.3.  Activation of NF-κB 
There are two well-established pathways for NF-κB activation and a novel 
third pathway, which comprises a distinct processing of the NF-κB proteins. 
Although their importance is unquestionable, the analysis for the current thesis 
will focus on the so-called canonical NF-κB activation pathway.  
 NF-κB activation is accomplished by stimuli that degrade IκBα. 
Phosphorylation of IκBα proteins and subsequent ubiquitination, targets them to 
the 26s proteasome and the IKK complex is primarily involved in this 
phosphorylation process (Karin & Ben-Neriah, 2000). The IKK components are 
IKKα and IKKβ and the NF-κB essential modulator (NEMO) or IKKγ. ΙΚΚα and ΙΚΚβ 
form homo or hetero-dimers however, IKKβ is mostly involved in the canonical 
pathway to phosphorylate IκBα (Delhase et al., 1999). NEMO is a scaffold, sensing 
protein that binds IKKα or IKKβ and amplifies the signal transduction pathway of 
kinases to phosphorylate IκBα (Hayden & Ghosh, 2012). The distinction between 
the canonical and non-canonical pathways is made by the requirement of NEMO. 
In the non-canonical pathway an upstream inducing kinase (NIK) activates IKKα 
and signals towards the activation of p100 which is phosphorylated and converted 
into p52 (Hayden & Ghosh, 2012).  
Generally, the two pathways can be activated concurrently but they have 
very distinct regulatory functions (Bonizzi & Karin, 2004; Silverman & Maniatis, 
2001). The activation of the canonical pathway is triggered by activation of 
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Tumour necrosis factor receptors 1/2  (TNFR1/2), T cell receptors (TCR), B cell 
receptors (BCR) and Toll like receptors (TLR). Upon upregulation of transcription of 
genes regulating chemokines, cytokines, adhesion molecules, cell survival and 
inflammatory responses, the canonical pathway shuts down. On the other hand 
the non-canonical pathway is triggered by activation of specific TNF receptor 
family members like LTβR (lymphotoxin β receptor), BAFF-R (B cell activating 
factor), CD40 or CD30. This pathway is controlling development of lymphoid 
organs and adaptive immune system (Gilmore, 2006; Hayden & Ghosh, 2004, 
2008, 2012). 
The above mentioned third mechanism of NF-κB activation does not 
necessarily result in the degradation of the NF-κB inhibitory protein and involves 
NF-κB kinases. IKKα, by itself, possesses NF-κB kinase activity as well as many 
other proteins, which are part of the NF-κB kinase family of proteins are able to 
phosphorylate RelA, in this way causing IκB dissociation but not ubiquitination 
(Hayashi et al., 1993). 
A.3.4.  Feedback loops and termination of NF-κB  
Active NF-κB in the nucleus promotes the transcription of several genes 
involved in inflammation, such as cytokines, cytokine receptors, growth factors, 
and adhesion molecules. It was mentioned earlier that pro-inflammatory cytokines, 
e.g. IL-1 and TNF-α, can trigger NF-κB activation; the cytokines expressed by these 
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genes, which make up a number of the NF-κB target genes, result in a positive 
feedback cascade, further enhancing the inflammatory response (Halliwell & 
Gutteridge, 2007). 
To counter the inflammatory cascade, NF-κB can also promote the 
transcription of anti-inflammatory cytokines such as IL-10 to generate a negative 
feedback (Macdonald et al., 2003). An important target gene of NF-κB is IκBα. By 
promoting the expression of one of its own inhibitors the signal is able to 
generate a negative feedback, which is normally sufficient to turn itself off. 
However, this mechanism does not explain how the active DNA-bound NF-κB is 
diminished once signalling is terminated. Newly synthesised IκBα can, in the 
nucleus, dissociate NF-κB from the DNA to stop the transcriptional activation of 
target genes and also, in the cytoplasm, sequester active NF-κB dimers to again 
inactivate them, as described earlier. However, p65, IKKα, suppressor of cytokine 
signalling (SOCS-1) are some of the molecules that can themselves affect the 
termination of the NF-κB response (Hayden & Ghosh, 2008). Efforts are under way 
to further analyse this aspect of NF-κB, which proves extremely important 
especially in diseases that have de-regulated NF-κB (Baeuerle & Henkel, 1994; 
Hayden & Ghosh, 2008; Li & Verma, 2002). 
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A.3.5.  Relation of NF-κB to apoptosis 
NF-κB targets many genes that promote cell proliferation and survival and 
has often been found to be associated with an ability to negatively influence the 
cell’s susceptibility to apoptosis (Aggarwal, 2000; Baichwal & Baeuerle, 1997; 
Bauerle et al., 2010; Clifton et al., 1998; Edderkaoui et al., 2008; Van Antwerp et al., 
1996; Van Antwerp et al., 1998). 
RelA–/– mice, for example, did not live to birth and showed high levels of 
apoptotic cell death in the developing liver, suggesting an anti-apoptotic activity 
for NF-κB (Baichwal & Baeuerle, 1997). TNF-α induced apoptosis is known to be 
variable in its effectiveness in different cell types. This property of the cytokine has 
been attributed to the activity of NF-κB, which we know it also activates (Baichwal 
& Baeuerle, 1997; Beg & Baltimore, 1996; Liu et al., 1996b; Van Antwerp et al., 
1996; Van Antwerp et al., 1998; Wang et al., 1996). NF-κB stimulates the 
transcription of TNF as was already mentioned, but also other anti-apoptotic 
molecules such as cellular inhibitors of apoptosis (cIAPs), caspase 8/FADD-like Ilβ-
converting enzyme inhibitory protein (cFLIP) and members of the Bcl2 family like 
Bcl-XL (Karin et al., 2002; Karin & Lin, 2002). Apoptosis induced by ionizing 
radiation and chemotherapeutics is also attenuated by NF-κB and this ability of 
NF-κB has led several groups to analyse this effect (Wang et al., 1999). Many 
cancers in which NF-κB subunits are highly expressed or NF-κB constitutively 
activated have been shown to become more susceptible to apoptosis when 
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treated with compounds that inhibit NF-κB activation (Edderkaoui et al., 2008). It is 
understood, too that some pathogenic bacteria activate NF-κB in their host cells in 
order to prevent apoptosis and promote cell survival (Clifton et al., 1998). 
With the aforementioned in mind, NF-κB is regarded as an anti-apoptotic 
protein system. Hence IκBα, in its cytoplasmic role as an inhibitor of NF-κB, is 
widely deemed to possess a pro-apoptotic function since it inhibits the anti-
apoptotic NF-κB. 
A.3.6.  Mitochondrial localisation of NF-κB and IκBα  
In recent years it has become apparent that NF-κB subunits and IκBα can 
also be found at mitochondria. Electron microscopy studies revealed that IκBα can 
be identified in all the mitochondrial compartments, the inter mitochondrial 
membrane space (IMS), the matrix and OMM (Bottero et al., 2001; Cogswell et al., 
2003; Lee et al., 2008; Zamora et al., 2004).  Emphasis was given to the IκBα 
localised in the IMS since it was found to be able to interact with ANT1. NF-κB 
subunits were also detected in mitochondria and were also found to negatively 
regulate apoptosis induced by ANT1 overexpression. NF-κB was recruited to 
mitochondria after ANT1 overexpression thereby abolishing its DNA binding, gene 
activation, and contributing to extensive apoptosis (Zamora et al., 2004).   
NF-κB that has been found to be localised to mitochondria and is believed 
to be involved in the regulation of mitochondrial gene expression (Cogswell et al., 
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2003; Lee et al., 2008; Reuther & Baldwin, 1999). However, using mitochondriaLly 
localised IκBα (IκBα when overexpressed is found to be localised in mitochondria 
as well as the cytosol) to block NF-κB activation in mitochondria during TNF-α 
treatment, revealed no reduction in the mRNA levels of proteins encoded by 
mitochondria-specific genes compared to the normal state where a reduction 
occurs when NF-κB can be normally activated (Cogswell et al., 2003). 
The IκBα:NF-κB complex has been found in the IMS, where it is currently 
thought to interact with ANT, one of the components of the PT-Pore and the 
IκBα:NF-κB complex is supposed to have at least some influence on the apoptotic 
cascade (Bottero et al., 2001; Zamora et al., 2004) since it was found that p65 and 
IκBα were released from mitochondria upon Fas-ligand induced apoptosis. 
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Figure A.8. Representation of IκBα. (A) Cartoon representation of IκBα 
domains (blue) which bind p65. Ankyrin repeats and the C-terminus are 
responsible of p65 binding. (B) Structural representation of IκBα binding to p65 
(Bergqvist S et al,. 2009). (C) Important residues and domains of IκBα protein 
A B 
C 
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A.4.  Cancer  
A.4.1.  Cancer and apoptosis 
Cancer is a disease that originates from diverse aetiologies and affects 
equally diverse cell targets, therefore resulting in an extremely heterogeneous 
appearance. Even though this complexity seems to make it daunting to define 
general mechanisms underlying all human cancers, defects in the programmed 
suicide machinery characterise all tumours. This apoptosis inhibition can 
contribute to cell immortality and represents one of the cancer hallmarks 
(Hanahan & Weinberg, 2000). It is supposed to thwart pro-apoptotic signals that 
arise during the transformation process. The discovery of oncogenes such as bcl-2 
or myc and their ability to inhibit apoptosis (Kerr et al., 1972; Strasser et al., 1990), 
initiated the now vast field of apoptosis investigation on cancer, at the molecular 
level. The emerging conclusion is that maintaining the balance of pro-apoptotic 
and anti-apoptotic signals within a normal cell is a fundamental prerequisite for its 
homeostasis. Current research so far suggests that obstructing the apoptotic 
machinery can then dramatically affect the dynamics of tumour progression. 
Moreover, a plethora of data indicate that anti-cancer compounds such as 5-
fluorouracil, cis-platin, and etoposide exert their effect by inducing apoptosis in 
malignant cells (Mow et al., 2001). So, apoptosis can be harnessed for cancer 
therapy. (Barry et al., 1990; Kaufmann, 1989; Walker et al., 1991). During treatment, 
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tumour cells are selected for the repression of this cell death program. In order to 
enhance current drug efficacy and discover more effective treatment options, it is 
essential to unravel how cells attain their insensitivity to cell death signals. 
Therefore, the molecular regulators of anti-apoptotic signalling pathways are 
currently the subject of intense investigation.  
A.4.2.  Cancer and PT-pore 
As mentioned above, the molecular pathways that govern apoptosis are 
pivotal for controlling tumourigenesis, cancer progression, and for cancer 
treatment. One of the molecular complexes that play such a role is the 
aforementioned PT-pore. During tumourigenesis, specific modulators of the PT-
pore are activated hence contributing to tumour formation. Evading hypoxia, 
metastasis, OMM permeabilisation, reactive oxygen species (ROS) formation or 
Ca+2 release are only some of the processes that contribute to carcinogenesis, 
relate to apoptosis and involve the PT-pore (Brenner & Grimm, 2006). 
More specifically, hypoxia is an environmental condition of reduced oxygen 
levels. It is a scenario that all tumour cells experience especially at the initial stages 
of tumour formation and metastasis. Normally, hypoxia constitutes a pro-
apoptotic signal and a stimulus for PT-pore activation. The mechanisms that 
cancer cells use in order to maintain survival under hypoxic conditions are largely 
unknown but inhibition of the PT-pore opening even in low oxygen is a 
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characteristic of cancer cells (Harris, 2002). Hypoxia inducible factor (HIF) and pro-
apoptotic Bcl-2 family members are thought to be involved in the PT-pore 
activation and in normal cells the PT-pore is very sensitive to hypoxia (Kubasiak et 
al., 2002; Vande Velde et al., 2000). 
A cell detached from the main tissue or tumour will, under normal 
conditions, undergo apoptosis in the blood stream through a form of apoptosis 
called anoikis. Tumour cells are able to bypass this process and survive forming 
metastases at a distant site. Anoikis is thought to be controlled by the pro-
apoptotic proteins Bid and Bax that can directly modulate the PT-pore (Valentijn & 
Gilmore, 2004; Valentijn et al., 2003) as described previously. 
Excessive levels of ROS have been shown to induce apoptosis through the 
PT-pore but at normal levels ROS are favouring cell proliferation (Pelicano et al., 
2004; Petronilli et al., 1994). Oxidative stress is caused by elevated ROS levels, 
which all cancer cells generate excessively putting them under permanent 
oxidative stress. It is logical to assume that such high levels of ROS would make 
cancer cells more prone to apoptosis induction but tumours are found to escape 
this signal as well. The PT-pore can be effectively activated by ROS but due to the 
upregulation of antioxidants, tumours are able to evade apoptosis and survive 
under conditions of stress (Brenner & Grimm, 2006; Le Bras et al., 2005). 
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Calcium levels between cell organelles and the balance of Ca+2 should be 
maintained for cell homeostasis. It was mentioned before that the PT-pore is 
extremely sensitive to Ca+2 and under several conditions Ca2+ increases and 
extensive permeability transition occurs leading to the rapture of the OMM and 
subsequently apoptosis. A large number of tumours show resistance to several 
chemotherapeutic drugs that force the release of calcium from intracellular stores. 
Calcium is released from the endoplasmatic reticulum (ER) under conditions of 
oxidative stress (Ermak & Davies, 2002) and, as it was noted before, cancer cells 
are under permanent oxidative stress. As a potent activator of the megapore, Ca+2 
is expected to activate apoptotic signaling extremely efficiently, however, again 
cancer cells seem to manipulate intracellular signalling circuits in order to evade 
apoptosis (Brenner & Grimm, 2006).   
The composition of the PT-pore is still under intense investigation but there 
is a consensus about the proteins that modulate the activation of this 
megachannel. Irrespective of being a component of the pore or a modulator of 
the pore, several proteins are found to mediate anti-apoptotic signals via PT-pore 
inhibition. Hence, protein-protein interactions and protein levels play a pivotal role 
in maintaining cell homeostasis. Cancer cells show differential expression of 
proteins associated with or comprising the pore, thereby contributing to cell 
survival and evading apoptosis. Peripheral Benzodiazepine Receptor (PBR), 
Cyclophillin D (Cyp-D), creatine kinase 1 (CK1) adenine nucleotide translocase 2 
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(ANT2) and hexokinase II are the PT-pore modulators or components that are 
found to be up-regulated in many cancers (Azoulay-Zohar et al., 2004; Baines et 
al., 2005; Bonod-Bidaud et al., 2001; Giraud et al., 1998; Hardwick et al., 1999; Katz 
et al., 1990; Nakagawa et al., 2005; Schubert & Grimm, 2004).  
Summarizing the above, it appears that tumourigenesis is accompanied by 
differential expression of PT-pore components/modulators and coincides with 
processes that inhibit apoptosis through opening of this megachannel. It seems 
that protein-protein interactions in general are absolutely pivotal for controlling 
apoptosis in contrast to cellular processes like the cell cycle that is mainly 
controlled by protein phosphorylation (Brenner & Grimm, 2006). The importance 
of protein levels in complexes should be also applicable to the PT-pore complex, 
which is so important in governing cell death via apoptosis and necrosis 
depending on the stimulus and the protein level of the pore constituents as 
described above. As it can be concluded from the above, the PT-pore appears to 
be a major modulator of apoptosis and since apoptosis evasion is a cancer 
hallmark, the PT-pore should be considered as one of the main determinants of 
cancer formation. 
A.4.2.1.  The PT-pore, the Warburg effect and cancer 
Nobel prize winner Otto Warburg has made a significant contribution to 
the cancer field after he discovered that cancer cells prefer to conduct glycolysis 
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over respiration even under conditions of sufficient oxygen. This high glycolytic 
rate observed in cancer was named the “Warburg Effect”. This effect is so universal 
that cancer imaging in the clinic makes use of the glucose analogue 2-18Fluoro-2-
deoxy-D-glucose in combination with positron emission tomography in order to 
detect primary tumours and metastases (Kroemer & Pouyssegur, 2008). The 
reason for this shift of cancer cells by metabolic reprogramming from oxidative 
phosphorylation (OXPHOS) to glycolysis relies on (1) a reduced dependence on 
oxygen that might be observed before angiogenesis takes place in the tumour, (2) 
a rearrangement of the tumour environment to recycle products of anaerobic 
metabolism, (3) the production of anti-oxidants through nicotinamide dinucleotide 
phosphate (NADPH) and (4) the usage of glycolytic pathway intermediates for 
anabolic reactions (Kroemer & Pouyssegur, 2008).    
Hexokinase catalyses the first step of glycolysis, namely the conversion of 
glucose to glucose-6-phosphate and in highly glycolytic tumours hexokinase II 
(HXKII) is localized at the OMM anchored to VDAC1 (Azoulay-Zohar et al., 2004). It 
is thought that the HXKII bound to the OMM prevents apoptosis via several 
routes, primarily by preventing the activation of the PT-pore through reducing the 
availability of VDAC sites that can bind BAX (Crompton et al., 2002; Pastorino et al., 
2002). It is also thought to prevent the localisation of Bad at the OMM or change 
the formation of the megachannel thus altering the conformation of VDAC and 
ANT (Mathupala et al., 2006). 
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The Akt protein and its signalling is widely accepted as a modulator of the 
VDAC-HXKII interaction through stabilisation of the complex. Akt can inhibit 
apoptosis via strengthening the VDAC-HXKII interaction irrespective of Bax and 
Bak. The VDAC-HXKII complex is now considered as an anti-apoptotic complex 
since it can prevent the activation of Bax and Bak by tBid (Majewski et al., 2004a; 
Majewski et al., 2004b). Another protein that showed that the stabilisation of the 
VDAC-HXKII complex and ultimately the inhibition of the PT-pore is crucial for 
cancer progression and tumour survival is the enterobacterial protein FimA. It was 
shown that FimA can inhibit apoptosis via strengthening the complex between 
VDAC1 and HXKII. It was shown to prevent Bax integration to mitochondria and 
inhibit cytochrome c release. In this study MOMP was inhibited by this interaction 
in human colon cancer cells, providing another link between cancer and the PT-
pore (Sukumaran et al., 2010b) since VDAC and hexokinase are modulators of the 
megachannel. 
Cyclophillin D along with ANT was also implicated in the complex of VDAC-
HXKII. It is thought that ANT, as a modulator of PT-pore, alters its conformation to 
a state so that permeability transition cannot occur. Also cyclophilin D, which is a 
core component of the megapore, can, when overexpressed, prevent pore 
opening and inhibit apoptosis. It is thought that this anti-apoptotic effect of Cyp-
D is due to the binding of HXKII and vice versa and directly correlates with the 
level of association. The way how a matrix component like Cyp-D can affect an 
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OMM associated component of the PT pore, is not known but it is believed that 
through conformational changes of other PT-pore components (Azoulay-Zohar et 
al., 2004; Chiara et al., 2008; Crompton, 1999; Machida et al., 2006; Majewski et al., 
2004b; Mathupala et al., 2006; Pastorino & Hoek, 2008b; Vyssokikh & Brdiczka, 
2003). 
Either by abrogating Bax binding to mitochondria or by changing the 
conformation of pore components or modulators, HXKII binding to VDAC1 is 
inhibiting the formation of the PT-pore and this is a phenomenon observed in the 
majority of cancers. Hexokinase, which was once considered only to mediate 
glycolysis in highly malignant tumours, has now been shown to be one of the 
most important anti-apoptotic effectors upon its binding to VDAC1. 
Understanding the molecular mechanisms that facilitate this interaction will 
provide more effective treatment choices via targeting the PT-pore and cancer 
metabolism since this complex (VDAC-HXK) is considered as cancer’s Achilles’ hill 
(Kroemer & Pouyssegur, 2008; Mathupala et al., 2006). 
A.4.2.2.  Cancer-associated mechanisms and NF-κB  
As already mentioned above NF-κB is a small family of closely related 
proteins that share a sequence domain that is able to bind to DNA and activate 
transcription of a large number of genes involved in the immune response, 
inflammation, and cell survival (Ghosh et al., 1998). A justification for analysing NF-
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κB mechanisms in the context of cancer is to obtain further insight in the already 
established link between NF-κB, apoptosis, the PT-pore and cancer. This study 
attempts to interconnect these major fields so as to provide a basis for targeting 
cancer through NF-κB and the PT-pore.  
The discovery that one of the subunits of NF-κB (p50) is a member of the 
reticuloendotheliosis family (REL) and the fact that v-REL is an retroviral 
oncoprotein, provided the first link between cancer and NF-κB (Gilmore, 1999). 
Moreover, p52 was found to be structurally mutated in myelomas and lymphomas 
and Bcl-3 (a member of the IκB family) was found overexpressed in leukemias. The 
IκBα gene contains deletions and mutations in a set of Hodgkin’s lymphomas and 
c-rel gene is found to be amplified in a number of such malignancies (Courtois & 
Gilmore, 2006). 
Biochemical and translational alterations might also occur along with 
genetic changes. Since NF-κB is a transcription factor controlling hundreds of 
genes, it was found that modification of the transcription of genes affecting 
apoptosis, angiogenesis, growth and proliferation are altered in cancers (Basseres 
& Baldwin, 2006). NF-κB-dependent targets include cytokines, chemokines, cyclin 
D1, anti-apoptotic proteins of Bcl-2 family, matrix metalloproteinases, c-Myc, 
cIAPs, c-FLIP, A20 and many more. The most important link between this 
transcription factor and cancer is that NF-κB has been shown to mediate the 
resistance to apoptotic stimuli (Ravi & Bedi, 2004). Hence, accumulating evidence 
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shows that NF-κB plays a major role in cancer initiation, establishment and 
progression at later stages (metastasis) (Baldwin, 2001; Karin et al., 2002).  
A.4.2.3.  Cancer, apoptosis and NF-κB 
NF-κB can promote the proliferation of cells by the regulation of target 
genes and cancer cells use this ability of NF-κB to proliferate and grow. Cyclin D1, 
which is involved in the cell cycle, is affected by the NF-κB activity directly or 
indirectly by Bcl-3 that potently trans-activates NF-κB through p52 (Karin, 2006; 
Kim et al., 2006b; Westerheide et al., 2001). IKKα is required for the expression of 
cyclin D1 during the development of mammary glands and HIF1 factor depends 
on NF-κB for its upregulation during hypoxia providing a direct link between 
cancer, PT-pore and NF-κB (Jung et al., 2003).  Consistent with the above are 
studies with mouse xenografts that use inhibitors of NF-κB and show a decreased 
growth and proliferation when NF-κB is impaired (Baldwin, 2001; Karin et al., 
2002). 
The link between apoptosis and NF-κB has already been discussed in this 
report. However, it provides the basis for a more direct link between NF-κB and 
cancer since apoptosis evasion is one of the cancer hallmarks. Bcl-2 and Bcl-XL are 
target genes of NF-κB and act on the mitochondrial pathway to inhibit apoptosis. 
Numerous cancers have been found to up-regulate these two genes thus creating 
conditions of robust apoptosis inhibition (Burstein & Duckett, 2003; Dutta et al., 
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2006). Blocking NF-κB by IκBα or transcriptional inhibitors of NF-κB leads to 
extensive apoptosis in many tumours confirming that survival of these cells are 
dependent on constitutive NF-κB activation (Baldwin, 2001; Karin et al., 2002; Kim 
et al., 2006b). Mutation or loss of expression of p53 and Foxo3 (both transcription 
factors) affect cell survival during cancer. Both are targets of NF-κB and also 
activate this transcription factor. NF-κB can supress c-Jun NH2-terminal kinase 
activation and generation of ROS thereby providing another method by which NF-
κB is blocking cell death (Basseres & Baldwin, 2006). Figure A.9. shows a 
representation of NF-κB target genes that affect different stages of oncogenesis. 
A.4.2.4.  NF-κB in cancers and mechanisms of its activation  
Major control points in the pathway of NF-κB activation are the activation 
of the IKK complex, the degradation of IκBα, the formation of p52 from p100, and 
the binding of NF-κB to specific promoters to activate transcription of target 
genes. It was described previously how this pathway is stimulated under 
physiological conditions but the same check points are also used in cancer cells to 
de-regulate NF-κB and escape apoptosis.  
Several reports show that the activation of oncoproteins is affecting the NF-
κB activation pathway. H-Ras and ErbB2 impact on the IKK complex and require 
Rel proteins for their transformation (Arsura et al., 2000). In chronic myeloid 
leukemias the oncoprotein Bcr-Abl is permanently activating NF-κB. The super 
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repressor IκBα–SR can inhibit this thus providing evidence for the dependence of 
these tumour cells on constitutive NF-κB activation by Bcr-Abl (Cilloni et al., 2006). 
Pim-2, Vav, B-Raf and Tax oncoproteins are only few of those drivers of cancer 
formation that were found to directly bind the IKK complex or the IKK scaffold 
protein NEMO and activate it (Basseres & Baldwin, 2006; Hiscott et al., 2006).  
Apart from the oncoproteins directly affecting the activation of NF-κB, 
oncogene-associated pathways and growth factors can also influence the NF-κB 
system. For instance the PI3/Akt–dependent signalling is stimulating NF-κB via 
IKKα and its level affects the tumour progression and cell survival in lymphoid 
malignancies or melanomas (Gustin et al., 2004). Additionally, the IKK complex can 
also be activated by FADD phosphorylation, CK2 and βTRCP1, which are all 
members of signalling pathways that can affect cancer progression and resistance 
in lung adenocarcinomas, breast cancer and pancreatic cancer respectively 
(Basseres & Baldwin, 2006). An example of a growth factor affecting NF-κB 
signalling is the epidermal growth factor (EGF), which can induce the recruitment 
of p65 to specific promoters without subsequent canonical NF-κB signalling and 
thereby affecting tumourigenesis (Sitcheran et al., 2005). 
 Nearly all malignancies include cancer sub-types in which NF-κB is 
constitutively active and the description of specific pathways or proteins that 
confer this would require a review of hundreds of papers and would probably be 
incomplete since the exact mechanisms are still not completely understood. A 
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basis for all those malignancies is that NF-κB contributes to the inhibition of 
apoptosis and thereby to chemotherapy resistance. A few major examples are 
breast cancers, melanomas, pancreatic cancers, and haematological malignancies, 
which provide evidence that NF-κB turned from friend to foe and hence to a major 
culprit for tumourigenesis (Basseres & Baldwin, 2006; Karin et al., 2002; Ravi & 
Bedi, 2004). Cancers with constitutive NF-κB activity are listed in Figure A.10. 
 Figure A.9. Schematic representation of NF-κB-dependent targets which are 
involved in different stages and aspects of tumourigenesis  
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Figure A.10. Constitutive NF-κB activation in human cancers (figure from 
Basseres DS & Baldwin AS, 2006). Representation of several cancers showing 
constitutive and enhanced NF-κB activation. The list is only showing a few types 
since it is currently extended. Many established cell lines are now shown to 
have constitutive NF-κB activation.  
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 96 
 
 
 
 
 
 
 
B.  Objectives and 
Hypothesis 
 
 
 
 
 
 
 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 97 
 
B.1.  Origin of the project 
Determining the mechanisms that underlie the resistance of cancer cells to 
apoptosis induction is important to improve current treatment regimes and to 
reveal novel strategies against cancer. NF-κB is a transcription factor that is 
constitutively active in many tumour cells and protects them from apoptosis by 
inducing the transcription of anti-apoptotic genes. However, because of the 
widespread importance of the NF-κB factor for inflammatory responses, it has 
been difficult to develop NF-κB inhibitors that act specifically in cancer cells and 
do not compromise the immune response in patients.  
Over the years the focus of the laboratory has been signalling of apoptosis 
and the isolation of genetic apoptosis inducers or inhibitors. The finding that ANT-
1 can dominantly induce apoptosis was a success story of our laboratory (Bauer et 
al., 1999). The effect on ANT-1 to induce apoptosis is dramatic given that even 
potent apoptosis inhibitors such as Bcl-XL are virtually unable to overcome the 
strong apoptosis signal of ANT-1 (Schubert & Grimm, 2004). Given that apoptosis 
inhibition is a hallmark of cancer cells (Hanahan & Weinberg, 2000), identification 
of molecules that can inhibit apoptosis are potentially targets for cancer treatment 
provided that the level of these proteins are altered during cancer progression.  
In 2001, Virginie Bottero and colleagues (Bottero et al., 2001) found that 
ANT-1 can interact with IκBα, the inhibitor of NF-κB. There was a direct implication 
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of IκBα in apoptosis since NF-κB subunits were found to be released from 
mitochondria upon Fas ligand binding and also it was found that ANT-1 
immunoprecipitates with IκBα in an overexpression pull-down. That finding was of 
specific importance to the laboratory since potential inhibitors of apoptosis and 
especially ANT-1 was studied. Two other studies revealed that IκBα resides in the 
IMS of mitochondria and it was speculated that is involved in mitochondrial 
apoptosis (Cogswell et al., 2003; Zamora et al., 2004). However, none of the above 
publications could demonstrate a functional role of IκBα and NF-κB in 
mitochondria and no mechanism was identified. The effect of IκBα on apoptosis 
was only indirect and was only put into a context of NF-κB inhibition.  
Dr Foy Osborne initiated experiments (Figure B.1.) in our laboratory that 
could potentially address the question of the role of IκBα in mitochondria. She 
found that IκBα-wt can reduce apoptosis induced by ANT-1 overexpression. The 
inhibitory potential of IκBα was also tested with other apoptosis inducers such as 
arsenic trioxide and TNF and apoptosis reduction was also observed upon IκBα 
overexpression. Consequently, a hypothesis was formulated that IκBα in 
mitochondria can inhibit apoptosis. Overexpression of IκBα was visualized on a 
western blot and fractionation experiments revealed that part of the over-
expressed IκBα is directed to mitochondria. In 2005 another paper was published 
on TRAIL apoptosis with one of the experiments showing that adenovirus-
mediated ectopic expression of IκBα could inhibit apoptosis of TRAIL. However, 
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this result was not discussed as a feature of IκBα itself but rather as related to its 
inhibitor activity of NF-κB.  
The current study was initiated taking into consideration all the preliminary 
results and the literature that existed until then. The aim of the project was to 
identify the role of IκBα in mitochondria in respect to apoptosis regulation. The 
identification of interaction partners was another part of the project’s aim since 
they could provide important information about the mechanism. The results 
section of this thesis provides information and experiments confirming the role 
and the mechanism of IκBα in apoptosis inhibition when associated with 
mitochondria.  
 
 
 
 
 
 
 
 
Figure B.1. Preliminary data for IκBα. HeLa cells were transfected with a 
luciferase vector and a vector for IκBα-wt. Fractionation was performed according to 
standard methods and lysates was loaded on a 10% SDS-PAGE. WT IκBα can inhibit 
apoptosis. HeLa were transfected with either luciferase or IκBα and cells were treated 
with hydrogen peroxide (250µM), arsenic trioxide (10µM) and TNF 20ng/ml with 
cycloheximide (100ng/ml). Apoptosis was assessed 24h post-treatment using PI 
staining and FACS 293T cells were transfected with ANT-1 and IκBα in a ratio 1:1 and 
apoptosis was quantified using PI staining  
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C.1.  Reagents and materials  
The following reagents were purchased from Sigma-Aldrich: 2-
mercaptoethanol (M7522), acrylamide (40% solution, A7168) actinomycin D 
(A1410), agarose (A9539), ammonium persulfate (A3678), ampicillin sodium salt 
(A9518), arsenic trioxide (A1010) bovine serum albumin (BSA, A7906), calcium 
chloride (C7902), clotrimazole (C6019), cycloheximide (C7698), dimethyl sulfoxide 
(D2650), Dulbeco’s modified eagles media (D6429), doxorubicin (D1515), EGTA 
(E4378), etoposide (E1383), faecal calf serum (F7524), glucose (G7021), HEPES 
(H3375), hexamethrine bromide (H9268), ionomycin (I3909), Kanamycin (K1876), 
Luria-Bertani broth (LB, L3022), L-glutamine (G7513), magnesium sulphate 
heptahydrate (63138), menadione (M5625) NP-40 (I3021), phosphate buffered 
saline (D8537) Polybrene® (H9268), propidium iodide solution (P4864), puromycin 
dihydrochloride (p8833), RPMI-1640 (R5886), sodium azide (S8032), sodium 
butyrate (30,341-0), sodium citrate (S1804) sodium deoxycholate (30970), sodium 
pyruvate (S8636), staurosporin (S4400), TEMED (T9281), Triton X-100 (T8532), 
Trypsin-EDTA (T4174), TWEEN® (P5927) and yeast extract (Y1625).  
DAPI (D3571), DiOC6 (D273), blotting filter papers (25mm thickness, 
LC2010) library efficiency® DH5a™ chemocompetent bacteria (18263-012), MAX 
efficiency DH5α (18258-012) non-essential amino acids (11140035)  OPTI-MEM 
(22600134), penicillin/streptomycin (100U/ml and 100µg/ml respectively, 15070-
063), pLenti7.3/V5-TOPO® TA cloning kit (K5310-00) PureLink™ HiPure plasmid 
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filter purification kit (K2100-07), TMRE (T669), were from Invitrogen or Molecular 
Probes (now both under Life Technologies). DNA oligos were also purchased from 
Invitrogen 
The reagents below were purchased from Fermentas (Part of Thermofisher): 
5x protein loading buffer (R0891), 6x DNA loading dye (R0611), 50x TAE buffer 
(#B49), Bradford (500-0006), GeneRuler™ 1kb DNA ladder (SM0314), GeneRuler™ 
1kb plus DNA ladder (SM1334), T4 DNA ligase HC (EL0013, PageRuler™ prestained 
protein ladder (SM1811 or SM0671), ProteoBlock™ protease inhibitor cocktail 
(R1321) and Phusion® polymerase (F530-L). All the restriction endonucleases from 
FastDigest™ series were also purchased from Fermentas. 
0.5M Tris-HCl pH 6.8 solution (161-0799), 1.5M Tris-HCl pH 8.8 solution 
(161-0798), 10x TGS buffer (161-0772) and SDS solution (10% w/v, 161-0416) were 
from Bio-Rad Laboratories; Hyper film™ high performance chemoluminescent film 
(28906837) was from GE Healthcare; PureProteome™ Protein G Magnetic Beads 
(LSKMAGG10) and PVDF membrane (IPVH00010) were from Millipore. 
QuickChange II site directed mutagenesis kit (#200523) and StrataClone 
mammalian expression vector systems (#240230) were from Agilent Technologies; 
potassium chloride (101984) and sodium chloride (10241) from BDH Laboratory 
Supplies; polyvinyl alcohol mounting medium with DABCO (10981) and saponine 
(47036) from Fluka; pAdVantage™ vector (E1711), Wizard SV gel PCR clean-up 
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system  (A9282) and TNT® Quick Coupled Transcription/Translation System (L1170) 
were from Promega; Effectene (301427), Superfect (301307) from QIAGEN.  
GelRed™ nucleic acid gel stain (41002) from Biotium; trypton (0123-17-3) 
was from DIFCO laboratories; TNF-α (520-002-C050) and N-Oleyldopamine (BML-
VR102-0025) from Enzo Lifesciences; LB-agar (852323) from OXOID Ltd.; enhanced 
chemoluminescent reagent (#32106) and mitochondria isolation kit for cultured 
cells (89874) and paraformaldehyde (28908) from PIERCE Thermo Scientific 
C.2.  Cell culture 
HeLa (human cervical carcinoma), MCF7 (Metkar et al., 2003), 293T (human 
embryonic kidney), 293FT (for viral production), MDA-MB-231 cells (human breast 
adenocarcinoma), HCT-116 (human colon carcinoma, gift from Dr Nabil Hajji), MEF 
WT (mouse embryonic fibroblasts), MEF PPiF -/-  (mouse embryonic fibroblasts), 
3T3 (mouse embryonic fibroblasts) and 3T3 IκBα-/- (mouse embryonic fibroblasts, 
gift from David Baltimore/Shengli Hao, California Institute of Technology) were 
cultivated in high glucose (4.5g/L) Dulbecco’s modified eagle medium (DMEM, 
Sigma-Aldrich). PC3 (human prostate cancer), were cultured in RPMI-1640 media 
(Roswell Park Memorial Institute) with HEPES modification (Sigma-Aldrich). Both 
culture media were supplemented with 10% v/v heat inactivated foetal calf serum 
(FCS, Sigma-Aldrich), 2mM L-glutamine (Sigma-Aldrich), 2mM sodium pyruvate 
(Sigma-Aldrich), penicillin (100U/ml, Invitrogen) and streptomycin (100µg/ml, 
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Invitrogen). Cells were cultured in tissue culture flasks or dishes and maintained in 
5% atmospheric CO2 at 37 
oC in a humidified incubator.  
The cell lines with stably down-regulated proteins by Lentiviral shRNA were 
cultured as above in the presence of 1µg/ml puromycin (Sigma-Aldrich).  
Cells were routinely passaged to a new tissue culture dish or flask by 
detaching them with trypsin-EDTA solution (final concentration of 0.05% diluted in 
phosphate buffered saline, Sigma-Aldrich).  
C.3.  Plasmid vectors 
All genes were cloned into mammalian expression vectors with 
Cytomegalovirus (CMV) promoters and U6 promoter for the expression of shRNA.  
The pcDNA3 (Invitrogen) vector was used for the expression of genes into cells. 
pLenti7.3 (Invitrogen) was used for the production of lentiviruses. pLKO.1 (Sigma-
Aldrich) was used for the production of lentiviruses for the expression of shRNA. 
pEGFP-N1 (Clontech), pEGFP-C1 (Clontech) were used for the expression and 
verification of targeting sequences to mitochondria and as intermediate vectors 
for the sub-cloning of mammalian genes. pCMV-SC-CF (Agilent technologies) was 
used to tag a gene with a FLAG®. Apoptosis inducing genes were isolated from a 
genetic screen for apoptosis inducers (Albayrak & Grimm, 2003) and subsequently 
tagged C-terminally with hemagglutinin (HA-tag). Bax-β was purchased from 
Origene into the Myc-DDK-tagged pCMV6-Entry vector. Mammalian expression 
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vectors coding for DsRed-ER, CFP-mito, YFP-mito or GFP-mito were a kind gift of 
Dr Remy Sadoul (INSERM U836, Grenoble, France). IκBα gene FLAG-tagged at the 
N-terminus was previously cloned into pCMV4 mammalian expression vector by 
Dr Foy Osborne. The Super-Repressor-IκBα (SR-IκBα) and IκBα-110A3 were a kind 
gifts from L. Schmitz, Giessen, Germany. The IκBα-110A3 protein contains alanine 
substitutions at leucine 115, leucine 117, and isoleucine 120 in IκBα. The reporter 
plasmid pNFkB-hrGFP was purchased from Stratagene (Agilent Technologies, UK). 
C.4.  Cloning 
Standard molecular biology techniques were used for cloning. Genes of 
interest were cloned either by recombinant PCR, restriction digest cloning, 
INFUSION cloning or TOPO cloning. It should be made clear that wherever IκBα 
gene is fused for targeting to the mitochondria, only the localization sequence 
(targeting) was used for fusion and not the entire gene.  
C.4.1.  Cloning of MCR1-IκBα 
The yeast MCR1 (NADH-cytochrome reductase b5) gene contains a 47 aa 
N-terminal sequence for mitochondrial targeting (Haucke et al., 1997). 
Recombinant PCR was used to amplify and fuse the MCR1 localization sequence 
with the IκBα gene. Primer set 1a was used to amplify 141 bp with the BamHI 
enzyme and a Kozak sequence and the set 1b to amplify the IκBα gene with XbaI 
restriction enzyme sequence. PCR products were mixed and the forward primer 
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from set 1a and the reverse primer for set 1b were used to amplify and fuse the 
sequences. Functionality of the construct was tested and will be analysed further in 
the results section. A C-terminal FLAG-tagged version of MCR1-IκBα was 
generated using primers that contained the FLAG-tag (primer set 1a and 1b). 
C.4.2.  Cloning of MEET-IκBα  
MitoNEET is an outer mitochondrial membrane protein with a very distinct 
and clear OMM localization signal. Primer set 2 was used to amplify only the N-
terminal 32 aa of MitoNEET that are sufficient to target any protein at the OMM 
(Wiley et al., 2007b). pEGFP-N1 vector was digested at HindIII/PstI sites and 
MitoNEET (1-32) was inserted in frame with the following eGFP gene of the vector 
creating MEET-eGFP vector. Primer set 3 was used to amplify IκBα (2-317) –full 
length human IκBα – with restriction sites KpnI and BamHI and 5’ and 3’ end 
respectively. The PCR product was inserted into the MEET-GFP vector in frame with 
MitoNEET (1-32). HindIII and BamHI was used to excise MitoNEET (1-32) and IκBα 
gene fusion and subsequently was inserted into pcDNA3 vector linearized with the 
same enzymes. The latter ligation generated MEET-IκBα. This encodes an IκBα 
protein targeted to OMM.  
C.4.3.  Cloning of S/D-IκBα 
The targeting sequence of Smac/DIABLO gene to the intermembrane space 
(IMS) of mitochondria was used for a fusion with eGFP and also IκBα. Following 
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the same procedure as for MEET-IκBα, the N-terminal 57 aa of Smac/DIABLO were 
amplified with Primer Set 4 and inserted into pEGFP-N1 (Ozawa et al., 2007b). That 
created the S/D-eGFP vector were IκBα was inserted afterwards. The full fusion 
was then inserted into pcDNA3 to create S/D-IκBα that encodes an IκBα protein 
targeted to OMM.  
C.4.4.  Cloning of MCR1(AAQQ)-IκBα  
The MCR1 targeting sequence was found after its discovery that is able to 
direct proteins to two different sub-mitochondrial compartments (Haucke et al., 
1997). In order to identify a more specific pathway we introduced alanine 
substitutions to the localization sequences at positions 23 and 24 that virtually 
abolish the ability of the precursor localization sequence to insert itself into the 
OMM so it only targets the fused protein to the IMS. To generate the MCR1(AAQQ)-
IκBα we used site directed mutagenesis using primer set 5 and introduced the 
mutations and amplified with long PCR the whole vector and transformed into 
super competent bacteria. The same principle is used with the Stratagene’s kit 
QuickChangeII Site-Directed mutagenesis kit II. 
C.4.5.  Cloning of IκBα/β-Actin 
Primer set 6 and primer set 7 were used to amplify by PCR IκBα and β-actin 
genes respectively. After amplification the constructs were mixed. A forward 
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primer from set 6 and reverse from set 7 were used for a recombinant PCR 
reaction to generate IκBα/β-actin fusion protein.  
C.4.6.  Cloning of FLAG-IκBα, MEET-IκBα and IκBα/β-actin 
into pLenti7.3  
A commercial lentiviral expression system was used to generate the transfer 
vector plasmids for the production of lentiviral particles for the reconstitution of 
3T3 IκBα -/- cells. pLenti7.3 is a TOPO cloning system and it was used according to 
the manufacturer’s instruction to generate pLenti7.3.FLAG-IκBα , pLenti7.3.MEET-
IκBα, pLenti7.3.IκBα/β-actin and pLenti7.3GW.lacZ.TOPO (Control). The plasmid 
backbone bares a cytomegalovirus high expression promoter and an SV40 
promoter in a bi-cistronic format. EM488 is a green fluorescence protein under the 
SV40 promoter within the LTRs of the HIV lentivirus. 
C.4.7.  Cloning of p65BD/β-actin and β-actin into pcDNA3   
p65 bears a site where it binds with high affinity IκBα (Ganchi et al., 1992) 
and its binding has no effect on the ability of p65 to bind DNA κΒ sites. Amino 
acids 151-312 from p65 (RelA) were amplified with PCR and restriction sites 
HindIII/KpnI and an ATG were inserted using primer set 8. The β-actin gene was 
amplified by PCR flanked with KpnI/BamHI sites using primer set 9. Both 
sequences were ligated into pcDNA3 sequentially with β-actin ligating first which 
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created the β-actin vector and after the ligation of p65’s where IκBα is binding to,  
the p65BD/β-actin was created.  
C.4.8.  Cloning of 326.CMV.β-actin and 326.CMV.p65BD/β-
actin. 
The 326.CMV is a monocistronic lentiviral expression vector that can 
facilitate high expression of a transgene stably and potently. β-actin and p65BD/β-
actin were cloned into the 326.CMV vector with the use of the INFUSION kit from 
Clontech. Primer sets used were set 10 for β-actin and set 11 for p65BD/β-actin. In 
short the kit makes use of homologous recombination. The designing of the 
primers is in a way they include a 15-20bp sequence identical to the insertion site 
of the vector. After linearization of the vector at the appropriate site that should 
be identical to the one included in the primer, purified vector and PCR product are 
mixed together and with the help of the INFUSION enzyme, homologous 
recombination is taking place between the same sequence so the transgene is 
inserted into the vector. Virtually any gene can be cloned into any vector 
directionally.  
C.4.9.  Cloning of deletion mutants  
In order to identify the necessary domain of IκBα that is responsible to 
inhibit apoptosis, deletion mutants were generated using site directed 
mutagenesis, in the same way as the generation of mcr1A23/24Q-IκBα (see above). In 
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order to identify the sufficient domain of IκBα for apoptosis inhibition, deletion 
mutants were generated using conventional cloning. The vector MEET-IκBα was 
used as the backbone and the primer set 12a (MEET-IκBα1-31), set 12b (MEET-
IκBα1-70), set 12c (MEET-IκBα1-109) and set 12d (MEET-IκBα1-142) were used to create 
the indicated deletions and subsequently cloned with the same strategy into 
pcDNA3 vector under the HindIII/BamHI sites. All the deletions contained a C-
terminal FLAG tag and was introduced into the reverse primer. 
Table B.1. Primer sets. Primer sets for the amplification of genes or sequences. Unless 
otherwise stated, Phusion high fidelity DNA polymerase was used for all normal PCR and 
mutagenesis reactions.  
 
Primer Set Sequence 
Set 1a    
(mcr1) 
(FOR)-ACTGTGGATCCCCGCCATGTTTTCCAGATT  
(REV)-ACTGTGAACACTTTATTAGA 
Set 1b   
(IκBα) 
(FOR)-ATGTTCCAGGCGGCCGAGCGC 
(REV)-TCTAGATCATAACGTCAGACGCTG 
Set 2 
(mitoNEET) 
(FOR)-GTAAGCTTCCACCATGAGTCTGACTTC 
(REV)-GCTGTCTGCAGTTTGTAAGCTAGATAACC 
Set 3    
(IκBα) 
(FOR)-ACTGTGGTACC ATTCCAGGCGGCCGAG 
(REV)-ACTGTGGATCCTCATAACGTCAGACG 
Set 4    
(Smac) 
(FOR)-ACTGTAAGCTTCCGCCATGGCGGCTCTGAGA 
(REV)-ACTGTCTGCAGAATAGGAACCGCACACAG 
Set 5  
(mcr1AAQQ) 
CAAAAGCATTACCGATTGCTCTAGGTACAGTTGCTATACAGCAGGCTACC
GCATTCTATTTTGCA 
TGCAAAATAGAATGCGGTAGCCTGCTGTATAGCAACTGTACCTAGAGCA
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ATCGGTAATGCTTTTG 
Set 6     
(IκBα) 
(FOR)-AAGCTTCCACCATGTTCCAGGCGGCCGAG 
(REV)-TAACGTCAGACGCTGGCCTCCAAA 
Set 7         
(β-actin) 
(FOR)-ATGGATGATGATATCGCCGCG 
(REV)-TCTAGACTAGAAGCATTTGCGGTG 
Set 8  
(p65BD)    
(FOR)-GTAAGCTTCCACCATGGACTACGACCTGAATGCTGTG 
(REV)-GTGGTACCGCTGAAAGGACTCTTCTTCATGATGCT 
Set 9          
(β-actin) 
(FOR)- GTGGTACCATGGATGATGATATCGCCGCGCTC 
(REV)- GTGGATCCCTAGAAGCATTTGCGGTGGACGATGGA 
Set 10        
(β-actin) 
(FOR)-TAGAGGATCCACCGGTGGTACCCCACCATGGATGATGATATC 
(REV)-GAGGTTGATTGTCGACGGATCCCTAGAAGCATTTGC 
Set 11        
(p65BD/β-actin) 
(FOR)-TAGAGGATCCACCGGTAAGCTTCCACCATGGACTAC 
(REV)-GAGGTTGATTGTCGACGGATCCCTAGAAGCATTTGC 
Set 12a 
(MEET-IκBα1-31) 
(FOR)-GTAAGCTTCCACCATGAGTCTGACTTCCAGTTCCAGCGTA 
(REV)-GGATCCTCACTTATCGTCGTCATCCTTGTAATCGTCGTGGCGGTCGTC 
Set 12b 
(MEET-IκBα1-70) 
(FOR)-GTAAGCTTCCACCATGAGTCTGACTTCCAGTTCCAGCGTA 
(REV)-GGATCCTCACTTATCGTCGTCATCCTTGTAATCGAGCTGCTGCTTCCA 
Set 12c 
(MEET-IκBα1-109) 
(FOR)-GTAAGCTTCCACCATGAGTCTGACTTCCAGTTCCAGCGTA 
(REV)-GGATCCTCACTTATCGTCGTCATCCTTGTAATCGTTGTTCTGGAAGTT 
Set 12d 
(MEET-IκBα1-142) 
(FOR)-GTAAGCTTCCACCATGAGTCTGACTTCCAGTTCCAGCGTA 
(REV)-GGATCCTCACTTATCGTCGTCATCCTTGTAATCAAAGTCTCGGAGCTC 
C.5.  DNA electrophoresis and DNA Recovery 
The DNA electrophoresis was performed using agarose (Sigma-Aldrich) 
gels. Briefly, agarose (usually 1% w/v) was dissolved in TAE buffer (Fermentas). The 
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Gel Red™ nucleic acid stain (Biotium) was then added (1/20000) dilution), cooled 
and poured into custom-made DNA gel electrophoresis cassette to solidify. The 
DNA was mixed with 6x DNA loading dye (Fermentas) and separated by gel 
electrophoresis in TAE buffer (Fermentas). The GeneRuler™ 1kb plus DNA ladder 
or GeneRuler™ 1kb DNA ladder (Fermentas) was used for the size estimation.  
Upon completion of DNA electrophoresis, the piece of agarose containing 
DNA of interest was excised under the UV lamp and subsequently DNA was 
recovered using Wizard SV gel and PCR clean-up system (Promega). Briefly, a gel 
piece was mixed with binding buffer to dissolve agarose. The dissolved gel and the 
buffer were transferred to a spinning column, centrifuged, washed twice and 
eluted with DNAase / RNAase-free H2O or TE buffer. 
C.6.  Transformation of E. coli 
 Plasmid DNA was transformed into chemo-competent, library 
efficient DH5α E. coli bacteria or MAX efficient DH5α E. coli bacteria (Invitrogen). 
Aliquots stored in -80°C were thawed on ice, the corresponding plasmid DNA was 
added to the cells. After 30 minutes of incubation on ice, the cells were treated by 
heat shock (45 seconds at 42°C) with a subsequent quick chill on ice (2 minutes). 
Then 1ml of SOC medium (2% tryptone, 0.5% yeast extract, 10mM NaCl, 10mM 
MgSO4, 2.5mM KCl, 20mM glucose) was added to the transformed cells and 
incubated for 1 hour at 37 °C in a shaker to allow bacteria to express resistance 
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gene. Afterwards, bacteria were either given LB medium containing appropriate 
antibiotics (usually 100µg/ml of Ampicillin or 50µg/ml Kanamycin) or were plated 
onto LB agar containing the appropriate antibiotics (usually 100µg/ml of 
Ampicillin) and cultured over night at 37°C incubator. 
C.7.  Extraction of DNA from bacteria 
For the extraction of plasmid DNA from transformed bacteria, the bacteria 
were grown (3ml for miniprep and 250ml for maxiprep) in a Lauria-Bertani broth 
supplemented with yeast extract (10g/L, Sigma-Aldrich) in the presence of 
appropriate antibiotics overnight in a shaking incubator at 37°C. The plasmid DNA 
was extracted from the bacteria using the Plasmid Maxi Prep kit (QIAGEN) or the 
PureLinkTM HiPure plasmid filter purification kit (Invitrogen). The resulting DNA 
pellet was re-suspended in 500-1000µl of DNase, RNase free water or TE buffer 
and the concentration measured using NanoDrop (ThermoScientific) or with 
PicoGreeen (Molecular Probes). Briefly, DNA was sequentially diluted to make 
concentration of approximately 0.1µg/µl. 1µl of diluted DNA was added to a well 
of a 96-well plate. 1µl of standard DNA (0.1µg/µl) was also included as a reference. 
Then 50µl of TE buffer was added to each well followed by 50µl of diluted 
PicoGreen (1:200 in TE buffer). Plate was incubated 5 minutes. The fluorescence 
was measured with FLUOstar OPTIMA (BMG Labtech) with excitation at 480nm and 
emission at 520nm. 
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C.8.  Plasmid vector transfections 
HeLa cells were plated onto either 24-well (2-2.4*104 cells/well) or 6-well (1-
1.2*105 cells/well) plates approximately 15 hours prior to the transfections. 
HEK293T cells were plated onto either 24-well (10-12*104 cells/well) or 6-well (5-
6*105 cells/well) plates approximately 15 hours prior to the transfections. 
Effectene (QIAGEN) was used for HeLa cells and either SuperFect (QIAGEN) or 
Xfect (Clontech), was used for HEK293T cells for the DNA transfection. Briefly, 
plasmid DNA (0.2µg per 24-well plate or 0.8µg per 6-well plate) was mixed in EC 
buffer with Enhancer, incubated for 5 minutes, Effectene reagent was added (2.5µl 
or 5µl for 24- or 6-well plate, respectively), incubated for 10 minutes, and the 
DNA-lipid mix was added to the cells for Effectene transfection. For SuperFect 
transfections, DNA was diluted in DMEM (1µg or 2µg for 24- or 6-well plate, 
respectively), SuperFect was added (5µl or 10µl for 24- or 6-well plate, 
respectively), incubated for 10 minutes and the DNA-lipid mix was added to the 
cells. For Xfect transfections, DNA was diluted in the Xfect Reaction buffer (1µg or 
7,5µg for 24- or 6-well plate, respectively) and was mixed with the same volume of 
reaction buffer with the Xfect polymer. After vortexing and incubating for 10 
minutes, complexes were transferred dropwise onto the HEK293T cells. 
Transfection mixes were removed from the plate after 5-6 hours, fresh medium 
added and incubated. 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 116 
 
C.9.  Mitochondria isolation and treatment 
Mitochondria were isolated with an established protocol (Gogvadze et al., 
2003), re-suspended in the protocol’s mitochondria buffer and kept at -80°C. 
Briefly, after trypsinisation, cell were harvested, washed with PBS and centrifuged 
for 5 minutes at 2100 rpm. 400µl to 600µl of mitochondria lysis buffer [Buffer A: 
(20mM HEPES pH 7.5, 1.5mM MgCl2 (6H2O), 10mM KCl, 1mM EDTA, pH 7.4), Lysis 
Buffer: 12ml Buffer A with 3ml sucrose 1.25M)] was added to the pellet and left for 
2 minutes on ice. Meanwhile a dounce homogenizer (Wheaton 357542) was 
washed with cold lysis buffer and homogenized by 60-80 strokes. 200µl of lysis 
buffer were added and lysed cells were left on ice for 20 minutes. A centrifugation 
step followed (3000rpm) for 10 minutes in which step the nuclei and debris were 
pelleted. The supernatant which contained the mitochondria was re-centrifuged at 
13000rpm for 20 minutes. The pellet contained the isolated mitochondria and the 
supernatant constituted the cytosolic fraction.  For greater mitochondria purity but 
smaller yield a commercial kit from Pierce (Thermofisher, UK) was also used. 
25ng/ml of Proteinase K (Sigma, UK) was applied to isolated mitochondria for 30 
min at 4 oC and PMSF was used to stop the reaction. Cleavage of outer 
mitochondria membrane (OMM) proteins was observed on western blots. 
Recombinant Bax was purchased from ProSpec-Tany TechnoGene LTD (Israel), 
diluted with mitochondria buffer and incubated with isolated mitochondria for 
30min at 25°C. Transfected mitochondria with IκBα were used or in vitro translated 
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(IVT) proteins using the TNT Quick Coupled Transcription-Translation kit 
(Promega). IVT proteins were run on an SDS page for their integrity determination 
and equal amounts were applied on isolated mitochondria for 30min at 25°C prior 
to addition of recombinant Bax. Association of IVT proteins to isolated 
mitochondria and the cytochrome c release induced by recombinant Bax protein 
from isolated mitochondria were analysed as described previously (Kim et al., 
2006a) 
C.10.  Nuclear protein extraction 
Cells were pelleted at 1200 rpm and were re-suspended in 300µl of L-Buffer 
(0,1 % Triton X-100, 0,1% NP-40 in PBS with the addition of protease inhibitors). 
Lysates were left on ice for 15 min and subsequently centrifuged at 1000g for 10 
min at 4oC. The supernatant which is the cytosol was removed and kept and the 
pellet was re-suspended in 1ml of L-buffer and centrifuged 7min at 1000g. This 
step was repeated 3 times and the pellet was lysed in RIPA buffer. It was left on ice 
for 40 min while vortexing every 10 min. The samples were finally centrifuged at 
15000rpm for 20 min at 4oC.  
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C.11.  Apoptosis assays 
C.11.1.  Quantification of cell death 
Mitochondria dyes TMRE (tetramethylrhodamine, ethyl ester) and DiOC6 
(3,3′-dihexyloxacarbocyanine iodide) were used in conjunction with propidium 
iodide to quantify apoptosis (Chiara et al., 2008; Majewski et al., 2004a). In short, 
floating and adherent cells were harvested and centrifuged at 2100 RPM. 
Supernatant was discarded and cells were re-suspended in 150µl of PBS were 
DioC6/PI mix was added. Cells were incubated in total for 90 minutes and were 
then analysed using FACS (BD Biosciences) with the CellQuest programme (BD 
Biosciences, UK). FlowJo (TreeStar Inc.) was used for data analysis. 
C.11.2.  Propidium Iodide staining 
The supernatant and the adherent cells were harvested, centrifuged 
(1500rpm, 5 minutes) and re-suspended in lysis buffer (0.1% sodium citrate and 
0.1% Triton X-100 in PBS) containing propidium iodide (PI, 20µg/ml). Upon the 
lysis of cells, resulting nuclei were acquired with flow cytometer (FACSCaliburTM, 
BD Biosciences) using FL-2 channel to quantify the percentage of cell population 
with subG1/G0 DNA content. The pan-caspase inhibitor, zVAD-fmk (MP 
Biomedicals), was used at a concentration of 20µM. 
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C.11.3.  DiOC6 / TMRE staining 
To quantify the percentage of cells undergoing mitochondrial outer 
membrane depolarization, supernatant and the adherent cells were harvested, 
centrifuged (1500rpm, 5 minutes) and re-suspended in 100-200µl of PBS 
containing 40nM DiOC6 or 40nM TMRE for 40 minutes in the incubator and further 
incubated for 40 minutes at room temperature in the dark. Cells were then 
analysed using a flow cytometer (BD Biosciences) using FL-1 (for DiOC6 staining) 
or FL-3 (for TMRE staining) channel. Bongkrekic acid (Sigma-Aldrich), a blocker of 
the permeability transition pore, was used at a concentration of 75µM. 
C.11.4.  Caspase-3 and Bax activity assay 
The supernatant and the adherent cells were harvested and centrifuged 
(1500rpm, 5 minutes) and fixed in 4% paraformaldehyde in PBS (PFA, Thermo 
Scientific) for 20 minutes at 4ºC, then blocked in 3% bovine serum albumin (BSA) 
for 30 minutes in Tris-buffered saline (TBS, 50mM Tris-HCl, 155mM NaCl, pH 7.6) 
and permeabilized with saponine (0.02% w/v) in TBS (TBSS) for 30 minutes in the 
incubator. Cells were then centrifuged (1500rpm, 5 minutes) and the primary 
antibody, diluted in TBSS, that recognizes either active caspase-3 (polyclonal 
rabbit anti-cleaved Caspase-3 Asp175, Cell Signaling, #9661) or Bax (monoclonal 
mouse anti-Bax, BD Pharmingen, 556467, clone 6A7) was added (50µl) at a dilution 
of 1/200 or 1/100, respectively, and incubated for 1 hour in the incubator. Cells 
were then washed with 2ml of TBSS, centrifuged and the isotype-matched 
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secondary antibody conjugated with Alexa Fluor 488 (Molecular probes), diluted in 
TBSS at a dilution of 1/500, was added to the tube (50µl) and incubated for 1 hour 
in the incubator. TBSS (2ml) was then added to wash the secondary antibody; the 
cells were centrifuged, re-suspended in TBSS (300µl), and analysed with flow 
cytometer (BD Biosciences) using the FL-1 channel. 
C.11.5.  Cleavage of poly ADP ribosome polymerase (PARP) 
The supernatant and the adherent cells were harvested and the pellet was 
lysed in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% w/v sodium deoxycholate, 
0.1% w/v SDS, 50mM Tris-HCl pH 8) containing protease inhibitors (Fermentas). 
The total cell lysate was separated and immunoblotted with PARP antibody to 
determine the procession of procaspase-3 or full length PARP (see section “SDS-
PAGE and Immunoblotting”). 
C.12.  Immunoprecipitation 
C.12.1.  Immunoprecipitation of endogenous proteins 
Cells were washed once with PBS and lysed in 500µl of RIPA buffer 
containing protease inhibitors (Fermentas). Approximately 7mg of total cell lysate 
per condition was used. The cell lysates were placed on ice for 30min, 
centrifugated (13x103 rpm) for 30 minutes at 4°C. The supernatant was pre-cleared 
twice with 50µl of protein G sepharoseTM 4 fast flow (GE Healthcare) or with 
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PureProteome magnetic protein G beads (Millipore) for 30 minutes each with 
gentle rotation at 4°C. After the pre-clearing, appropriate amount of antibody 
(usually what was suggested in the antibodies’ data sheets) was added to the 
supernatant and incubated overnight with rotation at 4°C. For VDAC1-HXKII 
interaction experiments, VDAC1 antibodies (D-16 or N-18) (dilution 1:50) were 
used to immunoprecipitate complexes from isolated mitochondria (~100µg of 
protein) following the protocol above. No antibody was added to the control 
immunoprecipitations. The antibody-protein complexes were then precipitated 
with 80µl or 20µl (for the VDAC1-HXKII experiments) of beads and incubated for at 
least 2 hours at 4°C. Beads were washed five times with the lysis buffer and re-
suspended in gel loading dye (Fermentas) supplemented with reducing agent 
(usually 2-mercaptoethanol). Each tube was immediately boiled for 10 minutes 
and immunoprecipitates were subjected to protein separation by SDS-PAGE (see 
section “SDS-PAGE and Immunoblotting”). For ANT-1 immunoprecipitation 10 mg 
of protein was used (5xT175) from Hela or MCF7 and lysed in a buffer containing 
mitochondria lysis buffer and 1% (final) n-dodecyl-D-maltoside. The lysates were 
incubated on ice for 35 minutes and subsequently centrifuged at 32000g for 30 
min. The rest of the procedure was the same as above.   
C.12.2.  Immunoprecipitation of overexpressed proteins 
HEK293T cells were transfected with the appropriate plasmids as indicated 
and cell lysates were prepared in RIPA buffer. Protein concentration was measured 
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(see section “SDS-PAGE and Immunoblotting”) and equal amounts of protein in an 
equal volume (adjusted with RIPA buffer) were pre-cleared once with 50µl of 
PureProteome magnetic protein G beads (Millipore) for 30 minutes with gentle 
rotation at 4°C. The supernatant was then immunoprecipitated with the indicated 
antibodies overnight. No antibody was added for the control tubes. The antibody-
protein complexes were then precipitated with 80µl of beads and incubated for 1 
hour at 4°C. Beads were washed five times with lysis buffer and re-suspended in 
gel loading dye (Fermentas) supplemented with reducing agent. Each tube was 
immediately boiled for 10 minutes and immunoprecipitates were subjected to 
protein separation by SDS-PAGE. 
Antibodies used were polyclonal rabbit α-Flag (Sigma-Aldrich, F7425, used 
at 1/50 dilution), monoclonal mouse α-HA (Sigma-Aldrich, H3663, used at 1/50 
dilution) and the protein raised antibodies where no tag was available.  
C.13.  SDS-Polyacrylamide gel electrophoresis 
(SDS-PAGE) and immunoblotting 
C.13.1.  Preparation of whole cell lysate 
Cells were trypsinized, centrifuged (1500rpm, 5 minutes) and lysed, or were 
directly lysed on the plate by adding RIPA buffer. Total cell lysates were then 
incubated on ice for 30 min and subsequently centrifuged for at least 45 minutes 
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(13x103 rpm) at 4°C. The resulting supernatant, which contained soluble proteins, 
was transferred to a new tube and used immediately or stored at -20°C until use. 
C.13.2.  Protein concentration measurement 
Protein concentration was determined using the Bradford assay (BioRad). 
To obtain a standard curve, BSA of known concentration was sequentially diluted 
(from 0-6µg/µl) and placed on a flat-bottom 96-well plate. To each well, 199µl of 
Bradford (diluted 5 times in water) was added and the absorbance measured at 
595nm using FLUOstar OPTIMA (BMG Labtech). The resulting absorbance values 
were plotted against BSA concentration and used as a standard curve to measure 
the protein concentration. 
C.13.3.  Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
Following the protein concentration measurement, 20-100µg of the total 
cell lysate was separated by SDS-PAGE (stacking gel: 4.8% polyacrylamide, 125mM 
Tris-HCl pH6.8, 0.1% SDS, 0.1% APS, 0.1% TEMED; resolving gel: 10-15% 
polyacrylamide, 375mM Tris-HCl pH8.8, 0.1% SDS, 0.1% APS, 0.05% TEMED) in 
TGS-running buffer (25mM Tris-HCl, 192mM Glycin, 0.1% w/v SDS). PageRulerTM 
pre-stained protein ladder (Fermentas) was used for the protein size estimation. 
Proteins were then transferred to nitrocellulose or PVDF membrane (Millipore) in 
transfer buffer (20% methanol in TGS buffer). Conditions used for the transfer were 
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as follows: limited to 500 mA and 20 volts. Proteins were transferred for 90 
minutes (if two gels are transferred together) or 60 minutes (if only one gel is 
transferred) in a semi-dry transfer system from Bio-Rad . 
C.13.4.  Immunoblotting 
The membranes were blocked with 3% BSA (Sigma-Aldrich) or 5% FCS in 
TBS containing 0.1% Tween (TBS-T) for minimum of 30 minutes, incubated with 
the primary antibody, washed three times with TBS-T (10 minutes each), and 
incubated with horseradish peroxidise-conjugated isotype-matched secondary 
antibody. The membrane was then washed as before, treated with enhanced 
chemoluminescent reagent (Pierce) and subjected to autoradiography using high 
performance chemoluminescence film (GE Healthcare). 
Antibodies used for immunoblotting and immunoprecipitation are listed 
below (Table B.2.). 
 
Table B.2. Antibodies used for immunoblotting and immunoprecipitation 
Antigen Source Clonality Dilution Company Cat. no 
IκBa   Rabbit polyclonal  
1:1000 (WB) 
1:100   (IP) 
Santa-Cruz sc-371 
IκBα  Goat  polyclonal  
1:750 (WB) 
1:100 (IP)  
Santa-Cruz sc-371-G 
IκBα   Rabbit  monoclonal  1:1000  Abcam ab-32518  
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IκBα  Mouse monoclonal 1:500(WB) Santa-Cruz sc-1643 
β-actin  Mouse  monoclonal  1:2000  
Sigma-
Aldrich  
A2228  
Bax  Mouse  monoclonal  1:2000  
BD 
Pharmingen  
556467  
FLAG Rabbit polyclonal 1:2000 
Sigma-
Aldrich 
F7425 
FLAG Mouse monoclonal 1:100 (IP) Origene TA50011-1 
GAPDH Mouse monoclonal 1:2000 Santa-Cruz sc-32233 
HA Rabbit polyclonal 1:2000 
Sigma-
Aldrich 
H6908 
PARP Rabbit polyclonal 1:1000 
Cell 
Signaling 
#9542 
ANT-1 Mouse monoclonal 1:100 
Mitoscience
s 
MSA02 
ANT-1 Rabbit monoclonal 1:500 Proteintech 15997-1 
VDAC1 Rabbit polyclonal 1:1000 Abcam 15895 
VDAC1 Mouse monoclonal 1:500 Santa-Cruz sc-58649 
VDAC1 Goat polyclonal 1:1000 Santa-Cruz sc-32063 
VDAC1/2/3 Rabbit polyclonal 1:500 Santa-Cruz sc-98708 
GRP75 Rabbit polyclonal 1:500 Santa-Cruz sc-13967 
HSP60 Goat polyclonal 1:500 Santa-Cruz sc-1722 
Tom20 Rabbit polyclonal 1:1000 Santa-Cruz sc-11415 
Cytochrome
-C 
Mouse monoclonal 1:1000 
BD-
Pharmigen 
556433 
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p65 Rabbit polyclonal 1:300 Santa-Cruz sc-372 
p50 mouse monoclonal 1:300 Santa-Cruz sc-8414 
Hexokinase
2 
Mouse monoclonal 1:500 
Sigma-
Aldrich 
SAB140222
1 
Bax Rabiit polyclonal 1:300 Santa-Cruz sc-493 
Creatine 
Kinase 1 
Rabbit polyclonal 1:750 Proteintech 15346-1AP 
Cyclophilin 
D (ppiF) 
Mouse monoclonal 1:500 Calbiochem AP1035 
Mouse HRP Goat  1:5000 
Molecular 
Probes 
G21040 
Rabbit HRP Goat  1:20000 
Sigma-
Aldrich 
   
Goat HRP Rabbit  1:20000 
Sigma- 
Aldrich 
 
Biotin HRP Mouse  1:20000 
Sigma- 
Aldrich 
A0185 
 
C.14.  Immunofluorescence 
C.14.1.  Immunofluorescence assay 
Cells, seeded on coverslips (CS), were transfected by mitoCFP, mitoGFP or 
mitoYFP with Effectene (Qiagen, UK) and grown for 24 hours, then fixed in 4% 
paraformaldehyde in PBS for 20 min at 4°C. After a blocking step with 3% BSA in 
Tris-HCl 50 mM, NaCl 155 mM, pH 7.6 and 0.02% saponine (TBSS) for 30 min at 
room temperature (RT), cells were incubated with the primary antibody (Table B.3.) 
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for 2 hours at RT. Cells were rinsed five times in TBSS and then incubated with the 
secondary anti-rabbit Alexa Fluor 594 antibody at a dilution of 1/500 in TBSS. Cells 
were washed five times in TBSS and incubated 30 minutes in DAPI (2 µg/ml, 
Invitrogen, UK) at RT, before being mounted in polyvinyl alcohol mounting 
medium with DABCO (Sigma). Cells were examined with confocal laser-scanning 
microscope (Leica) with a 63x objective and analysed with LAS AF software. 
Plasmid vectors conjugated with fluorescent protein used are: mitoCFP, 
mitoGFP or mitoYFP are all fluorescent proteins conjugated at the N-terminus with 
a mitochondria localization signal from the precursor protein of human 
cytochrome c oxidase subunit VIII. Those plasmids were a kind gift of Remy Sadoul 
(Inserm U836, Grenoble, France). S/D-GFP and MEET-GFP were fused and cloned 
and verified by immunofluorescence (see above). 
 
Table B.3. Primary antibodies used for Immunofluorescence 
Antigen Source Clonality Dilution Company Cat. no 
IκBα Rabbit polyclonal 1:50 Santa-Cruz sc-371 
Cyt.-C mouse monoclonal 1:50 Santa-Cruz sc-13560 
FLAG Rabbit polyclonal 1:50 Sigma-Aldrich F7425 
p65 Rabbit polyclonal 1:50 Santa-Cruz sc-372 
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C.14.2.  Mitochondrial staining 
Mito Tracker® Red CM-H2XRos (MitoTracker) and tetramethylrhodamine 
ethyl ester (TMRE) were used at a concentration of 50nM (Molecular Probes) for 
the visualization of mitochondria. Both probes were diluted in a culture medium 
and added to the cells for 15-20 minutes at 37ºC. When specific mitochondrial 
staining was visible, dyes were removed, washed three times with DMEM and fresh 
medium (minimum quantity, ~250µl per a well of 24-well plate) was added. 
C.15.  Production of lentiviral particles  
Virulent media was produced in HEK293FT cells (Invitrogen, UK) using the 
following optimised protocol for lentiviral production: Plasmids encoding Vesicular 
Stomatitis Virus Glycoprotein (pVSV-G), group antigen and reverse transcriptase 
(pGag.Pol) and mRNA export helper protein (pRev) were isolated from ViraPower™ 
lentiviral packaging mix (Invitrogen). Expression vector for the pAdVantage was 
from Promega. The cell line used was 293FT cells from Invitrogen.  
The day before the transfection, 293FT cells were plated onto 10cm2 dishes 
so that the plate would be approximately 50-60% confluent on the day of 
transfection. Two hours prior to transfection, the medium was replaced with fresh 
DMEM. 5.4µg of the pVSV-G, 3.8µg of the pRev, 7.8µg of the pGag.Pol, 9µg of the 
pAdVantage and 20µg of the lentiviral transgene plasmid were mixed in a 2ml 
eppendorff tube and made up to 437.5µl with H2O. Then 62.5µl of 2M CaCl2 was 
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added, mixed thoroughly and incubated for 5 minutes. Meanwhile, 500µl of 2xHBS 
(50mM HEPES, 281mM NaCl, 1.5mM Na2HPO4 pH 7.08-7.1, filter sterilized) was 
prepared in a 15ml conical tube. After 5 minutes incubation, the DNA/CaCl2 
mixture was added drop by drop into 15ml conical tube while vigorously shaking 
the tube on a vortex machine. The mix was immediately added to the dish drop by 
drop.  
The culture medium was replaced with fresh warm medium containing 
sodium butyrate (10mM, Sigma-Aldrich), dissolved in PBS, on the following 
morning (16 hours post transfection). Note that sodium butyrate was freshly 
prepared every time. After 2 to 3 days post transfection, the supernatant was 
harvested and centrifuged (500g, 10 minutes, RT) to remove cells and large debris, 
then passed through a 0.45µm sterile filter. Note that 0.2µm filter should not be 
used as it can damage viral outer glycoproteins. 3T3-IkBα-/- cells were transduced 
for 6 h in the presence of polybrene (6 µg/ml, Sigma) for the reconstitution with 
IκBα variants (pLenti7.3-G.O.I.). After infection, cells were sorted through a BD 
FACSAriaIIu fluorescent activated cell sorter for eGFP since the pLenti7.3 vector 
allows the expression of a fluorescent marker along with the gene of interest 
through a bi-cistronic vector system. 
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C.15.1.  Calculation of viral titre  
In order to measure the viral titre, the cells of interest (HEK293T or HeLa 
cells) were seeded on the 12-well plate to make a plate ~30% confluent on the 
day of transduction. On the day of the transduction the viral stock was diluted 
(three different dilution to achieve accurate measurements) in 400µl of DMEM 
containing polybrene® (hexadimethrine bromide, 6µg/ml, Sigma-Aldrich). The 
diluted viruses were added to the cells and incubated for 48 hours to allow 
integration of genome and the expression. The number of cells present in a well 
was counted. The cells were then selected with puromycin (2-6µg/ml) for 24 hours 
and the number of surviving cells was recorded.  
The viral titre was calculated using the following equation:  
    
	


 Where TU is the transforming unit (=number of virions), F 
is the percentage of surviving cells, N is the number of cells at the time of 
transduction, D is the dilution factor, and V is the volume of diluted viral sample 
added into each well in ml. TU can also be referred as CFU which is the Colony 
Forming Unit (number of virions) and is calculated on the same way. In order to 
avoid under-estimation of the virus titre, only the dilution that was showing less 
than 20% transduced cells was used. In the case of pLenti7.3 based virions 
puromycin and selection was not used since the backbone contains a GFP variant 
for an easy estimation of viral titer.   
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C.15.2.  Production of stable cell lines 
The cell line of interest was seeded on a well of 6-well plate 15 hours prior 
to the transduction. On the following day, cells were transduced with the viral 
supernatant supplemented with 1µg/ml of Polybrene® (Sigma-Aldrich) for 6 hours 
or overnight. The viral supernatant was then removed; fresh medium added and 
incubated for a further two to three days. The medium was replaced with DMEM 
containing puromycin (varying concentration, 5µg/ml for HeLa cells) after 72-96 
post-infection and further cultivated for three days for the selection. Upon 
completion of the selection, cells were maintained in DMEM containing 1µg/ml of 
puromycin to retain the resistance.  
C.16.  IκBα, VDAC and hexokinase II down-
regulation by shRNA  
Commercial shRNA constructs for IκBα, VDAC1 and Hexokinase II from 
Sigma-Aldrich were tested with western blots for sufficient down-regulation of 
IκBα and two constructs were validated. The appropriate controls were also 
purchased from Sigma. The vectors were packaged into lentiviruses using the 
same approach as described above. Transductions of cells with constitutively 
active NFκB activity (MDA-231, PC3) and non-constitutively active (Hela, 293T), 
were performed with the help of polybrene and stable cell lines were established. 
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The sequences of the synthetic oligonucleotides (Invitrogen, UK) used for IkBα 
shRNA constructs and VDAC1 were the following:  
Table B.4. Sequences of short hairpin DNA used to knock-down the proteins 
of the indicated genes 
 
IκBα (sh42) 
3’UTR targeting 
5’3’ 
CCGGGACGAGAAAGATCATTGAAATCTCGAGATTTCAATGATCTT
TCTCGTCTTTTT 
IκBα   (sh88) 
CDS targeting 
5’3’ 
CCGGAGAGTCAGAGTTCACGGAGTTCTCGAGAACTCCGTGAACTC
TGACTCTTTTTT 
VDAC1        
CDS targeting 
5’3’ 
CCGGGCTTGGTCTAGGACTGGAATTCTCGAGAATTCCAGTCCTAGA
CCAAGCTTTTT 
mVDAC1 
CDS targeting 
5’3’ 
CCGGACCAGGTATCAAACTGACGTTCTCGAGAACGTCAGTTTGAT
ACCTGGTTTTTT 
Hexokinase2 
CDS targeting 
5’3’ 
CCGGCCAAAGACATCTCAGACATTGCTCGAGCAATGTCTGAGATG
TCTTTGGTTTTTT 
Scramble 
Non-targeting 
5’3 
CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAA
CCTTAGGTTTTT 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 133 
 
C.17.  NF-κB activity assay in 293T and 3T3 
IκBα re-constituted cells  
293T cells were transfected with the reporter plasmid pNFkB-hrGFP along 
with expression constructs for ANT-1, Bax and Tax (Munoz & Israel, 1995). The 
pan-caspase inhibitor zVAD (MPBio, UK) was applied at 20µΜ to avoid late 
degradation of proteins through apoptosis by Bax and ANT-1. 24 hours post-
transfection, 293T cells were collected for FACS analysis. For the rest of the cell 
lines a non-radioactive biotinylated-oligo-pull-down assay was used to quantify 
the level of NFκB activity. In short, sense and antisense oligonucleotides encoding 
tandem κB sites (sense, AGCTTACAAGGGACTTTCCGCTGGGGACTTTCCAGGG) were 
annealed after denaturing and slow cooling in a buffered solution. The sense 
strand was biotinylated at the 5′ position, while a non-biotinylated oligonucleotide 
was used as control. Nuclear extracts were prepared as described above and 
incubated with annealed oligonucleotides for 60 minutes at 4°C. The 
oligonucleotides were subsequently precipitated by streptavidin agarose beads 
(Invitrogen, UK) and rinsed 3 times before proceeding to Western blot analysis. 
C.18.  In vivo experiments 
MDA-MB-231 cells were obtained from ATCC and were transduced using 
previously prepared lentivirus for scramble of shIκBα(42) at M.O.I. of 100. Stable 
clone pools were generated and cells were expanded 2 weeks post infection. 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 134 
 
Down-regulation of IκBα was checked with western blots. Cells were maintained in 
puromycin at concentration 1µg/ml.  
Eight 4 week old, female, Balb/c nu/nu athymic mice were purchased under 
license 70/7173. Animals were always treated under the rules and conditions of 
the Animals Act 1986.  
A 20µl 1:1 mixture of matrigel and cells containing 2x106 cells were injected 
using an insulin needle into the mammary fat pad. Both MDA-231/sc and MDA-
231/shIκBα were injected in each mouse on different sides. Preparation of cells for 
injection was done as following: 
• Cells in T175 flasks were washed 3 times with PBS 
• After final wash, 5mL trypsin was added 
• When the majority of cells were detached 20mL of media (RPMI + 10% FCS) 
was added 
• Cells were thoroughly mixed, transferred to 50mL conical tube and 
subsequently centrifuged. 
• The supernatant was discarded, pellet re-suspended with 5mL fresh media 
• Re-suspended cells from multiple conical tubes were combined into one 
conical tube where the cells were counted 
• Cells were centrifuged and supernatant was removed 
• Cells were re-suspended in a volume of PBS to give 4x106 cells in 20µL 
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• Equal volumes of Matrigel and cell suspension were gently but thoroughly 
mixed together which provided 2x106 cells in 20µl (50% PBS/50% Matrigel). 
Mice were observed on daily basis for tumour formation.  This type of cells 
was shown before to produce xenografts in nude mice but since they have been in 
culture for longer they were tested for tumour formation potential. Positively 
engrafted mice were separated in groups and treated in weekly intervals with PBS 
or Doxorubicin (6mg/kg). Administration of drug or vehicle was done through the 
intravenous (i.v.) route. An electronic calliper was used to measure the three 
dimensions of tumour and the following formula was used to calculate the volume 
V =

∗∗∗
  . 
 
C.19.  Densitometry analysis 
A scanned image of a western blot was uploaded onto ImageJ programme 
and converted to 8-bit image (image → type → 8-bit). The image was then 
inverted (Edit → invert) and appropriate fields selected using “rectangular 
selection” tool. The plot profile (analyse → plot profile) was created and the 
background intensities were removed by drawing a straight line using “straight 
line selection.” Then distinctive peaks were separated with “straight line selection” 
and the intensities of bands were analysed upon selection of the appropriate area 
with “wand tool” followed by the measurement (analyse → measure). Note that 
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pressing the “Shift” key during line drawing allowed me to draw a straight line and 
“Ctrl+D” allowed me to approve my line draw.  
C.20.  Statistical analysis  
Statistical analysis was performed using unpaired student’s t-test. Two 
samples were regarded to have an equal variance when the f-test between two 
sample sets gave p>0.05. Data were regarded as statistically significant if p<0.05 
based on the t-test.  
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C.21.  Common buffers used  
Solution/Media Composition 
2M CaCl2 11.1 gr in 50ml  and sterilize by filtering 
2X HBS  
50mM HEPES (Sigma, UK), 280 mM NaCl, 1.5mM 
Na2HPO4. Bring pH to 7.06-7.08 and sterilize 
Blocking Buffer 
Wash Buffer + 3% BSA (Sigma,UK) or Wash buffer+5% 
FCS 
Lactacystin 40ng/ml in DMSO (Cayman Europe, Estonia) 
Loading Buffer 3X 
4% SDS, 10% 2-Mercaptoethanol, 20% Glycerol, 0.125M  
Tris-HCl pH 6.8 (Fermentas, UK)  
Luria-Bertani (LB) 
Broth 
1% Bacto tryptone, 0.5% Bacto-yeast extract, 1% NaCl 
Bring pH 7.5 by adding NaOH  
Mitochondria Lysis 
Buffer 
Buffer A: 20mM HEPES pH 7.5, 1.5mM MgCl2 (6H2O), 
10mM KCl, 1mM EDTA, 1mM EGTA, H2O up to 1L, pH to 
7.4  
Lysis Buffer: 12ml Buffer A + 3ml Sucrose 1.25M  
Paraformaldehyde 
4% (60ml) 
4g of paraformaldehyde dissolved in 50 ml of ddH2O, add 
100µl of NaOH, allow to dissolve completely, add 10ml of 
PBS and cool down to RT. pH: 7.4 via HCl 
Phosphate Buffered 
Saline (PBS) 
8g/L NaCl, 0.2g/L KCL, 0.2g/LKH2PO4, 1.15g/L Na2HPO4, 
pH 7.4 (Invitrogen, UK) 
Polyacrylamide 40% (Bio-Rad, UK) 
Propidium Iodide 
staining lysis buffer 
0.1% sodium citrate, 0.1% Triton X-100 in PBS + 
propidium iodide 20µg/ml (final) 
Resolving gel 
10-15% polyacrylamide, 375mM Tris-HCl pH 8.8, 0.1% 
SDS, 0.1% APS and 0.05% TEMED 
RIPA Lysis Buffer  150 mM Sodium Chloride (NaCl), 1% NP-40 or Triton X-
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100, 0.5% Sodium Deoxycholate, 0.1% SDS,  50 mM Tris. 
pH 8.0, add before using PMSF and the protease inhibitor 
Cocktail (Roche, UK) 
Running Buffer 1X 25mM Tris base, 190mM Glycine, 0.1% SDS (Bio-Rad,UK) 
S.O.C. media 
2% tryptone, 0.5% yeast extract, 10mM NaCl, 10mM 
MgSO4, 2.5mM KCl and 20mM glucose  
 
TBS 20X (2L) 
400ml 1M Tris ph7.4, 175.22gr NaCl, 100ml 0.5M EDTA, 
pH8.0, 40ml Tween-20, Water up to 2 litres 
Stacking gel 
4.8% polyacrylamide, 125mM Tris-HCl pH 6.8, 0.1% SDS, 
0.1% APS and 0.1%TEMED 
TAE buffer 
40 mM Tris-acetate and 1 mM EDTA at pH 8.3  
TE buffer 100 mM Tris-HCl (pH 7.5) and 10 mM EDTA (pH 8.0) 
Transfer Buffer 
before use 
400 ml Methanol, 200 ml Running Buffer (10X), 1.4 L 
Water 
Wash Buffer (TBS-T) TBS + 0.1% Tween 20 (Sigma, UK) 
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D.  Results  
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D.1.  Localisation of IκBα  
For more than a quarter of a century IκBα has been thought to only shuttle 
between the cytosol and the nucleus of every mammalian cell type in order to 
regulate NF-κB. While its function as a NF-κB inhibitor in these different locales 
has been extensively investigated, it was recently found by two groups to also 
reside in mitochondria of cells with an unknown function in this organelle. Since 
this study set out to give further insight into the function of IκBα associated with 
mitochondria we attempted to reproduce the finding of the IκBα localisation at 
mitochondria and subsequently explore its biochemical function in terms of 
apoptosis regulation. 
Here I show that IκBα resides both in the cytosol and the mitochondria. The 
mitochondrial IκBα undergoes normal degradation upon TNF treatment following 
similar kinetics than its cytosolic counterpart but in contrast to the cytosolic IκBα, 
its degradation is proteasome independent. Furthermore, IκBα resides not only at 
the IMS as the previous studies reported but also at the OMM of all the cell lines 
that we tested and we are the first to show that in tumour cell lines with 
constitutive NF-κB activity, the majority of IκBα protein is actually found 
associated with the OMM of these cell types.  
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D.1.1.  Defining the correct experimental setting 
In order to confirm previous findings of Cogswell et al (2002) that IκBα 
resides at mitochondria of some cell types I initiated the study by determining a 
suitable experimental setting. Mitochondria were isolated from HeLa cells (cervical 
carcinoma) and separated from the cytosol. Proteinase K, which has the ability to 
cleave any protein was utilised to assess the localisation of proteins. 
To determine the correct setting, several conditions were investigated to 
identify the buffer, the temperature and the concentration needed to be able to 
cleave non-specifically all the OMM proteins without destroying the OMM and 
being able to access the IMS. The suitable concentration was identified to be 
25ng/ml in PBS on ice for 30 minutes. As figure D.1 shows, 25ng/ml of PK was able 
to cleave most of VDAC1, but it did not alter the level of Cyt-c in samples that 
were free from any cytosolic contaminants as the GAPDH probe shows. 
 
Figure D.1   25ng/ml of Proteinase K 
(PK) is sufficient to distinguish 
proteins within mitochondria from 
those at OMM and in the cytosol. 
Several concentrations of PK were used on 
isolated mitochondria. Samples were 
treated for 30 min on ice, mitochondria 
were washed again in mitochondria buffer 
and lysed with RIPA buffer. A 12% SDS-gel 
was used to separate the proteins and 
suitable antibodies to detect for the specific 
antigens.  
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D.1.2.  The kinetics of IκBα degradation by TNF in 
mitochondria are similar to those in the cytosol 
It is known that upon binding of TNF, IκBα gets phosphorylated, 
ubiquitinated with K48 ubiquitin chains and then targeted to the proteasome for 
its degradation. Since IκBα was found in the mitochondria we wanted to 
investigate its degradation kinetics since the proteasome is unlikely to have access 
to the mitochondria. We hypothesized that IκBα would be protected from 
proteasomal degradation and show no or slower degradation since it resides in 
the IMS where it is protected. We first showed by immunofluorescence that the 
TNF concentration used was sufficient to induce the translocation of RelA (p65) 
subunit into the nucleus (Figure D.2A) confirming the activation of the NF-κB 
pathway. We show in figure D.2C that mitochondrial IκBα follows the same kinetics 
as the cytosolic IκBα.  
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C 
Figure D.2. Upon TNF treatment, IκBα is degraded with the same kinetics 
in the mitochondria as in the cytosol. (A) Hela cells were treated with 20ng/ml 
TNF to activate NF-κB. The activation is confirmed by the translocation of p65 and p50 
from the cytosol into the nucleus. (B) Hela cells were treated with TNF and the IκBα 
and subsequently the p-IκBα antibody were used to probe for activated IκBα. (C) WB 
of cytosolic and mitochondrial HeLa lysates indicate that upon TNF application IκBα is 
degraded with the same kinetics in both cell fractions. Mitochondria were treated with 
Proteinase K to ensure mitochondria purity. (WCL: Whole Cell Lysate) 
 
 
 
 
 
 
D.1.3.  IκBα degradation in mitochondria is proteasome-
independent 
The results of the degradation kinetics of mitochondrial IκBα upon TNF 
treatment served as a reference for an experiment in which we checked the IκBα 
degradation when the proteasome was inhibited. We used the cell permeable and 
irreversible proteasome inhibitor lactacystin, which specifically inhibits the 26s 
proteasome (MCP; multicatalytic proteinase complex). It blocks the proteasome 
activity by targeting its catalytic β-subunit and has no effect on other serine or 
cysteine proteases. Blocking the proteasome inhibited IκBα degradation in the 
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Figure D.3. Mitochondrial IκBα degradation upon TNF treatment is 
proteasome independent. HeLa cells were treated with DMSO or lactacystin 
(40ng/ml) for one hour and subsequently with TNF (20ng/ml) for the indicated times. 
Mitochondrial and cytosolic fractions were separated with standard methods and 
loaded on a 12% SDS gel, which was probed with the indicated antibodies. 
cytosol upon TNF treatment but had no effect on mitochondrial IκBα degradation. 
This result suggests that TNF also activates a separate protease that degrades the 
mitochondrial IκBα (Figure D.3).  
 
 
 
 
 
D.1.4.  IκBα associates with the OMM of several cell lines 
Following our hypothesis that IκBα at mitochondria plays a role on 
apoptosis, we wanted to examine the level of its protein at the mitochondria and 
also the sub-cellular residence of IκBα within the organelle. We used 
immunofluorescence and determined that in Hela, MCF7, and 3T3 cells IκBα partly 
co-localised with mitochondria. In MDA-231, PC3, and HCT-116 cells that display 
constitutive NF-κB activity (Dejardin et al., 1999; Nakshatri et al., 1997b; Sakamoto 
et al., 2009; Suh et al., 2002), the co-localisation of IκBα with mitochondria was 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 145 
 
even more pronounced (Figure D.4A). This distribution was substantiated in cell 
fractionation experiments which revealed that MDA-MB-231 cells show high 
expression levels of IκBα at mitochondria whereas its cytosolic levels were 
diminished. In contrast MCF7 cells, which are also a carcinoma cell line from the 
breast tissue, revealed only partial localisation of IκBα to mitochondria and the 
cytosolic levels were much higher (Figure D.4B). These results implied that there is 
a preference for IκBα localisation to mitochondria in cell lines with constitutive NF-
κB activity. In order to test the exact localisation of IκBα in several cell lines we 
utilized the conditions that we optimised earlier for the proteolytic cleavage of 
proteins at the OMM. Treatment of intact mitochondria with proteinase K isolated 
from Hela cells revealed that the enzyme gained access to IκBα as it could 
substantially reduce the IκBα signal in a protein blot and likewise that of the OMM 
protein Tom20 as a control. In contrast, the inner mitochondrial protein 
cytochrome c was protected (Figure D.4C). With mitochondria from the remaining 
cell lines we likewise found that IκBα could be cleaved by proteinase K suggesting 
that it was also associated with the OMM (Figure D.4D). 
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Figure D.4. IκBα is found at the outer mitochondrial membrane. (A) Confocal 
photomicrographs of IκBα distribution in normal cells (upper panels) and cells with 
constitutively active NF-κB (lower panels) (B) Mitochondrial and cytosolic fractions 
from HeLa, MCF7 and MDA-231 cells were loaded on a 12% SDS gel. Cytosolic fractions 
were 10X more concentrated than the mitochondrial fraction since mitochondrial 
proteins represent ~10% of the total protein content. (C) Mitochondrial and cytosolic 
fractions were isolated from HeLa cells and treated with proteinase K to identify the 
localisation of IκBα. IκBα was found to associate with the OMM. (D) Mitochondrial 
fractions of the indicated cell lines were treated with proteinase K to validate the 
localisation of IκBα within the organelle. The same conditions and mitochondria purity 
were used as in (C). (* indicates an unspecific band). 
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D.2.  IκBα is an apoptosis inhibitor 
Having identified that IκBα resides at mitochondria of several cell lines and 
with some of them its expression level being high, we employed transient 
expression of IκBα to check its effect on apoptosis. Various genes, implicated in 
apoptosis induction or inhibition, have the dominant capacity to exert their effect 
upon overexpression. This feature is even conserved across species (McCarthy & 
Dixit, 1998). Several constructs directing IκBα to mitochondria (OMM and IMS) or 
sequestering it in the cytosol were employed to address its apoptosis regulation 
from different subcellular locales. 
Using specific N-terminal fusions of ΙκΒα to the mitochondrial localisation 
sequences of mitoNEET (Wiley et al., 2007a) and Smac/DIABLO (S/D) (Ozawa et al., 
2007a), we aimed to target IκBα to the OMM and to the mitochondrial 
intermembrane space, respectively. Immunofluorescence confirmed the 
localisation of the fusion constructs to mitochondria and proteinase K digest on 
isolated mitochondria in combination with Western blotting supported their 
residence in the expected compartments. We then tested the activity of the fusion 
constructs in an apoptosis assay. MitoNEET-IκBα (ΜΕΕΤ-IκBα) completely 
abolished apoptosis induced by ANT1 transfection. WT IκBα led to an intermediate 
apoptosis reduction, while the S/D-IκBα fusion had no effect on apoptosis. IκBβ 
was likewise ineffective for cell death inhibition. A fusion of IκBα to the 
mitochondria localisation sequence of yeast mcr1, which among other membranes 
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also associated with the OMM (Hahne et al., 1994b), led to inhibition of ANT1-
induced apoptosis in 293T, MCF7, and Hela cells (Figure D.6B). To determine how 
general the inhibitory effects on apoptosis were, we tested additional apoptosis-
inducing genes and observed a strong apoptosis reduction when the pro-
apoptotic genes Bax, VDAC1, and tBid were co-transfected with MEET-IκBα, while 
apoptosis induced by caspase-8 was only weakly affected. 
D.2.1.  Generation and validation of constructs allowing 
targeting of IκBα to the mitochondria 
For the yeast mcr1 gene we used the first 141 bp in order to direct IκBα to 
the mitochondria. According to the model that Haucke et al. (1997) have 
published, the first 12 amino acids of MCR1 are inserted into the inner 
mitochondrial membrane and amino acids 13 to 47 reside in the intermembrane 
space where they are cleaved in order to release the fused protein. The constructs 
for IκBα, mcr1-IκBα and mcr1-IκBα-FLAG were inserted into a mammalian 
expression vector and were verified by sequencing and western blotting. To 
confirm the localization of the MCR1-IκBα protein, HeLa cells were transfected 
with the fusion gene mcr1-IκBα and cell fractionation for mitochondria and cytosol 
was performed. The results show the correct localization of mcr1-IκBα at 
mitochondria with minimal or no contamination of overexpressed protein in the 
cytosol (Figure D.5).  
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Figure D.5. Mcr1-IκBα is targeted to mitochondria. (A) Cartoon 
representation of IκBα fused with the localization signal of yeast mcr1. (B) Confocal 
photomicrographs of Hela cells transfected with mcr1-IκBα-FLAG, mitoGFP and ER-
DsRed. (C) Hela cells were transfected with the indicated constructs and 
mitochondrial extracts were separated from cytosol with standard procedures.  
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D.2.2.     IκBα is a strong apoptosis inhibitor 
The investigation of IκBα at the mitochondrial level required the 
establishment of an experimental setting relevant for the localisation of the 
endogenous protein. Our lab has identified that the Adenine Nucleotide 
Translocase 1 (ANT-1) which resides at the IMM is a strong apoptosis inducer 
when overexpressed (Bauer et al., 1999). We initially applied this finding to induce 
apoptosis in 293T, HeLa and MCF7 cells and investigated if IκBα can have any 
effect on this apoptosis. IκBα could indeed completely abrogate the strong 
apoptosis inducer ANT-1 and this effect was even more pronounced when it was 
targeted to mitochondria (Figure D.6A). A titration experiment revealed that even 
wt-IκBα could completely inhibit ANT-1 apoptosis. The effect was not cell-specific 
since similar results were obtained in HeLa and MCF7 cells (Figure D.6B). IκBα and 
mcr1-IκBα could also inhibit the apoptosis observed in Hela cells after 
administration of ionomycin. This drug initiates an influx of calcium to 
mitochondria, which leads to mitochondrial membrane potential dissipation and 
collapse of the OMM integrity. IκBα targeted to mitochondria could potently 
inhibit this apoptosis signal (Figure D.6C) 
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Figure D.6.  IκBα is a strong apoptosis inhibitor at mitochondria. (A) IκBα 
wt and mcr1-IκBα inhibit ANT-1 apoptosis in a dose-dependent manner. 293T cells 
were transfected using Superfect with the indicated constructs and after 24h, 
apoptosis was quantified by PI staining with cell lysis. (B) MCF7 and HeLa cells were 
transfected using Effectene and 24h post transfection cell death was quantified by PI 
staining with lysis. (C) IκBα can inhibit the loss of ∆Ψm. HeLa cells were transfected 
with Effectene and 24 post transfection Ionomycin was used at 20µM. 2 hours later 
the mitochondria membrane potential was quantified using DioC staining. 
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D.2.3.  Generation and validation of constructs allowing 
targeting of IκBα to specific sub-mitochondrial localisation  
The mitochondrial NADH-cytochrome b5 reductase gene (mcr1) is an 
example of a gene encoding a protein that is directed to two sub-mitochondrial 
compartments (Haucke et al., 1997). The N-terminal 47aa of the yeast mcr1 gene 
are able to target the same protein to the OMM and IMS. Likewise, any protein 
fused to the first 47 amino acids of the mcr1 gene would be targeted both to the 
OMM and the IMS. On the contrary it has been shown in the past that alanine 
substitution for glutamine at positions 23 and 24 can direct any protein almost 
exclusively to the IMS (Haucke et al., 1997).  
In order to identify the locale of IκBα that is required for its anti-apoptotic 
effect, mcr1AAQQ-IκBα was generated in order to determine if the IMS localisation 
is responsible. Moreover, the constructs S/D-IκBα and MitoNEET-IκBα were 
generated that can potently and exclusively direct IκBα to the IMS and OMM, 
respectively. Figure D.7 shows that the constructs were validated by 
immunofluorescence and western-blotting for their expected sub-organelle 
localisation.  
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Figure D.7. MEET-IκBα and S/D-IκBα are targeted to the OMM and IMS 
respectively. (A) Cartoon representation of MEET-IκBα and S/D-IκBα. (B) Confocal 
photomicrographs showing co-localization of the indicated constructs at 
mitochondria. HeLa cells were transfected with mito-GFP and the indicated fusions of 
IκBα and 24h post transfection immunofluorescence was performed. (C) Fusion 
constructs reside in the correct sub-mitochondrial fractions. Proteinase at 25ng/ml 
was utilized to cleave OMM proteins leaving the IMS unaffected.   
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D.2.4.  IκBα inhibits apoptosis at the OMM 
After the validation of the constructs we proceeded with the same 
experimental setting as previously to assess the locale at which IκBα exerts its anti-
apoptotic effect. It was found that IκBα inhibits apoptosis at the outer 
mitochondrial membrane and is ineffective when targeted to the IMS (Figure 
D.8A-B). ANT-1 was not the only apoptosis inducer that IκBα could inhibit. 
Transfection of other pro-apoptotic genes such as Bax, VDAC1, or tBid led to 
apoptosis initiation and IκBα could inhibit this effect as well. When it was targeted 
to the OMM the effect was even more pronounced (Figure D.8C).  
 
 
 
 
 
 
 
 
*** 
ANT-1 apoptosis 
*** 
*** 
N.S. 
N.S. 
A 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 156 
 
 ** 
*** *** *** 
Figure D.8. IκBα is a strong apoptosis inhibitor at the OMM. (A) 293T 
cells were co-transfected with ANT-1 and the indicated constructs at a ratio 1:2 
using calcium phosphate. 24 hours post-transfection cells were collected and 
DioC/PI staining was used to quantify apoptosis. Data represent six independent 
experiments with triplicates. (B) Expression pattern of IκBα-fusions for the 
indicated experiment. Numbers represent the sequence of the upper panel (1:β-gal, 
2:IκBαwt, 3:mcr1-IκBα, 4:MEET-IκBα, 5:S/D-IκBα, 6:AA23/24QQmcr1-IκBα  (C) tBid, 
Bax-β, VDAC1, and Caspase 8 were co-transfected with the IκBα-wt and MEET-IκBα 
to assess the inhibition profile of IκBα. Four independent experiments with 
triplicates were combined in the graph. (***p<0.0001, **p<0.001) 
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D.2.4.1.  IκBα but not IκBβ can inhibit apoptosis and its effect 
is specific at mitochondria 
After the discovery that IκBα can inhibit apoptosis especially when targeted 
to mitochondria, the investigation of its specificity was the next step. IκBα shares 
extensive sequence similarity with IκΒβ and its effect on apoptosis was tested in a 
similar assay. As figure D.9C shows, IκBβ was completely incapable to inhibit 
apoptosis compared to IκBα-wt. Furthermore, the specificity of apoptosis 
inhibition at mitochondria was tested in order to assess if the locale was 
specifically required or if the inhibitory ability was due to non-specific effects of 
over-expression. In order to investigate that possibility we generated a fusion of 
IκBα with the β-actin gene (Figure D.9A) to sequester IκBα in the cytosol and avoid 
its mitochondrial localisation. Figure D.9B shows that the actin fusion of IκBα was 
not co-localised at mitochondria in contrast to MEET-IκBα and was unable to 
inhibit apoptosis induced by ANT-1 (Figure D.9C). 
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Figure D.9. IκBα but not IκBβ inhibits apoptosis exclusively at the OMM. 
(A) Cartoon representation of IκBα/βActin in pcDNA3 expression vector. (B) Confocal 
images of HeLa cells transfected with mito-YFP, MEET-IκBα or IκBα/βActin. Cells were 
stained for IκBα antibody. (C) 293T cells were transfected using Xfect with ANT-1 and 
the indicated plasmids and apoptosis was quantified 24h post transfection using PI 
staining. IκBα sequestered in the cytosol is unable to inhibit apoptosis in contrast to 
IκBα targeted to mitochondrial OMM (left panel). ***p<0.001, **p<0.01  
*** *** 
N.S. 
N.S. 
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D.2.5.  Reconstitution of IκBα in 3T3 IκBα-/- cells renders 
them resistant to apoptosis 
Genetic knockouts have provided an experimental tool for the identification 
of possible consequences of the absence of the respective protein under 
investigation. IκBα-/- mice show constitutive NF-κB activation, and neonatal 
lethality. We tried to investigate the effect on apoptosis using a re-constitution 
model for IκBα at different subcellular compartments and in parallel to confirm the 
results from the ectopic expression experiments described earlier. We utilized a 
lentiviral expression strategy in order to reconstitute IκBα only at the outer 
mitochondrial membrane or only in the cytosol. MEET-IκBα and IκBα/βActin 
proved to be the suitable fusions for this purpose. We used a lentiviral vector 
which contains a CMV promoter for the transgene expression, followed by a SV40 
promoter expressing a GFP mutant so that the positive colonies would be visually 
identified.  
We reconstituted IκBα at the OMM at a level similar or lower than the one 
observed in wild type fibroblasts (Figure D.10B) by modifying the multiplicity of 
infection of the virus. Reconstitution of IκBα at mitochondria of IκBα -/- fibroblasts 
significantly reduced the sensitivity of these cells to several apoptotic stimuli 
whereas IκBα sequestered in the cytosol had the opposite effect (Figure D.10C). 
We checked the level of active NF-κB in order to have a baseline for comparison 
and interpretation of the results. A non-radioactive assay with a biotinylated-
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tandem-κΒ-oligo-pulldown, showed that both MEET-IκBα and IκBα/βActin 
inhibited the NF-κB activation to the same extent, which made the experimental 
setting more accurate since the comparison could be made (Figure D.10E) 
NF-κB activity and especially constitutive NF-κB activation has been 
observed in several aggressive tumours as discussed in the introduction chapter. 
Since NF-κB has an anti-apoptotic activity in these tumours we investigated if NF-
κB has an anti-apoptotic activity on these cells so we can take that under 
consideration when interpreting the reconstitution results. Using a specific NF-κB 
inhibitor (N-Oleoyldopamine) and two signals for apoptosis we inhibited the NF-
κB system in IκBα -/- cells  (reconstituted with an empty vector) and we found that 
these cells are more sensitive when NF-κB is inhibited showing that in those cells 
constitutive NF-κB activation confers an anti-apoptotic signal (Figure D.10D).  
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Figure D.10. Effect of IκBα reconstitution at the OMM and the cytosol in 
IκBα -/- cells.  (A) Cartoon representation of the lentiviral constructs used for the 
reconstitution of the indicated genes in 3T3 IκBα-/- cells. A GFP variant was also 
expressed in a bi-cistronic format for easier sorting of the cells. (B) Two weeks post-
transduction, cells were selected in a FACS sorter for GFP and WB from total lysates 
(left panel) was used to identify the level of expression after reconstitution. Both 
IκBα/βActin and MEET-IκBα are expressed at a lower level than 3T3-WT cells. 
Mitochondrial IκBα after reconstitution was examined after fractionation and 
separation from the cytosol. (EV: Empty Vector, WT: Wild type) (C) Effect on apoptosis 
of mitochondria-specific IκBα reconstitution in IκBα-/- (constitutive NF-κB positive) 
cells. IκBα-/- cells were reconstituted and treated with the indicated signals for 
apoptosis. Apoptosis was assessed by FACS analysis. (D) 3T3 IκBα-/- reconstituted 
cells with an empty vector were assessed for their dependence on constitutive NF-κB 
activation. N-Oleyoldopamine (OLDA) was used to inhibit NF-κB and cells were 
subsequently treated with the indicated drugs. Apoptosis was quantified 24h post 
treatment. (NT: Non-treated) (E) Reconstitution of mitochondrial or cytosolic IκBα 
equally inhibits the constitutive NF-κB activation observed in IκBα-/- cells. Biotin 
conjugated κB tandem repeats was immunoprecipitated from nuclear extracts of the 
indicated reconstituted cells and SDS-PAGE was used to assess the level of active NF-
κB. 
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D.2.6.  Knock down of IκBα in cancer cell lines with 
constitutive NF-κB activity sensitises them for apoptosis 
Having established that IκBα can potently inhibit apoptosis at the OMM 
and possibly contributes to the apoptosis resistance observed in many cancers, we 
progressed to investigate its function in those cancer cells. We established the 
experimental setting in a way so that the cells we used had IκBα at mitochondria, 
had constitutively active NF-κB, and were very resistant to apoptosis. PC3 and 
MDA-MB-231 cells were found to fulfil these criteria. It was shown earlier that 
MDA-231 cells accumulate IκBα at mitochondria with minimal expression in the 
cytosol (Figure D.4B). These cells have constitutively active NF-κB that is not 
dependent on IκBα degradation and are extremely resistant to several 
chemotherapeutics. 
Since IκBα has an anti-apoptotic role when expressed at mitochondria and 
since in MDA-231 cells IκBα is found mainly at mitochondria, we reduced the 
expression of IκBα by lentiviral shRNA so that the mitochondrial IκBα is 
significantly down-regulated. We observed, that when IκBα was knocked-down, 
MDA-231 cells were sensitized to several apoptotic signals, which were ineffective 
previously (Figure D.11C-E). Likewise, PC3 cells in which immunofluorescence 
likewise showed enhanced localization of IκBα at mitochondria and proteinase K 
treatment revealed that IκBα is located at their OMM, were sensitized to apoptotic 
signals (Figures D.4A, D.4D). HCT-116 cells show the same trend for apoptosis 
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sensitization after IκBα knock-down (Figure D.11F). In order to exclude off-target 
effects of the shRNA sequence that we used (sh IκBα-42) we generated an 
additional stable cell line with an alternative targeting sequence for IκBα knock-
down. Figure D.11C shows that the effects were specific and shIκBα(88) likewise 
sensitized MDA-231 cells for apoptosis induction. A cell viability assay (MTT) 
revealed that MDA-231 cells with reduced IκBα expression showed reduced 
viability compared to normal cells (scramble) (Figure D.11D) confirming the 
sensitisation to apoptosis observed previously (Figure D.11B)    
Since NF-κB activation is conferring an anti-apoptotic signal to several 
cancers we investigated the effect of IκBα knock-down to MDA-231 and PC3 cells. 
If the NF-κB system was affected the results would have been interpreted 
accordingly. We show in figure D.11A that shRNA-mediated knock-down of IκBα 
in MDA-231 and PC3 cells did not affect the level of endogenous constitutively 
active NF-κB. 
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Figure D.11. Knock-down of IκBα in cells with constitutively active NF-
κB sensitizes them to apoptosis. (A) Lentiviral-based knock-down of IκBα by 
shRNA diminished the expression of its protein in MDA-MB-231 cells (upper 
panel) and in PC3 cells (lower panel). NF-κB was not affected by the down-
regulation as indicated by a biotinylated-oligo-pull-down assay. (SC*: Non-
labelled oligo in 1000X excess) (B) MDA-231 cells were treated with the indicated 
drugs (arsenic 10µΜ, clotrimazole 40µΜ-4 hours- and doxorubicin 1µΜ for 24h) 
and apoptosis was assessed by FACS and PARP cleavage. (C) An alternative 
shRNA construct for IκBα was also used to exclude possible off-target effects, 
showed similar results with (B) after treatment under the same conditions. (D) 
MDA-231 cells were treated with 1µΜ doxorubicin and subjected to an MTT assay 
for cell viability. (E) Identical approach with (B) was used for PC3 cells which were 
treated with 1,4 µΜ actinomycin D, 1µΜ Staurosporine (STS) and 5nM Docetaxel 
for 24h. Apoptosis was assessed with FACS and PARP cleavage. (F) Knock-down of 
IκBα in HCT-116 cells was confirmed by semi-quantitative RT-PCR. Ionomycin 
10µΜ and STS 1µΜ were used to induce apoptosis in those cells.***p<0.001, 
**p<0.01  
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D.2.7.  In vivo MDA-231 tumour shrinkage with doxorubicin 
after knock-down of IκBα 
Following the above observations in vitro for the role of IκBα on the 
resistance to chemotherapeutics that is observed in cells lines with increased levels 
of IκBα at mitochondria, we sought to examine the role of IκBα in vivo. MDA-231 
as the in vitro study shows are extremely resistant to chemotherapeutics such as 
doxorubicin. We transduced MDA-231 cells with lentiviruses encoding for 
scramble or for shRNA targeting IκBα. We used these cells to generate xenografts 
by injecting 2x106 cells of each cell line in the mammary fat pad of 8 Balb/c nu/nu 
mice. After four weeks the mice were examined for tumour formation. Tumour 
growth was observed only in the MDA-231/shIκBα cells but we decided to 
proceed to the treatment in order to determine relevant concentrations of 
doxorubicin.  
Two out of eight mice did not develop palpable tumours. We randomly split 
the 6 mice into two groups for PBS or doxorubicin treatment. Mice were weighted 
and PBS or doxorubicin (6mg/kg) was administered intravenously (i.v.). Figure 
D.12A shows the days when the tumours were measured and the drug was 
administered. 14 days after the initiation of the treatment PBS treated mice 
showed tumour formation in both sides which grew substantially to the same 
level. 21 days post treatment initiation MDA-231/scramble also started growing 
and eventually continued growing even when they were under doxorubicin 
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treatment. MDA-231/shIκBα tumours despite being substantially bigger and the 
only ones growing at the initial treatment stages, were re-sensitized and shrank 
even stronger that the MDA-231/scramble cells. Figure D.12B shows the average 
tumour size on the various days of measurement for PBS- and doxorubicin-treated 
mice. However, statistical significance was not achieved due to the small mice 
number. Results shown were derived from a small pilot study to determine the 
ability of MDA-231 cells to develop tumours and determine an effective 
doxorubicin dose for a later, large scale study. All in vivo experiments were 
conducted following the 1986 Act for Animals (Scientific Procedures) and under 
PPL : 70/7173    
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Figure D.12. Mouse xenografts from chemotherapy-resistant MDA-231 
cells are re-sensitized after IκBα knockdown. Random grouping of 
previously engrafted mice in the mammary fat pad (mfp) with MDA-231/scramble 
and MDA-231/shIκBα cells were injected i.v. with PBS (upper graph and upper 
panel) or doxorubicin (6mg/kg)(lower graph and lower panel) for the days 
indicated in the graphs. Calliper measurements were taken on the same days as 
treatment. Graphs are showing average tumour sizes from 3 Balb/c nu/nu mice in 
each group. Tumour size was calculated following the formula: 
V (mm3) =

∗∗∗
  . PBS mice were sacrificed at D30 to comply with 
the conditions of the Act since tumour sizes reached the limit of the project licence.  
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D.3.  IκBα is a PT-pore modulator 
In an effort to explore the function of IκBα at the OMM we tried to identify 
the interaction partners of IκBα at this locale. Using immunoprecipitations we 
discovered a strong signal with the OMM protein VDAC1 and Hexokinase II, but 
not with cytochrome-c. IκBα was also able to co-immunoprecipitate with CK1 and 
ANT1, which are localised in the intermembrane space and the inner mitochondrial 
membrane, respectively (Figure D.13). This suggested that IκBα can associate with 
molecules that are part of the permeability transition (PT) pore. Accordingly, 
deletion of cyclophilin D, which inhibits the PT pore (Baines et al., 2005; Basso et 
al., 2005; Nakagawa et al., 2005; Schinzel et al., 2005), also completely inhibited the 
activity of MEET-IκBα to reduce apoptosis (Figure D.14). In addition, ANT1-induced 
apoptosis was efficiently inhibited by IκBα and is mediated by the PT pore as it is 
dependent on cyclophilin D (Figure D.14). Moreover, the shRNA-mediated 
knockdown of VDAC1 or Hexokinase II also reduced the potential of MEET-IκBα to 
inhibit apoptosis (Figure D.15). These experiments suggested that IκBα targets 
VDAC1 and/or HKII to inhibit apoptosis. In an effort to determine the behaviour of 
IκBα under apoptotic conditions, it was found that IκBα loses its interaction with 
VDAC1 while maintaining its interaction with hexokinase II (Figure D.15).  
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D.3.1.  Endogenous interaction of IκBα and components of 
the PT-pore 
Having identified the locale of IκBα that is required for apoptosis inhibition 
I sought to identify those molecules that are necessary for IκBα to interact and 
exert its anti-apoptotic effect. I used isolated mitochondria from HeLa cells and 
immunoprecipitated IκBα. I found that IκBα can interact with VDAC1, ANT-1, CK1 
and Hexokinase II but was un-able to interact with cytochrome-c (Figure D.13A-B) 
establishing a physical interaction with members of the PT-pore.  
In the previous section IκBα was found to exert its anti-apoptotic effect at 
the OMM. One prominent molecule that resides at the OMM is VDAC1 and IκBβ 
was not found able to interact with VDAC1 as IκBα (Figure D.13C). The latter was 
performed after the finding that IκBα, but not IκBβ, can inhibit apoptosis (see 
chapter D.2.4.1).   
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Figure D.13. IκBα interacts with subunits of the PT-pore. (A) Hela cells were 
lysed with RIPA buffer and 5% n-dodecyl-D-maltoside added and the lysates incubated 
on ice for 30 min. After high speed centrifugation the supernatant was recovered and 
IKBα was immunoprecipitated using a monoclonal antibody. The pulled-down proteins 
were separated by SDS-PAGE (IP: ImmunoPecipitation, C: Control). The blot was probed 
with several antibodies against subunits of the PT pore or proteins of the IMS. (B) MCF7 
cells, which express high levels of HXKII, were used to pull-down IκBα and identify the 
IκBα-HXKII interaction (C) Whole cell lysates were used to pull down IκBα or IκBβ and a 
sequential staining for IκBα and IκBβ was performed for the pull-down/input while a 
monoclonal VDAC1 antibody was used to identify interaction.  
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D.3.2.  IκBα requires the PT-pore to exert its anti-apoptotic 
effect 
The PT-pore is acknowledged to play an important role in apoptosis as a 
protein complex, but individual members such as ANT-1, VDAC1 and cyclophilin D 
have also independently been implicated in apoptosis regulation. We sought to 
identify the importance of the PT-pore for IκBα to exert its anti-apoptotic effect. 
We used cells in which cyclophilin-D is absent (ppif-/-) and which, as a 
consequence, show increased resistance to apoptotic stimuli since the PT-pore 
cannot be activated.  
As described in previous sections we used ANT-1 to induce apoptosis and 
IκBα as an apoptosis inhibitor. Previous findings from our lab show that ANT-1 
apoptosis can be inhibited by bongkrekic acid (Bauer et al., 1999), a specific 
inhibitor of the PT-pore. We initially tested ANT-1 and found that its apoptosis 
induction is mediated by the PT-pore since transfection of ANT-1 in ppif-/- cells 
rendered ANT-1 incapable of inducing apoptosis (Figure D.14A). Likewise, we 
tested the ability of IκBα to inhibit apoptosis when the PT-pore cannot be 
activated (using ppif-/- cells). We found that IκBα could inhibit apoptosis induced 
by several drugs in normal mouse embryonic fibroblasts but was not able to 
further inhibit apoptosis in cells with a defective PT-pore (Figure D.14B).  
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Figure D.14. IκBα exerts an anti-apoptotic effect through the PT-pore. (A) 
MEF-WT and MEF-ppiF-/- were tested with a WB for the validation of the gene knock-out 
(right panel). MEF-WT and MEF-ppiF-/- were transfected with X-fect with ANT-1 and 24h 
post transfection DiOC/PI was measured to quantify apoptosis. (B) MEF-WT and MEF-
ppiF-/- were transfected with an empty vector and with MEET-IκBα. 24 hours post-
transfection cells were treated with ionomycin (10µM, 3h), menadione (15µM, 20h), and 
H2O2 (500µM, 24h). Apoptosis was quantified by DioC/PI staining and FACS. (***: 
p<0.0001, N.S.: Non-significant)  
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D.3.3.  IκBα targets VDAC1 to exert its anti-apoptotic effect 
An important modulator of the PT-pore that induces apoptosis when over-
expressed is VDAC1 as mentioned in the introduction. We established that IκBα 
has a very strong anti-apoptotic effect when targeted to the outer mitochondrial 
membrane and that the PT-pore is necessary for this inhibitory effect. Bearing in 
mind the above we attempted to identify the interaction partner that IκBα is 
targeting to exert its effect. At the OMM two important proteins that form an 
essential anti-apoptotic complex were tested for this purpose. VDAC1 and 
Hexokinase II (HXKII) were found to be required for IκBα’s anti-apoptotic effect.  
Using knock-downs of VDAC1 and HXKII in 293T cells and in 3T3 IκBα-/- 
reconstituted cells we determined that both VDAC1 and HXKII are necessary for 
apoptosis inhibition via IκBα. Knock-down of VDAC1 completely abolished the 
ability of IκBα to inhibit apoptosis (Figure D.15A, D.15C) and the effect was 
observed both with overexpressed IκBα and reconstituted IκBα. Likewise, HXKII 
reduction abrogated the inhibitory effect of IκBα (Figure D.15B). 
Immunoprecipitation of IκBα from cells with stably reduced VDAC1 left the IκBα-
HXKII interaction unaffected as similar to when HXKII was knocked-down and the 
interaction between VDAC1 and IκBα was examined (Figure D.15D).   
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Figure D.15. IκBα targets VDAC1 to exert its anti-apoptotic effect. (A) 
VDAC1 was stably knocked-down in 293T cells using lentiviral particles. Its expression 
was checked in a WB after 7 days of puromycin selection. ANT-1 and 20µΜ ionomycin 
were used for apoptosis induction and transfection of empty vector or MEET-IκBα. 
Apoptosis was quantified by FACS. (B) The same procedure as (A) was used to knock-
down HXKII and likewise the ability of IκBα to inhibit apoptosis was examined. (C) 3T3 
IκBα -/- cells reconstituted with an empty vector or with MEET-IκBα were transduced 
with lentiviral particles to reduce VDAC1. Apoptosis was induced with Ionomycin 
(20µΜ) or clotrimazole (40µΜ). (D) Stable knock-down 293T cells for the indicated 
proteins were used to immunoprecipitate IκBα and its HXKII interaction or VDAC1 
interaction was assessed.  
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D.3.4.  IκBα dissociates from VDAC1 upon apoptosis 
IκBα was found to interact endogenously with members of the PT-pore 
under physiological conditions. Since IκBα is able to inhibit apoptosis via its 
interaction with VDAC1 and HXKII, we anticipated that upon apoptosis these 
interactions might change. We used HeLa and HCT-116 cells and identified the 
conditions, which induce apoptosis after 24h but without any morphological or 
biochemical sign of cell death after 10 hours of induction. We chose 2 different 
cell lines to avoid cell type-specific effects and used the 10h time point to avoid 
degradation of proteins due to apoptosis initiation.  
Using immunoprecipitations of IκBα we found that upon induction of 
apoptosis with arsenic trioxide IκBα lost its ability to interact with VDAC1 but 
maintained the HXKII interaction (Figure D.16B). In parallel the lack of overt 
apoptosis was assessed biochemically using DioC/PI staining 10 hours post 
treatment with As2O3 (Figure D.16A). 
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Figure D.16. IκBα dissociates from VDAC1 upon apoptosis. (A) HeLa and 
HCT-116 cells were treated with arsenic trioxide (As2O3) for 10 and 24 hours and 
apoptosis was assessed with DioC/PI double staining. (B) DMSO- and arsenic-
treated HeLa and HCT-116 cells were collected 10 hours post-treatment and IκBα 
was immunoprecipitated from total cell lysates. Hexokinase II and VDAC1 protein 
levels were examined.  
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D.4.  The anti-apoptotic effect of IκBα is 
structurally and functionally independent 
from its function on NF-κB inhibition  
The discovery of IκBα as a mitochondrial apoptosis inhibitor prompted 
questions about this role and the exact mechanism of action. The well-established 
role of IκBα as the inhibitor of NF-κB gives it characteristics of an pro-apoptotic 
molecule but at the same time IκBα can very potently inhibit several forms of 
mitochondrial apoptosis signals. We took the initial step to determine if the NF-κB 
activity played any role in the anti-apoptotic activity of IκBα. Using functional NF-
κB inhibitor mutants of IκBα we discovered that the anti-apoptotic activity was not 
altered. A non-degradable form of IκBα (ΙκBα-S) and an IκBα mutant impaired in 
NF-κB inhibition (IκΒα-110A3) (Sachdev et al., 1998a) were as effective as WT-IκBα 
for inhibition of apoptosis by Bax and ANT1 (Figure D.17). A reporter assay 
confirmed that under these conditions the endogenous NF-κB system was not 
activated (Figure D.17). In order to explore whether the effect on apoptosis could 
structurally be separated from the known activity of IκBα to inhibit NF-κB, we 
generated MEET-IκBα deletion mutants including one of the IκBα N-terminus and 
one of its C-terminus that are dispensable and required for NF-κB inhibition, 
respectively (Hatada et al., 1993a). An inverse structural requirement was found for 
apoptosis inhibition: The N-terminus of IκBα was necessary for apoptosis 
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inhibition, while the C-terminus could be deleted without compromising apoptosis 
repression by IκBα (Figure D.18). The N-terminus of IκBα interacts with VDAC1, 
which is the required domain for apoptosis inhibition (Figure D.18B-C). 
Furthermore, The N-terminus and the first ankyrin repeat constitute a domain 
sufficient for apoptosis inhibition as identified by sequential deletions of the IκBα’s 
C-terminus (Figure D.19). All together these experiments strongly suggested that 
the effects on apoptosis exerted by IκBα were independent of NF-κB inhibition. 
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D.4.1.    Functional mutants of IκBα can still inhibit apoptosis 
Several IκBα mutants have been established, which alter its function on NF-
κB inhibition. The IκBα super-repressor (IκBα-SR) is a mutant of IκBα with 
alterations of the amino acids 32 and 36, which render IκBα resistant to 
degradation by the proteasome. The protein product of this construct is able to 
permanently inhibit NF-κB. Mutations at the ankyrin repeat 2 of IκBα have been 
shown to neutralise the ability of IκBα of inhibiting NF-κB. The product of the 
construct IκBα-110A3 is permanently incapable of NF-κB inhibition. We used these 
constructs along with IκBα-wt in order to determine if alteration of IκBα for NF-κB 
inhibition activity had also any effect on its ability to inhibit apoptosis. We tested if 
the NF-κB system was induced by ectopic expression of ANT-1 or Bax in order to 
establish a system that allows making comparisons. It was found that IκBα mutants 
maintained their ability to inhibit ANT-1 or Bax apoptosis (Figure D.17A). NF-κB 
activation initiates an anti-apoptotic signal so we sought to ensure that such 
conditions were not realised. Under our conditions the endogenous NF-κB system 
was not induced as confirmed by an assay using a reporter plasmid for NF-κB 
activation while the TAX gene expression potently activated the system (Figure 
D.17B). That further indicated that IκBα inhibits apoptosis independently of its 
function on NF-κB.    
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*** 
*** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D.17. Mutants of IκBα for NF-κB inhibition function can 
diminish apoptosis. (A) ANT-1 or BAX were co-transfected with β-gal, IκBα-wt, 
IκBα-SR, and IκBα-110A3 at a ratio 1:2 in 293T cells. X-fect was used to ensure a 
high transfection efficiency and apoptosis was quantified 24 hours post-
transfection. Means from 4 independent experiments are shown. (B) 293T cells 
were transfected with pcis-hNF-κB and β-gal, TAX, BAX or ANT-1. EGFP was 
measured 24 hours post transfection to quantify the activation of NF-κB using 
FACS-FL1 channel. zVAD was used in all cases to inhibit apoptosis and potential 
degradation of proteins. (***p<0.0001)  
A 
B 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 188 
 
D.4.2.  The N-terminal domain of IκBα is necessary for 
apoptosis inhibition 
Using site-directed mutagenesis and recombinant PCR we generated 
deletion mutants of IκBα to identify the domain necessary for apoptosis inhibition. 
We used the MEET-IκBα fusion in order to ensure validity of the effect since MEET-
IκBα expression completely abrogates even strong apoptosis signals and allows to 
separate domains responsible for apoptosis inhibition from those responsible for 
mitochondrial targeting. We deleted the N-terminus, the ankyrin repeats 1-3, the 
ankyrin repeat 4-5 and the C-terminus. We examined the correct localisation and 
expression of these constructs (-FLAG-tagged) with immunofluorescence (Figure 
D.18A) 
In order to identify the necessary domain for apoptosis inhibition we tested 
these deletions in an apoptosis assay and expressed them together with ANT-1. 
We found that the N-terminal domain of IκBα (1-70) was not able to inhibit 
apoptosis as the other deletions did (Figure D.18B). Having established VDAC1 as 
the primary target of IκBα at mitochondria we used immunoprecipitations to test 
the ability of mutants to interact with this protein. It was found that deletion of the 
N-terminus renders IκBα incapable to interact with VDAC1 (Figure D.18C) 
explaining why this construct cannot inhibit apoptosis.  
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Figure D.18. The N-terminal domain of IκBα interacts with VDAC1 and is 
necessary for apoptosis inhibition. (A) Schematic representation of the deleted 
domains of IκBα (upper panel). Confocal microphotographs of HeLa cells transfected with 
the indicated deletion mutants of MEET-IκBα, which were co-transfected with mitoYFP 
and stained for FLAG (fused at the C-terminus of IκBα) 24h post transfection. (B) ANT-1 
was co-transfected with the indicated deletion mutants of MEET-IκBα and 24h post-
transfection apoptosis was assessed by FACS. (C) Deletions of MEET-IκBα were 
transfected into 293T cells and a FLAG antibody was used to pull-down. A VDAC1 
antibody was used to determine interaction.   
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D.4.3.  The IκBα domain sufficient for apoptosis inhibition 
consist of the N-terminus and the first ankyrin repeat 
As it was found in the previous chapter that the N-terminus of IκBα is 
necessary for apoptosis inhibition, the next question we asked was if that N-
terminus represents a functional moiety of IκBα, which is also sufficient to inhibit 
apoptosis. We used the MEET-IκBα fusion protein to generate deletion mutants by 
starting with the expression of only the first 31 amino acids (immediately before 
the phosphorylation site) of IκBα, the first 70 amino acids, the amino acids 1-109 
(N-terminus and 1st ankyrin repeat) and amino acids 1-142 (N-terminus and 
ankyrin repeats 1 and 2). A schematic representation of all the deletions for 
determining the necessary and sufficient domain can be found in figure D.19C 
Expression of the above constructs was confirmed by western blotting and 
they were tested in an apoptosis assay using ANT-1 transfection. The N-terminus 
only, irrespective of its stability and expression level, was unable to inhibit 
apoptosis. When the first ankyrin repeat was expressed along with the N-terminus, 
ANT-1 apoptosis could completely be inhibited as figure D.19A shows. 
Immunoblotting of cells transfected with the above plasmids confirmed the 
expression of the genes and the results of the apoptotic assay evaluated with 
DioC/PI (Figure D19A).  
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C 
Figure D.19. IκBα’s N-terminal domains with the first ankyrin repeat are 
sufficient to inhibit apoptosis. (A) Deletion mutants of MEET-IκBα were 
generated with recombinant PCR and tagged with FLAG® (in parentheses are the 
amino-acids of IκBα that are present in each construct). Their potency to inhibit 
apoptosis was tested in an ectopic expression assay with ANT-1 and quantification 
was done with FACS and DioC/PI staining. (B) Cells from (A) were lysed with RIPA 
buffer and lysates were blotted on a 15% SDS-PAGE for each deletion’s expression 
level. (C) Schematic representation of MEET-IκBα deletion mutants that were used for 
identification of the domains necessary and sufficient for apoptosis inhibition. On the 
right the characteristics of each construct are summarized. Ankyrin repeats are shown 
in red and N- or C-termini are represented by letters N or C.  
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D.5.  Mechanism of apoptosis inhibition by 
IκBα 
In this report we unravelled a novel pathway of apoptosis inhibition by IκBα 
at mitochondria. We observed a strong inhibitory effect on several signals for 
apoptosis and complete abrogation on apoptosis induced by ANT-1. The 
observation that OMM-targeted IκBα is a stronger inhibitor of apoptosis led us to 
its target at the outer mitochondria membrane which is VDAC1. Re-constitution, 
over-expression and knockdown studies, all reveal that IκBα acts on VDAC1 to 
inhibit apoptosis and this inhibition is mediated by a domain on IκBα, which is 
separable from domains affecting its ability to inhibit NF-κB. Although the effect 
was very clear, the mechanism by which IκBα exerts its effect was, till then, only 
based on observations and possible interaction partners of IκBα at the 
mitochondria level. Further analysis and experiments helped to identify the 
mechanism involved. IκBα inhibits apoptosis by inhibiting Bax integration by its 
association with VDAC1, thereby stabilizing the VDAC1-HXKII complex.     
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D.5.1.  IκBα inhibits Bax-induced cytochrome-C release 
VDAC1 was found to be the target of IκBα at the mitochondrial level as 
shown in the previous sections. As a member or effector of the PT-pore VDAC1 is 
a key molecule involved in apoptosis since upon apoptosis induction it allows the 
docking of Bax and eventually the permeabilisation and rapture of the OMM 
leading to cytochrome-C release. The release of apoptogenic factors is the “point 
of no return” for apoptosis execution and so far anti-apoptotic Bcl-2 family 
members were the sole guards of the OMM integrity acting directly on Bax (a 
mechanism that is extensively described in the introduction).  We investigated if 
IκBα can have any effect on cytochrome-C release since VDAC1 is its target and is 
involved in this function. We used Bax-β to induce apoptosis in 293T cells and IκBα 
targeted to the OMM was able to nearly completely inhibit Bax-β apoptosis 
(Figure D.20B). Using in vitro-translated (IVT) IκBα and recombinant Bax we 
induced cytochrome-C release from isolated mitochondria. When IVT-IκBα was 
present cytochrome-C release was completely abrogated (Figure D.20A). We used 
the same setting but instead of IVT-IκBα we transfected these cells with MEET-
IκBα. This had the same effect on cytochrome-C release (Figure D.20C). We 
showed previously that PC3 cells are resistant to apoptotic stimuli but when IκBα 
is reduced, these cells are re-sensitized to apoptosis. IκBα levels at mitochondria 
are found elevated in those cells, so knockdown would be a physiologically 
relevant system to explore its function on BAX and VDAC1.  We used staurosporin 
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that induces Bax translocation to mitochondria and sought to investigate the 
effect of IκBα on cytochrome-C release. When IκBα (PC3/scramble) was present 
and after staurosporin administration, cytochrome-C was released after 6-12 hours 
and Bax was moderately integrated in the OMM. When PC3/shIκBα cells were 
used and IκBα was found absent in mitochondria fractions, cytochrome-C could 
be released after only 2 hours of STS administration. Bax was found to be strongly 
integrated in the OMM when compared with the PC3/scramble cells on the same 
membrane (Figure D.20D). All the above results indicated a clear effect of IκBα on 
Bax-induced cytochrome-C release.  
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Figure D.20. IκBα inhibits Bax-induced cytochrome-C release. (A) 
Mitochondria from 293T cells were isolated and kept on ice. Reticulocyte lysate from 
IVT-β-gal and reticulocyte lysate from IVT-IκBα were incubated with mitochondria at 
25oC for 30min. Increasing concentration of recombinant-Bax were added afterwards 
and cytochrome release assessed. (B) 293T cells were transfected with an empty vector 
(EV) and MEET-IκBα and 24h later they were transfected with Bax-β. Apoptosis was 
quantified by DioC/PI staining and FACS. (C) 293T transfected either with an empty 
vector or MEET-IκBα were used and their mitochondria were isolated. Increasing 
concentrations of recombinant Bax were added and cytochrome-C release was assessed. 
(D) PC3/scramble and PC3/shIκBα cells were treated with 1µM staurosporine (STS) for 
the indicated times. Subsequently, alkali wash was used on isolated mitochondria 
according to standard methods and cytochrome-C release or Bax integration was 
qualitatively measured by a 15% SDS-PAGE. IκBα levels were measured before the alkali 
wash. An unspecific band was observed showing equal loading. 16 hours after STS 
administration integrated Bax appears cleaved in both cell lines possibly due to general 
protein degradation from excessive STS apoptosis. 
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D.5.2.  IκBα stabilizes the VDAC1-HXKII complex 
The ability of IκBα to inhibit Bax-induced cytochrome-C gave further insight 
into the mechanism that IκBα uses to inhibit apoptosis. Since Bax integration was 
delayed and cytochrome-C was inhibited, VDAC1 was the most obvious molecule 
to be investigated for a postulated mechanism. VDAC1 forms a complex with 
Hexokinase II (HXKII) and this complex is anti-apoptotic since HXKII, which is 
found bound to VDAC1 especially in cancer cells, makes the VDAC1 docking sites 
for Bax inaccessible., I speculated that IκBα could act on this complex and possibly 
stabilise it so that apoptosis is inhibited. We described in the introduction that the 
enterobacterial E. coli protein FimA was found to stabilise this complex and to 
confer resistance to colon cancer cells. We followed the same strategy to explore if 
IκBα had similar characteristics comparable to the bacterial protein. We designed a 
peptide that resembles the initial 15 amino acids of HXKII and when applied to 
isolated mitochondria, dissociates HXKII from them. The antibiotic clotrimazole has 
the same properties as the peptide but its effects are more unspecific.  
We obtained indications that IκBα is probably involved in this complex, 
initially when we knocked-down VDAC1 or HXKII (see figure D.15). The finding that 
IκBα was able to endogenously interact with HXKII (Figure D.13) was an additional 
step towards the characterization of the mechanism. IκBα was found to stabilise 
the VDAC1-HXKII complex in mitochondria from HeLa cells transfected with IκBα-
wt since even maximal amounts of HXK2VBD peptide were unable to dissociate 
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HXKII when IκBα was present (Figure D.21A). Moreover, mitochondria from HeLa 
cells transfected with IκBα-wt became more resistant to dissociation caused by 
clotrimazole since greater amounts of the drug were required for the dissociation 
(Figure D.21C). Similar results were observed in a genetically more defined system 
when we used IκBα-/- and MEET-IκBα reconstituted cells (Figure D.21B).  
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Figure D.21. IκBα stabilizes the VDAC1-HXKII complex. (A) 
Mitochondria from control- or IκBα-transfected HeLa cells were treated with 
the HKII-release peptide HXK2VBD and the interaction between HKII and 
VDAC1 was monitored with immunoprecipitations. (B) Mitochondria isolated 
from IκBα-/- or ΜΕΕΤ-IκBα-reconstituted 3T3 cells were treated with 
clotrimazole (CTZ, 80µM, 30 min). Subsequently, mitochondria were washed 
extensively, pelleted and then the indicated proteins were detected associated 
with mitochondria. (Note that all lysates were loaded on the same gel and 
blotted onto the same membrane but between 0 and 80µM CTZ the lanes used 
for controls and the drug were not added. Only the necessary parts of the blots 
are shown. (C) Mitochondria from control- or IκBα-transfected HeLa cells were 
treated with increasing amounts of clotrimazole. The stability of the VDAC1-
HXKII interaction was monitored with immunoprecipitations of VDAC1.  
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E.  Discussion 
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E.1.  Summary of the study 
In most cell types the activation of the transcription factor NF-κB leads to 
an anti-apoptotic response through the transcriptional upregulation of cell death 
inhibitors. I have demonstrated here that, unexpectedly, the NF-κB target gene 
IκBα, besides its inhibitory effect on NF-κB and its pro-apoptotic consequence, 
also guards the integrity of the OMM and thereby represses the intrinsic pathway 
for apoptosis. IκBα can exert its anti-apoptotic effect due to its stable interaction 
with VDAC1 and HKII through its N-terminal domain as mapping experiments 
revealed. IκBα stabilises the VDAC1-HXKII complex and inhibits Bax recruitment 
and cytochrome-C release. The PT-pore, which spans the mitochondrial 
membranes, is actively involved in this process since I could demonstrate that IκBα 
uses the PT-pore to exert its anti-apoptotic effect. Re-constitution and mapping 
studies reveal that the domains of IκBα involved in apoptosis inhibition and in NF-
κB inhibition are separate. Overall, I show here that IκBα constitutes a target for 
cancer therapeutics since specific down-regulation sensitised previously non-
sensitive tumour cells to chemotherapeutics: tumours in nude mice were 
considerably more sensitive to chemotherapy when IκBα was knocked-down in 
comparison with control tumours that showed no sensitivity to small doses of the 
drug. Further research will be required for the design of molecules specifically 
targeting the VDAC1/HKII-IκBα interaction. 
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E.2.  Mitochondrial localisation of IκBα and 
apoptosis inhibition 
Consistent with the identification of ΙκΒα in mitochondria (Bottero et al., 
2001; Cogswell et al., 2003) we confirm in this study that ΙκΒα is indeed found 
associated with mitochondria of several cancer cell lines (Figure D.4). Of note is the 
fact that in cell lines with constitutive NF-κB activity the mitochondrial localisation 
of IκBα is almost complete (Figure D.4A). The kinetics of IκBα degradation within 
mitochondria upon TNFα treatment were almost identical with the cytosolic effect 
(Figure D.2). That was an interesting finding since the proteasome does not have 
access to the inner compartments of mitochondria (Cogswell et al., 2003) and a 
possible transport of ΙκΒα out of mitochondria is unlikely unless it is very fast. We 
tested the kinetics of mitochondrial and cytosolic ΙκΒα degradation upon specific 
blockage of the proteasome using the specific and irreversible inhibitor lactacystin. 
The results indicate that the mechanism of IκBα degradation in mitochondrial 
differs from the one in the cytosol (Figure D.3). Under these conditions ΙκΒα in 
mitochondria is still degraded upon TNFα treatment but at the same time its 
degradation is blocked in the cytosol. Consequently, a different mechanism for 
IκBα degradation is suggested by these results. This could be another protease 
that is recruited into the mitochondria where it degrades ΙκΒα. Calpain has been 
shown to cleave ΙκΒα by interacting with residues 50-51 but the degradation effect 
was so far not tested on mitochondrial ΙκΒα (Schaecher et al., 2004). Although the 
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finding that mitochondrial IκBα is possibly degraded by another mechanism is 
interesting, it is not providing additional information about the OMM-associated 
IκBα that we show here is anti-apoptotic. The lactacystin experiments were looking 
at the IκBα localised at the IMS.  
  As a predominantly cytosolic protein with a pro-apoptotic function (since 
it inhibits the anti-apoptotic NF-κB transcription factor) mutational changes in 
IκBα were so far mainly connected with constitutive NF-κB activity (Biswas et al., 
2004; Gasparian et al., 2002a; Robe et al., 2004; Romieu-Mourez et al., 2001). 
Trying to identify possible differences between cells with normal NF-κB activity or 
cells with constitutively active NF-κB, we separated mitochondria and cytosol from 
HeLa, MCF and MDA-231 cells. There are so far no data showing the expression 
levels of the ΙκΒα protein in mitochondria and our results compared for the first 
time three different cell lines, one with constitutively active NF-κB  (MDA-MB-231) 
and two with normal NF-κB activity (Hela, MCF7). When analysing the results 
shown in figure D.4B we observed that in the MDA-MB-231 cell line, ΙκΒα levels in 
mitochondria are comparatively higher than in MCF7 cells (from the same tissue) 
or in HeLa cells (another carcinoma). On the other hand, the levels of the protein 
in the cytosol are diminished in MDA-MB-231 cells, probably because of the 
constitutive degradation by the proteasome as observed in other tumours (Biswas 
et al., 2004; Gasparian et al., 2002a; Robe et al., 2004; Romieu-Mourez et al., 2001). 
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Using a proteinase K assay, IκBα was found within the mitochondria and at 
the OMM of several cell lines including tumour or normal cell lines (Figure D.4D). 
Various genes implicated in apoptosis induction or inhibition have the dominant 
capacity to exert their effect upon overexpression. This feature is even conserved 
across species (McCarthy & Dixit, 1998). For this reason and since IκBα  is found to 
accumulate at mitochondria in cells with constitutive NF-κB activity, it was 
interesting to investigate the effect of ΙκΒα when over-expressed. We generated a 
fusion protein with the first 47 amino acids of the MCR1 yeast protein to target the 
ΙκΒα to the mitochondria intermembrane space (IMS) and the outer mitochondrial 
membrane (Figure D.5). The localisation of this protein to mitochondria is of 
particular interest since they are pivotal organelles for apoptosis control that 
contain numerous cell death regulators. Ultimately, they govern the disruption of 
the outer mitochondrial membrane and the release of pro-apoptotic factors such 
as cytochrome c and AIF, which cause cell destruction. We show here that when 
IκBα is specifically targeted to mitochondria it can inhibit even strong apoptosis 
signals such as ANT-1 (Figure D.6). One recent report suggests that ANT-1 induces 
apoptosis by titrating out nuclear NF-κB. However, the Hela cells used in this study 
do not contain constitutively active NF-κB (Grimm et al., 1996; Zamora et al., 2004). 
Rather, we believe that ANT-1 is a specific inducer of the PT pore for apoptosis, 
which is supported by its dependence on Cyp-D (Figure D.14). Upon IκBα 
expression we have also observed a reduced break-down of the mitochondrial 
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membrane potential ∆Ψm, an early sign of apoptosis induction, when cells were 
treated with an ionophore that increases the mitochondrial Ca2+ level (Figure 
D.6C). This, together with ANT-1 apoptosis inhibition, supports the notion of IκBα 
at mitochondria as an apoptosis inhibitor. A dose response was also tested by 
transfecting different amounts of IκBα or mcr1-IκBα plasmids while maintaining 
the ANT-1 levels. At a 2:1 ratio with an ANT-1 expression construct IκBα-wt and 
mitochondria-targeted IκBα (mcr1-IκBα) could completely abrogate the ANT-1 
apoptosis signal (Figure D.6A). The effect was not cell-specific since MCF7 and 
HeLa cells responded in the same manner upon IκBα and ANT-1 co-transfection 
(Figure D.6B).  
The localisation signal of the yeast MCR1 gene is not specific for any sub-
organelle compartment, however specific mutagenesis on two amino acids 
targeted mcr1-IκBα almost completely to the IMS. (Hahne et al., 1994a; Haucke et 
al., 1997; Meineke et al., 2008). For this reason I generated fusion constructs for 
this specific targeting of IκBα. Localisation sequences from Smac/DIABLO for the 
IMS and mitoNEET for the OMM were fused with IκBα thereby generating S/D-
IκBα and MEET-IκBα (Figure D.7). Upon ANT-1 transfection only MEET-IκBα and 
IκBα-wt were able to inhibit the apoptotic signal suggesting that only when IκBα 
associates with the OMM, it can inhibit apoptosis (Figure D.8). Other apoptosis 
inducers were likewise tested such as t-BID, VDAC1, Bax or Caspase-8. In all cases 
IκBα targeted to the OMM could inhibit apoptosis. For caspase-8 the effect of 
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IκBα-wt or of MEET-IκBα was only moderate suggesting a specificity of the signals 
that mitochondrial IκBα can inhibit. Caspase-8 activation can be the end result of 
apoptosis induced by the extrinsic pathway but a communication exists between 
the plasma membrane receptor and the mitochondria-mediated pathways 
through BID. Caspase-8 can cleave and activate BID and this is possibly underlying 
the effect on apoptosis inhibition that we observe (Figure D.8C). 
IκBβ was not found at mitochondria in the study that discovered IκBα in 
this organelle (Cogswell et al., 2003). However, IκBβ shares extensive homology 
with IκBα, consequently our intention was to evaluate the capacity of IκBβ to 
inhibit apoptosis. Figure D.9C shows that IκBβ does not inhibit apoptosis. The 
specificity of the apoptosis inhibition was further highlighted by an experimental 
setting that had IκBα sequestered in the cytosol, which rendered it unable to 
inhibit apoptosis: the IκBα/β-actin fusion protein was generated in order to retain 
the IκBα protein in the cytosol (Figure D.9A-9B). ANT-1 apoptosis could not be 
inhibited by this fusion construct (Figure D.9C). Hence, the sole site for apoptosis 
inhibition by IκBα remained the outer membrane of mitochondria.  
Re-constitution studies have long served as an option to evaluate the 
function of a protein. We obtained IκBα-/- fibroblasts in order to examine the 
effects of IκBα on apoptosis since such an investigation was not performed when 
the IκBα-/- mice were generated (Beg et al., 1995a). These mice show constitutive 
NF-κB activation, which we confirmed confers apoptosis resistance to those cells 
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(Figure D.10D). In order to avoid overexpression of proteins we used a lentiviral 
system that allowed us to transduce the knock-out fibroblasts with different 
M.O.I.s so that the reconstitution of the proteins would be at the same or lower 
level than the 3T3 WT fibroblasts. We used IκBα/β-actin, and empty vector (EV) 
and MEET-IκBα to target IκBα only to the cytosol or to the OMM. Since these cells 
show constitutive NF-κB activity we used a non-radioactive-κΒ-oligo-pull-down 
assay using nuclear extracts to determine the status of NF-κB before and after re-
constitution. Figure D.10E show that upon reconstitution of IκBα at physiological 
levels (Figure D.10B) NF-κB activity was diminished in both cases making our 
results comparable and independent of any apoptosis resistance conferred by NF-
κB activation (Figure D.10E). After setting up our cellular system, I used apoptosis 
assays in order to evaluate the effect of IκBα variants in specific cellular 
compartments after apoptosis induction. OMM-targeted IκBα conferred resistance 
to all apoptotic stimuli used in re-constituted cells, despite the in-activation of the 
anti-apoptotic NF-κB (Figure D.10C). Cytosol-sequestered IκBα was unable to 
inhibit apoptosis and in most cases even sensitised the cells for apoptosis possibly 
due to the inhibition of NF-κB (Figure D.10E).  
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E.3.  Evidence for resistance to apoptosis 
through mitochondrial IκBα: proof of concept 
In order to investigate the role of IκBα at the OMM for apoptosis regulation 
and its function as a NF-κB target gene we made use of cells with constitutive NF-
κB activity that express high level of IκBα at the OMM (Figure D.4A-B). The 
selection of this cell type was particularly important since I previously identified 
that these cells (MDA-MB-231), apart from the high levels of IκBα at mitochondria, 
have diminished levels of IκBα in the cytosol. Hence, RNAi against IκBα would 
primarily down-regulate the mitochondria-associated IκBα. Using lentiviruses we 
stably knocked down IκBα in MDA-MB-231 cells. NF-κB remained unaffected 
indicating that it is activated by a process other than IκBα degradation in these 
cells (Prasad et al., 2009) (Figure D.11A). The treatment with various apoptosis 
inducers revealed that IκBα reduction rendered these cells significantly more 
sensitive to apoptosis (Figure D.11). A similar effect was observed when IκBα was 
targeted in PC3 cells, which likewise display constitutively active NF-κB and a high 
amount of IκBα at mitochondria (Figure D.11). 
Treatment-resistance of tumour cells with constitutively active NF-κB has 
been reported extensively (Lee et al., 1999; Nakshatri et al., 1997a; Sovak et al., 
1997; Wang et al., 1996) emphasising the importance of our experimental findings. 
Indeed MDA-MB-231 cells are extremely resistant to apoptosis (Ciucci et al., 2006) 
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and several studies report that inhibition of NF-κB made these cells more sensitive 
to apoptosis signals. However, we have emphasised in the introductory sections of 
this thesis the importance of NF-κB in scenarios other than apoptosis. Targeting 
NF-κB would have detrimental effects on the immune response, something that 
needs to be avoided. MDA-MB-231 cells have constitutively active NF-κB and the 
knockdown of IκBα, which resides primarily at mitochondria, did not affect its 
activation and IκBα. Targeting IκBα proved to be an effective method to sensitise 
these cells to the well-established chemotherapeutic doxorubicin. A small in vivo 
pilot study using mice engrafted with MDA-MB-231 cells confirmed my in vitro 
results and doxorubicin-treated tumours with IκBα shrank substantially, whereas 
normal tumours were unresponsive to doxorubicin and continued to grow (Figure 
D.12).   
PC3 cells display the same characteristics as the MDA-MB-231 cells in terms 
of resistance to apoptosis and chemotherapy agents due to constitutive NF-κB 
activation (Gasparian et al., 2002a; Gasparian et al., 2002b; Lu et al., 2004; 
Muenchen et al., 2000). The underlying mechanism for constitutive NF-κB 
activation is not known but IκBα was also found associating with the OMM in 
those cells (Figure D.4) and knock-down of IκBα had no effect on further activating 
NF-κB (Figure D.11A). Docetaxel has been identified as an efficient 
chemotherapeutic to target breast, lung and prostate cancer and has extensively 
been used in the clinic (Morse et al., 2005). However, PC3 cells display resistance to 
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this drug (Figure D.11E). IκBα knockdown sensitised these cells to docetaxel and 
efficiently induced apoptosis (Figure D.11E).  
MDA-MB-231 and PC3 are two cell lines that exhibit the enhanced 
accumulation of IκBα at mitochondria and both of them were sensitised upon IκBα 
RNAi-mediated reduction. In order to explore how universal is the effect on 
apoptosis resistance we also tested the human colon cancer cell line (HCT-116) 
which likewise is extremely resistant to apoptosis and displays constitutive NF-κB 
activity. An effect on apoptosis sensitisation was also observed with those cells 
when IκBα was reduced. We used staurosporin and ionomycin, which initiate 
apoptosis through Bax translocation to mitochondria and activation of the PT-pore 
through calcium influx, respectively (Schubert & Grimm, 2004; Zhang et al., 2004). 
In both cases IκBα was found to be the gatekeeper of mitochondria protecting 
their integrity through a mechanism that we will discuss below in more detail. Our 
findings supported our initial concept that IκBα accumulates at mitochondria, is 
protected from constitutive degradation and protects cells from apoptosis. We 
demonstrated that IκBα is, possibly among others, a molecule that confers 
resistance to apoptosis and chemotherapeutics through its interaction with 
mitochondria.   
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E.4.  Mechanism of apoptosis inhibition by 
IκBα  
The outer mitochondria membrane is a very important site for apoptosis 
regulation since it is there where several protein-protein interactions take place to 
protect or permeabilise this organelle in order to induce apoptosis. The 
localisation of NF-κB subunits to mitochondria was revealed previously (Bottero et 
al., 2001; Cogswell et al., 2003), but this was limited to the matrix and the 
intermembrane space of this organelle and its role for apoptosis remained 
unknown. In those studies overexpressed ANT-1 and IκBα were found to interact. 
We proved a more direct involvement of IκBα in apoptosis. The mechanism that 
underlies the inhibition effect of mitochondrial ΙκΒα was the subject of this study. 
Testing a set of ΙκΒα interactors (Figure D.13) indicated many potential 
mechanisms. As endogenous ΙκΒα is able to physically interact with endogenous 
VDAC1, ANT-1, HXKII and CK1, all of which are members of the classical PT-pore, 
this protein complex became the prime candidate for the target of IκBα (Figure 
D.13). Indeed, my work revealed that IκBα specifically associates with the OMM 
and inhibits apoptosis via its most prominent partners VDAC and HXKII. IκΒα 
stabilises the complex of HKII and VDAC1 since a peptide able to specifically 
dissociate HXKII from VDAC1 was incapable to do so when IκBα was present 
(Figure D.21). Clotrimazole, which also has the ability of HXKII dissociation from 
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mitochondria, was also diminished by the presence of IκBα since greater amounts 
of the drug were required for dissociation (Figure D.21C). 
 Hexokinase II was also found to be necessary for the inhibitory effect of 
IκBα. shRNA-mediated reduction of the protein levels rendered IκBα incapable of 
inhibiting apoptosis even when overexpressed (Figure D.15B). However, since 
HXKII is itself an apoptosis inhibitor (Pastorino et al., 2002), silencing could have 
contributed to the enhanced apoptosis that was observed. Therefore, HXKII might 
also be an important component of the mechanism of IκBα inhibition but with our 
data we cannot claim its necessity for apoptosis inhibition through IκBα. 
HKII is known to bind to VDAC1, the most abundant VDAC isoform, via its 
N-terminus and its putative BH4 domain (Pastorino & Hoek, 2008a). This seems to 
favour the oligomeric association of VDAC proteins and keeps these proteins in a 
state, which renders them unable to interact with Bax for apoptosis induction. With 
this novel activity at the OMM, IκBα exerts the same effect as the enterobacterial 
fimA protein, which likewise stabilises the VDAC-HKII interaction and inhibits 
apoptosis (Sukumaran et al., 2010a). IκBα can therefore potentially represent the 
human equivalent of this bacterial protein and contribute to apoptosis inhibition 
observed in cancer cells, in particular since we have data showing increased levels 
of IκBα at mitochondria of several cancer cell lines (see chapter D.1.4 above). The 
importance of our findings is striking for cancer cells but one can extrapolate the 
same level of significance to normal cells. The overall expression of IκBα in a 
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cancer cell with constitutive NF-κB is either not altered or reduced (Nakshatri et al., 
1997a). However, our results indicate that there is a preferential shift of the 
localisation of IκBα from the cytosol to the mitochondria altering the apoptosis 
sensitivity of the cell. The best binding partner of IκBα, p65 (relA), resides in the 
nucleus of cells with constitutive NF-κB activity and that disturbs the interaction of 
IκBα and p65. Newly synthesized IκBα or IκBα resistant to degradation would 
therefore complex with the VDAC1 as its alternative interactor. On the other hand, 
we have also observed IκBα at mitochondria of 3T3 WT cells. IκBα appears to be 
able to bind both p65 and VDAC1 simultaneously but since the affinity of p65 with 
IκBα is much greater the ability of VDAC1 binding, despite being present, appears 
reduced (Figure E.1) .  
Using recombinant and IVT proteins we were able to show that Bax-
mediated cytochrome-C release was blocked by IκBα (Figure D.20A). Using PC3 
cells, which have previously been shown to be resistant to apoptosis by 
chemotherapeutics but became sensitive upon IκBα knockdown, we observed that 
mitochondrial IκBα delays the release of cytochrome-C via its ability to inhibit 
enhanced Bax integration into the OMM (Figure D.20D). This effect is possibly due 
to the stabilisation of the VDAC1-HXKII complex since VDAC sites are occupied by 
HXKII and are not accessible for Bax.  
Cyp-D knockout fibroblasts (ppif-/-) show increased resistance to cell death 
(Baines et al., 2005) and are unable to undergo permeability transition since they 
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cannot open the PT-pore. With the help of these cells ANT-1 was found to induce 
apoptosis through the PT-pore confirming the observation of Bauer et al (1999) 
with bongkrekic acid, a compound that specifically inhibits the PT-pore (Bauer et 
al., 1999). The requirement for cyp-D in the mitochondrial matrix to observe IκΒα’s 
apoptosis repression (Figure D.14B) suggests that mitochondrial IκΒα is a 
component or an effector of the PT pore. This protein complex connects the inner 
with the outer mitochondrial membrane and is converted into an unspecific 
channel for apoptosis induction (Zamzami et al., 2005). Its structure consists of 
cypD, ANT and VDAC proteins as the core constituents with probably many more 
associated regulatory factors (Verrier et al., 2004). The role of the latter two 
components has been questioned, though (Baines et al., 2007; Kokoszka et al., 
2004) but an extensive collection of publications in the scientific literature exists 
arguing for their function in mitochondrial apoptosis (Shoshan-Barmatz et al., 
2010; Tsujimoto & Shimizu, 2002).  
One of the publications critical of the contribution of VDAC molecules to 
apoptosis induction via the PT pore observed no effect on cell death when VDAC1 
and VDAC3 were genetically removed and VDAC2 was reduced by knock-down 
with RNAi (Baines et al., 2007). Our results could contribute to an explanation as 
IκΒα’s apoptosis inhibition ability depends on VDAC1 (Figure D.15A). Firstly, above 
study used VDAC1/3(-/--/-) cells with only a knockdown of the VDAC2 isoform since 
VDAC2-null mice are not viable. One cannot exclude a compensatory effect of 
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VDAC2 for apoptosis since complete knockdown would have killed the cells. 
Secondly, while VDAC silencing would make the cells more resistant for cell death 
it would also mask the anti-apoptotic activity of IκΒα and – on balance - could 
thereby abrogate any net effect on cell death. Analysis of the IκBα-re-constituted 
MEF cells with shRNA against VDAC1 indicated similar effects as observed in 
human cell lines (Figure D.15C), which contributed to the identification of VDAC1 
as a target of IκBα. The PT pore has been shown to mediate necrosis but a 
growing body of evidence also implicates it in apoptosis regulation (Kinnally et al., 
2010) as extensively described in the introductory sections of this study. Possibly, 
the concentration of the cell death inducers in those studies claiming sole 
involvement in necrosis could have been too high to detect apoptosis via the PT 
pore (Baines et al., 2005; Nakagawa et al., 2005). As was previously analysed the 
intensity and the quality of the signal are the crucial modulators of apoptosis 
versus necrosis execution through the PT-pore.   
We are now able to explain the effects that we see on apoptosis 
sensitisation upon down-regulation of IκBα. PC3 cells that are responding poorly 
to staurosporin became extremely sensitised to apoptosis when IκBα was not 
present to protect them from Bax integration and cytochrome-C release (Figure 
D.20D). IκBα guards the integrity of the OMM by stabilising the VDAC1-HXKII 
complex and thereby inhibiting Bax translocation to mitochondria and 
cytochrome-C release. Since IκBα is a gatekeeper of the PT-pore opening we 
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sought to investigate the initial stages of apoptosis when only biochemical 
changes upstream of effector pathways occur. We induced apoptosis with As2O3 
which was previously shown to be executed through VDAC1 (Yu et al., 2007; 
Zheng et al., 2004) and observed the VDAC1-IκBα interaction ten hours after drug 
administration when no morphological changes to cells were observed and 
mitochondria and plasma membrane integrity were not affected (Figure D.16A). 
Upon apoptosis induction and early in the apoptotic phase, IκBα was released 
from VDAC1 (Figure D.16B). This result confirms our hypothesis that IκBα is a 
gatekeeper of the mitochondrial permeability transition. Cells exhibited extensive 
apoptosis after 24hours when IκBα was absent and could not stabilise the VDAC1-
HXKII complex to inhibit Bax translocation and binding to VDACs for subsequently 
cytochrome-C release.   
Whether VDAC1 contributes to apoptosis or not and whether it is a 
member of the PT-megapore, along with ANT-1, was not the main subject of this 
study. However, all our data indicate that VDAC1 constitutes the target of IκBα at 
the OMM and this transporter therefore does regulate apoptosis. Through this 
interaction IκBα is able to stabilise the anti-apoptotic VDAC1-HXKII complex and 
inhibit apoptosis. If ppif-/- cells are regarded as a suitable tool to show the role of 
the PT-pore in apoptosis, then IκBα is most probably a member of the PT-pore 
complex, since I could show the requirement of Cyp-D for apoptosis inhibition by 
IκBα (Figure D.14). Nevertheless, the mechanism that we propose in this study is 
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based on mitochondrial apoptosis effectors that are not part of the scientific 
debate on the identity of the PT pore components. The VDAC1/HXKII complex has 
been established as an anti-apoptotic complex at the OMM, which IκBα can 
stabilise thereby inhibiting cytochrome-C release and Bax integration.  
The current status of the debate on the composition of the PT-pore is that 
no clear conclusions can be derived on the dispensability of any of its 
components. The classical PT-pore seems to be the key complex for the 
interpretation of our results since we can see in all cases the requirement of 
cyclophilin-D, VDAC1 and hexokinase from IκBα to inhibit apoptosis. IκBα requires 
all three and possibly other proteins in this complex to exert its anti-apoptotic 
effect. Whether any of the three components is or is not at the same time a 
member of the PT pore, is unresolved. Still, our data indicate that IκBα is most 
likely an effector of a protein complex that includes all the aforementioned factors 
and is possibly by the same token a component of the PT- pore since the 
associations were detected in resting cells.  
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E.5.  IκBα domain mapping and its dual 
activity 
As the inhibitor of the anti-apoptotic transcription factor NF-κB, IκΒα exerts 
a pro-apoptotic function, which is counteracted by its novel activity to repress 
apoptosis at the OMM as revealed in this work. Therefore, during its degradation 
in the activation cycle of NF-κB, while it is re-synthesised as a consequence of its 
being a target gene of the transcriptional activity of NF-κB, IκΒα contributes to the 
balance of survival and cell death signals.. This is especially important as many of 
the signals that activate NF-κB constitute cell stress. 
Our mapping experiments indicated that, in contrast to the inhibition of 
NF-κB, which is exerted through the C-terminus and the ankyrin repeats, the N-
terminus of IκBα is responsible for its repression of apoptosis (Figure D.18). The N-
terminus is a regulatory domain for degradation of IκBα (Traenckner et al., 1995) 
in the canonical NF-κB signalling but it does not display domain interactions with 
p65/p50 heterodimers (Baeuerle, 1998; Van Antwerp & Verma, 1996). 
Immunoprecipitations with MEET-IκBα lacking the N-terminus displayed a minimal 
ability to interact with VDAC1 explaining the inability of this deletion mutant to 
inhibit apoptosis (Figure D.18). Moreover, specific IκBα mutants with either 
reduced or constitutive NF-κB inhibition (Sachdev et al., 1998b; Traenckner et al., 
1995) showed an identical ability to inhibit Bax- or ANT1-induced apoptosis 
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(Figure D.17A). IκBα-SR, for example, is able to constitutively retain NF-κB in the 
cytosol making its canonical activation impossible. The IκBα 110-A3 mutant 
responds normally to degradation signals but is not able to dissociate NF-κB from 
the nucleus making the NF-κB inactivation impossible. This construct was likewise 
active for apoptosis inhibition. These experiments gave credence to the hypothesis 
that IκBα has a dual activity. The N-terminus is responsible for apoptosis inhibition 
at mitochondria and the rest of IκBα is able to respond and act on NF-κB 
signalling.  
The N-terminus is the domain necessary for apoptosis inhibition but further 
mapping experiments showed that is not sufficient. IκBα requires the N-terminus 
and the first ankyrin repeat for apoptosis inhibition (Figure D.19). On the other 
hand, deletion of nearly the total IκBα domain, which is required for NF-κB 
retention and inhibition, did not have any effect on the ability of IκBα to inhibit 
apoptosis (Figure D.19).  
Our assays, on which we based the discovery that IκBα inhibits apoptosis, 
involved overexpression of ANT-1 and Bax. In order to define if the experimental 
settings were clean in terms of other effects on apoptosis we tested the activation 
of NF-κB. NF-κB activation confers, for the majority of times, an anti-apoptotic 
signal, so a possible activation during overexpression of ANT-1 or Bax would have 
masked any net effect of apoptosis inhibition by IκBα. We used a fluorescence 
based NF-κB activation assay to see if ANT-1- or Bax-induced apoptosis involves 
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NF-κB activation. As a positive control we used the viral TAX gene which was 
previously reported to induce NF-κB activation (Arima et al., 1991; Sun et al., 1994). 
Under conditions of ectopic expression with several transfection reagents ANT-1 
or Bax could not activate the NF-κB system in contrast to TAX (Figure D.17B). This 
result supported the mapping results and contributed to the hypothesis that there 
are distinct domains on IκBα which allow apoptosis inhibition irrespective of its 
ability to inhibit/retain NF-κB.  
IκBα and IκBβ share extensive homology and some of their domains are 
identical. Analysis with the protein database Uniprot revealed this homology. 
However, the N-terminal part of IκBα seems to have the least homology with any 
other part of IκBβ. Only the regulatory domain responsible for IκBα degradation 
(DSGLDS-31/36) is identical with a domain on IκBβ. However, we have shown that 
mutations in this domain (IκBα-SR) did not affect the ability of IκBα to inhibit 
apoptosis. There is also a domain in the IκBα-Ν-terminus that is completely 
unique compared to IκBβ since it does not match with any sequence in IκBβ. 
Amino-acids 13-30 and 50-54 showed no similarity and since the N-terminus (1-
70) is the necessary domain for apoptosis inhibition and since IκBβ cannot inhibit 
apoptosis we can hypothesize that those domains are possibly the domains 
relevant for the effect of IκBα on apoptosis. The sequence alignment of the two 
proteins can be found in the Appendix of this thesis and further experimentation 
will shed new light on this hypothesis.     
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Differences in the N-terminus of IκBα and IκBβ can potentially explain the 
functional differences of these two molecules on apoptosis. However, the two 
proteins share extensive functional similarity for NF-κB signalling. They are both 
degraded upon cytokine administration, they can both sequester NF-κB in the 
cytosol and inhibit NF-κB activation (Rao et al., 2010). Mice lacking IκBα and with 
the gene of  IκBβ knocked-in under the IκBα promoter, show a normal phenotype 
compared to the severe effects of IκBα knock-out (Cheng et al., 1998). One would 
expect that since they share so many functions they should also have the same 
effect on apoptosis. Our experiments, however, show the opposite for apoptosis 
regulation. IκBβ cannot inhibit apoptosis and the reason might be that only IκBα is 
a target gene of NF-κB. Indeed, IκBα is rapidly degraded and re-synthesized within 
30 minutes of cell stimulation. IκBβ shows much slower kinetics. IκBβ is claimed to 
be a stronger cytoplasmic inhibitor of NF-κB since it is able to mask both NLS on 
NF-κB in resting cells. On the contrary, IκBα is only masking one NLS and show a 
more dynamic localization pattern shifting between cytosol and the nucleus 
(Malek et al., 2001). The latter finding might explain the dual role of IκBα. A 
molecule with two activities should be able to preferentially function on both 
systems that can affect in order to maintain homeostasis. IκBβ would not have 
been able to do so since it is a very good sequestering molecule but with poor NF-
κB dissociation ability. However, since IκBα has a dual function its degradation 
creates a window in which cells should appear more sensitive to apoptosis since 
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IκBα is not present in the cytosol but also not in the mitochondria. Since IκBα is a 
target gene, cells up-regulate it rapidly so the equilibrium between pro- and anti-
apoptotic proteins is restored.   
 IκBα variants with differential localisations (Figure D.9) allowed the 
separation of the pro- and the anti-apoptotic activity of IκBα. Moreover, 
experiments under conditions with (Figures D.10-D.11) or without (Figure D.6-D.8) 
constitutive NF-κB activity, indicated that the novel activity of IκBα to repress 
apoptosis at the OMM is distinct from its known ability to inhibit NF-κB. Of note, 
the C-terminus of IκΒα is mutated in Hodgkin’s lymphoma, while its N-terminus 
remains intact (Cabannes et al. 1999). This would disturb only its effect on 
retaining NF-κB and preserves its anti-apoptotic effect at the OMM. 
If the equilibrium of NF-κB-activating and -inhibiting factors is disturbed 
this inducible transcription factor can contribute to various diseases. In a number 
of tumour models NF-κB is found to be constitutively active and this seems to be 
required for the survival of the malignant cells (Prasad et al., 2009). Permanently 
activated NF-κB also contributes to chronic inflammation in a variety of disease 
models (Gordon et al., 2011; Nichols et al., 2008; Rangan et al., 2009; Roman-Blas 
& Jimenez, 2008; Yao & Rahman, 2009). As a consequence, NF-κB is targeted by 
pharmacological interference in inflammatory and autoimmune diseases (Karin et 
al., 2004) and in cancer therapy (Baud & Karin, 2009). These efforts could benefit 
from our findings on the novel mitochondrial activity of IκBα as it reveals more 
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specific interference options. A successful compound could bind to IκBα and 
either degrade it or block the N-terminus in order to prevent association with 
VDAC1. Since NF-κB is the key modulator of the immune response, compounds 
that target its subunits would have a great effect on the inflammatory and immune 
responses. Targeting the IκBα-VDAC1 interaction could prove a more relevant 
option since one could achieve an apoptosis sensitising effect by the dissociation 
of IκBα from mitochondria without affecting the ability of IκBα to function 
properly on NF-κB. In the context of cancer therapy IκBα dissociation from 
mitochondria could be therapeutically relevant but in the physiological context of 
normal cells such a dissociation would have no or minimal effects on the normal 
functioning of NF-κB.  
 
 
 
 
 
 
 
 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 226 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
Cancer cell with 
constitutive NF-κB 
Normal Cell 
p50/p65 
IκBα  
PT-pore 
Hexokinase 
A 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 227 
 
 
  
B 
Imperial College  
London   
  
 
Evangelos Pazarentzos | PhD Thesis                                                        P a g e  | 228 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure E.1. Model of IκBα localisation and function. (A) In normal cell 
IκBα is sequestering the NF-κB heterodimers in the cytosol. The N-terminus 
of IκBα allows the association with VDAC1 in parallel with the NF-κB 
association. IκBα contributes to NF-κB signalling and also inhibits apoptosis 
at mitochondria maintaining the equilibrium for homeostasis. When a cell 
shifts to a cancerous state NF-κB is constitutively active by mechanisms 
independent of IκBα degradation. This allows the translocation of the NF-κB 
dimer to enter the nucleus and transcribe target genes. Such translocation 
creates an imbalance for the association of IκBα with p65 and VDAC1. IκBα 
then preferentially shifts to a mitochondrial localisation. This, in turn, allows 
IκBα to exert its second function, namely to inhibit apoptosis through the 
PT-pore. NF-κB activation and IκBα-VDAC1 association occur concurrently 
with enhanced IκBα localisation at mitochondria. The overall net effect is 
apoptosis resistance. (B) In normal and tumour cells that lack constitutive 
active NF-κB some IκBα proteins are associated with VDAC1 and HXKII. 
Upon apoptosis induction, they dissociate from VDAC and Bax is recruited 
for apoptosis induction (Lower left hand panel). In those tumour cells that 
suffer mutations that render NF-κB constitutively activeand in which IκBα 
accumulates at the OMM, the VDAC1-HXKII interaction is stabilized and 
inhibits Bax recruitment, PT-pore opening, cytochrome-c release and 
apoptosis induction (lower right hand panel). 
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S/D-IKBa@2
6579 bp
Smac/Diablo-IKB alpha
P CMV
T7
SP6
BGH polyANeo R (geneticin)
BamHI (2041)
EcoRI (2072)
HindIII (890)
Sma I (3226)
XmaI (3224)
EcoRV (2084)
BglII (13)
NotI (2099)
XbaI (2117)
F.1.  Plasmids 
  
IκBα gene without ATG fused with the localization sequence for 
mitochondria from the Smac/Diablo gene. S/D first 171 bp were first 
inserted into pEGFP-N1 and IκBα followed into KpnI/BamHI sites. The 
whole fusion from HindIII/BamHI was then inserted into pcDNA3. The 
plasmid was tested for correct localization of the protein with 
immunofluorescence. Between Smac/Diablo and IκBα there is a linker 
sequence  CTG CAG TCG ACG GTA CC in frame to produce the fusion. All 
the above apply for the generation of MEET-IκBα vector.  
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pEGFP-S/D (mito seq IMS)
4908 bp
Smac (171bp+GFP fusion)
P CMV
Kanamycin/Neomycin Cassette
BamHI (837)
ClaI (2773)
EcoRI (806)
HindIII (623)
Pst I (815)
Sma I (835)
XmaI (833)
Not I (1577)
XbaI (1587)
 
  
171bp from the Smac/Diablo gene of mouse origin and a Kozak 
consensus were into the HindIII and PstI sites of pEGFP-N1 vector 
to create a fusion protein with EGFP gene. The same strategy was 
followed for the generation of MEET-GFP plasmid. The plasmids 
can be used as fluorescent markers for the Intermembrane space 
of mitochondria (IMS) or the OMM respectively. The constructs 
were sequenced–verified and validated with Immunofluorescence. 
It can be used to visualize mitochondria.     
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pCMV4-IKBa (N-FLAG)
5850 bp
IKB alpha
Ampicillin R+
P- CMV
pBABE 3 primer site
FLAG
BglII (968)
ClaI (987)
HindIII (992)
Sma I (2005)
XbaI (1987)
XmaI (2003)
BamHI (1998)
BamHI (3062)
EcoRI (962)
EcoRI (3193)
XhoI (1192)
XhoI (2994)
Pst I (1181)
Pst I (1364)
Pst I (3163)
IκBα gene human was inserted into pCMV4 plasmid and a FLAG 
tag was inserted with recombinant PCR technology in the N- 
terminal part of IκBα. The plasmid was sequence-verified and 
validated  using transfections. Restrictions sites BglII, HindIII and 
ClaI with XbaI, XmaI can be used to excise the IκBα TAGGED gene. 
pCEP forward and pBABE Reverse primers can be used with 
relevant safety to sequence the gene 
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pLenti sin CMV lacZ SV40 GFP V paz 3rd Gen3
11066 bp
pUC ori
Amplicillin
pRSV/5'LTR
RRE
cPPT
pCMV promoter
WPRE
pSV40
GFP
deltaU3/3'LTR
SV40 pA
lacZ
HIV-1 psi packaging signal
RSV promoter
 HIV-1 5ELTR
V5tag
delta U3
3' LTR
bla promoter
BamHI (2529)
Pst I (2561)
Sma I (6754)
XhoI (5734)
XmaI (6752)
ApaI (5750)
XbaI (2523)
XbaI (5740)
  
lacZ control gene in the commercial pLenti7.3 vector that also 
contains eGFP under the SV40 promoter. The lacZ is under a 
strong mammalian expression pCMV. The plasmid is to be used for 
production of control lentiviral particles with a 3
rd
 generation 
lentiviral production system. MEET-IκBα and IκBα/βactin were 
also cloned into this vector.  
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pLenti7.3 puro
7706 bp
AmpR
HIV-1 5' LTR
Delta U3/3' LTR
HIV-1 psi packaging signal
delta U3
WPRE
3 stops
V5 epitope
RRE
pRSV/5' LTR
3' LTR
SV40 promoter
Puromycin R+
SV40 pA
RSV promoter
CMV Promoter
pUC ori
3' splice acceptor
3' splice acceptor
TATA box
cPPT
ApaI (2619)
BamHI (2529)
ClaI (1924)
Pst I (2579)
EcoRV (2582)
NheI (3546)
XhoI (2603)
BstBI (2626)
SpeI (2535)
AgeI (2676)
AgeI (3296)
KpnI (3297)
KpnI (4161)
Not I (921)
Not I (2597)
XbaI (2523)
XbaI (2609)
Lentiviral transfer vector plasmid with Puromycin gene for 
selection in mammalian cells  
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  pLKO.1 vector for the expression of shRNA. The vector contains a 
puromycin resistance cassette for mammalian selection in a bi-cistronic 
format with U6 promoter. PvuII restriction digest can be used for pattern 
checking 
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pEYFP-mito encodes a fusion of EYFP and the mitochondrial targeting 
sequence from the subunit VIII of human cytochrome c oxidase which 
targets the EYFP gene to the mitochondrial matrix. Substitutions of the EYFP 
gene with the CFP or DsRed gene created alternatives for fluorescent 
labelling of mitochondria.The mitochondrial targeting sequence finishes at 
the 683th bp and before BamHI site.  
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F.2.  IκBα and IκBβ 
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